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Abstract 
The objectives of this thesis are to develop a simple method of synthesising 
glyconanoparticles, use these particles to explore the impact of particle size and 
hardness on lectin binding, and to develop a targeted antibiotic delivery system.  
Nanoparticles have various properties that can be modified to improve their 
performance such as: size, morphology and surface charge. They can also be surface 
functionalised with sugars such that they target a specific location through interaction 
with cell surface lectins. Glyconanoparticles may be synthesised in a variety of ways. 
One suitable method of preparation is emulsion polymerisation, a classic emulsion 
polymerisation being free radical with the addition of surfactant. Methods to improve 
the biological properties of the resulting latex include RAFT emulsion polymerisation 
and a classic free radical emulsion polymerisation, without the addition of a surfactant. 
The former potentially suffers from being prohibitively expensive and time 
consuming, and the latter from poor size control and lack of surface functionality.   
Glycosylated nanoparticles were initially synthesised via RAFT emulsion 
polymerisation; subsequently a simplified free radical surfactant free emulsion 
polymerisation was used, with the addition of a hydrophilic co-monomer, to improve 
size control and impart surface functionality. Glyconanoparticles between 50-350 nm 
in diameter were produced with both methods. The particles were subsequently used 
to determine the effect of particle size and core glass transition temperature (Tg) on 
lectin induced aggregation. Larger particles, and those with a “soft” core above their 
Tg were quantitatively shown to aggregate to a greater extent, with more particles per 
aggregate. The free radical technique was further used to produce a pH responsive, 
mannosylated nanoparticle, capable of: targeting macrophages, selectively releasing 
isoniazid intracellularly and breaking up after endocytosis. This system was shown to 
eradicate intracellular mycobacteria (BCG) in cellulo at physiological concentrations. 
Overall this thesis presents the facile synthesis of glyconanoparticles suitable for a 
wide range of applications and uses them to explore the influence of size and hardness 
on particle-lectin interactions. The same synthetic technique is used to produce a 
macrophage targeted, dual pH responsive nanoparticle capable of delivering isoniazid 
intracellularly.  
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1 Chapter 1 
Biomedical uses of nanoparticles and their synthesis via 
emulsion polymerisation 
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1.1 Nanoparticles in Biomedicine  
According to the definition from the National Nanotechnology Initiative, a 
nanoparticle is a system with a diameter between 1-100 nm.1 Commonly, and in this 
thesis, the term is applied to particles with diameters below 1000 nm.  Nanotechnology 
has found uses from the oil industry to the production of photonics.2-4 One area in 
which it has had a major impact though, is biomedicine.1 Nanoparticle research in the 
biomedical arena has, over recent decades become a vastly expanding area of research. 
Particles of varying composition based on polymers, liposomes, metals or silica have 
found uses throughout the field.5-9 Their applications have included use as: imaging 
agents, diagnostics and drug delivery agents.10, 11  
1.1.1 Nanoparticles as Imaging and Diagnostic Agents  
The use of nanoparticles as diagnostic and imaging aids has commonly utilised metal 
particles such as gold, silver and metal oxides (e.g. Fe3O4).
12 Gold nanoparticles have 
received a considerable amount of attention as imaging aids, due to their high X-ray 
attenuation, low toxicity and ease of synthesis. The synthesis is typically achieved 
through the reduction of a gold salt (e.g. HAuCl4) with citric acid that further acts as a 
stabilising agent.13, 14 The high electron density of gold nanoparticles compared to the 
standard iodine contrast agents has made them useful in Computerised Tomography 
(CT) imaging, particularly when entrapped within a polymeric structure such as a 
dendrimer.15-17 Non-functionalised gold nanoparticles may be used to show blood 
pooling, or potentially a tumour environment via accumulation from the enhanced 
permeability and retention (EPR) effect, although the efficiency of the EPR effect for 
targeting tumours is potentially very low and discussed fully in section 1.3.1.18 
Functionalising their surface however, not only can improve their colloidal stability 
but direct them to a site of interest for higher contrast imaging in vivo.14 Some 
examples using this concept include functionalising nanoparticles with “prostate 
specific antigen” (PSA) in order to obtain a clear image of a prostate tumour, or the 
use of a targeting peptide to reveal thrombus location.19, 20 As diagnostics tools for 
purposes other than in imaging, the relative ease of functionalisation has led to a 
number of reports using metal nanoparticles in “bio-barcode” assays. In these assays 
a magnetic microparticle and a metal nanoparticle are coated in separate targeting 
moieties for a marker of interest (e.g. an antibody). The nanoparticle also has thiolated 
single strand oligonucleotides (also known as “barcode DNA”) attached to it. In the 
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presence of the marker, an aggregate of magnetic microparticle, receptor and gold 
nanoparticle forms, which is then isolated. After purification the oligonucleotides are 
cleaved using a reducing agent such as dithiothreitol and quantified. In this way 
previously undetectable levels of a specific target may be revealed.21, 22 This method 
has further been developed in many ways, including modifications by Nam et al. to 
make the analysis colorimetric.23 Here, targeted silica nanoparticles with barcode 
DNA attached are used to capture the target of interest. After isolation, the barcode 
DNA is cleaved and incubated with gold nanoparticles that target it, causing particle 
aggregation. The aggregation induces a red to blue colour change due to the difference 
in surface plasmon resonance of the nanoparticle aggregates (Figure 1.1). This same 
colorimetric change has since been applied to the detection of bacterial pathogens by 
the Gibson group, using a microarray of glycosylated gold nanoparticles to create a 
“QR” like read out specific for pathogenic lectins.24  
 
Figure 1.1: Visual explanation of the colorimetric “bio-barcode” assay developed by Nam et al. for the detection 
of interleukin-2. Image adapted from Nam et al.23 
Inorganic nanoparticles have also been widely explored in delivering therapeutics, due 
again, in no small part, to their relative ease of synthesis and high surface area to 
volume ratio.12 The volume of loading for an inorganic nanoparticle, though relatively 
high is limited to the surface area, this may however be enhanced by the use of 
mesoporous silica.25, 26  By producing a porous particle, not only is the accessible 
surface enhanced, properties such as pore size may be modified to further control the 
particle properties, such as drug release.27 
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1.1.2 Nanoparticles as Drug Delivery Agents 
 
Figure 1.2: Representation of challenges in using nanoparticles as drug delivery agents 
For use as drug delivery agents, organic nanoparticles of various forms have also been 
widely studied.28-30 The reasons for this plethora of research include the ability of 
organic nanoparticles to have many of their physical characteristics easily modified.1 
The particle properties also allow organic nanoparticles to deliver many potentially 
effective drugs that cannot be, or are difficult to use due to poor solubility and high 
toxicity in the body.10, 31, 32 Ideally, a drug molecule is bound to, or loaded into a 
biocompatible particle, which transports the drug to its site of action where it is 
released, and the polymer is subsequently metabolised and/or excreted.33 Each of these 
steps poses a challenge in creating a suitable drug delivery nanoparticle, summarised 
in Figure 1.2.  
Clinically the most commonly used organic nanoparticle systems for drug delivery are 
vesicles, primarily liposomes.34, 35 First reported in 1965 by Bangham et al. vesicles 
are self-assembled lamella structures surrounding an aqueous core, that resemble the 
cell membrane phospholipid bilayer.36 These systems were the first to gain FDA 
approval, for delivering doxorubicin (Doxil®, an antineoplastic) and Amphoteirin B 
(an antifungal).37, 38 They benefit from their facile synthesis (suspension of a suitable 
surfactant in water), the ease in which multiple drugs may be encapsulated 
simultaneously and the availability of previously approved materials for use.34, 39, 40 As 
such, not only are they one of the most successful nanotherapies, but remain at the 
forefront of biomedical nanoparticle research.41, 42 One of the down sides to the use of 
vesicles is their relatively short half-life in the body due to rapid clearance and immune 
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recognition. Strategies to overcome this issue have included the use of “self” cell 
membrane materials as extracellular vesicles and functionalisation with polymers to 
limit immune recognition.42-44 
Next to vesicles, protein nanoparticles are one of the most common clinically used 
nanoparticle formulations.34, 35 Protein nanoparticles are most commonly composed of 
a protein conjugated to a drug, in efforts to improve the drug’s formulation and 
pharmacokinetics. These have gained most use for the administration of hydrophobic 
cancer drugs.45 One of the earliest and well known examples of such a system is 
Abraxane® used to deliver paclitaxel.46 Previously paclitaxel was administered with 
the formulation vehicle Cremophor, now widely shown as toxic, and requiring co-
administration with antihistamines and steroids.47 Abraxane® combines paclitaxel 
with human serum albumin to produce a protein bound nanoparticle 130 nm in 
diameter, which has been shown to eliminate the need for a co-solvent and improve 
clinical results compared to paclitaxel alone.48 More recent developments have taken 
the concept further and produced self-assembling temperature responsive protein 
nanoparticles.49 Elastin is a protein known to possess a thermoresponsive self-
assembly, a chimeric cyclic peptide derived from it has been shown by McDaniel et 
al. to form nanoparticles in conjugation with hydrophobic drugs.50 The same group 
went on to show that a conjugate of the same cyclic peptide with doxorubicin could 
self-assemble, and showed a phase transition upon heating to between 39-42 °C. This 
improved its cytotoxicity against cancerous cells upon exposure to mild 
hyperthermia.51  
One of the most active areas of research into nanoparticle drug delivery is with 
polymeric nanoparticles, either as polymer-drug conjugates or polymeric vehicles for 
the controlled/targeted release of a drug.52-55 This is an area that at first glance has thus 
far failed to make a large impact in the clinic, however synthetic polymers in hybrid 
systems are now commonly on the market, albeit most commonly as poly(ethylene 
glycol) (PEG) conjugates such as Nuelasta, used to improve drug/biological drug 
solubility and circulation time.34, 56-58 The number of these systems only looks set to 
rise with the patents of many biological drugs expiring, and the FDA approving “bio-
similars” such as Fulphila in June 2018, the generic PEGfilgrastim equivalent of 
Nuelasta.59, 60 Nevertheless there continues to be a large amount of promising research 
using polymeric nanoparticles, not least due to the facile synthetic methods such as 
Chapter 1 
Andrew Lunn                                                                                                                   6 
 
emulsion polymerisation and polymerisation induced self-assembly (PISA), and the 
wide variety of functionalities and physical properties that may be imparted on the 
particle, which will be explored in depth later.  
Crucial to the clinical success of a polymer nanoparticle therapy is its safe and efficient 
clearance after its cargo has been delivered, and/or it has exerted its biological 
response.  Indeed one of the main drawbacks to polymeric nanoparticles being used in 
the body is their accumulation. Most studies in the area will report that after injection 
of a nanoparticle, bioaccumulation occurs majorly in the liver, and also the spleen, 
lungs and pancreas.62 Generally speaking a move towards biodegradable and 
responsive nanoparticles that can be cleared to avoid accumulation, seems necessary 
for larger polymeric architectures to fulfil their clinical potential in a variety of 
applications.63-66 Much of the work in this area has focussed on incorporating 
hydrolysable esters into the polymer backbone, with polymers such as poly(lactide) 
and poly(caprolactone).28, 66, 67 Other studies have focussed on preparing nanoparticles 
that are held together by responsive cross linkers, such as the work by Zhang et al. 
who reported the synthesis of polymeric nanoparticles based on the photosensitive 
monomers 2-nitrobenzyl methacrylate (NBMA).68 After producing a variety of 
particle morphologies they showed that UV irradiation was able to cleave NMBA 
moieties, resulting in polymeric carboxylic acid groups. This caused the previously 
hydrophobic particle core to become hydrophilic, inducing particle break up. The 
system was subsequently shown to potentially increase drug release in Henrietta Lacks 
(HeLa) cells. This strategy provides an interesting way of spatiotemporal controlled 
drug release, the use of UV light poses problems however due to poor tissue 
penetration, with IR light a more suitable option.69, 70 A stimulus endogenous to the 
body that has been explored to trigger particle break up and drug release, is the reactive 
oxygen species (ROS) hydrogen peroxide, found in increased levels in inflamed or 
cancerous tissues. Recent work from Sobotta et al. showed relevant concentrations of 
hydrogen peroxide to cause the break-up of particles with an N-acryloyl 
thiomorpholine (NAT) core, due to peroxide induced oxidation (Figure 1.3).61, 71 
Strategies such as this hold promise as release should only be triggered in pathological 
tissues, however the speed of the response is still slow, with break up occurring over 
a period of hours to days. Furthermore, many responsive particle systems have utilised 
pH as a stimulus to trigger particle break up. This may be an acidic pH accelerating 
ester hydrolysis, or again a solubility switch from hydrophobic to hydrophilic. 
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Polymers bearing amines are known to exhibit pH responsive behaviour, one specific 
example being poly(2-(dimethylamino)ethyl methacrylate) P(DMAEMA), known to 
exhibit a change in solubility from hydrophobic in basic/neutral environments, to 
hydrophilic in acidic ones due to protonation of its tertiary amine.72, 73 74 The change 
in solubility is rapid, proceeding over minutes to hours, and thus would be suitable for 
particle break-up in vivo. Such a pH shift is however found in many cells throughout 
the body, so without further targeting it would not necessarily confer a directed drug 
delivery. 
 
Figure 1.3: Graphical representation of the oxidative response of poly(N-acryloyl morpholine)-b-poly(N-acryloyl 
thiomorpholine) micelles switching from amphiphilic to hydrophilic in the presence of hydrogen peroxide. Figure 
adapted from original paper by Sobotta et al.61 
Nanoparticles present a promising way of delivering a wide range of drugs in a targeted 
manner. Their use has been widely studied, particularly in the area of cancer therapy. 
They also hold promise however for other disease states, particularly those where an 
accumulation of nanoparticles is favoured or where a specific targeting moiety is 
present.75, 76 
1.1.3 Drug Loading and Release 
The effective use of nanoparticles as drug delivery agents requires efficient loading of 
a drug into the nanocarrier and for the drug to be released at the site of action. The 
loading of a drug to a nanoparticle will typically be by an incorporative or an 
absorption/adsorption (ab/adsorption) method.77 Drug loading is generally 
characterised as loading content and loading efficiency, determined using Equations 
1.1 and 1.2.  
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𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 (𝑤𝑡%) =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
 × 100 
Equation 1.1: Equation for determining the percentage of drug loading achieved in a nanomedicine 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑓𝑒𝑒𝑑
 × 100 
Equation 1.2: Equation for determining the drug loading efficiency achieved in a nanomedicine 
The distinction between the two of these expressions is important. Drug loading 
describes the content of drug that will be found per mass of formulation, and therefore 
will dictate how much of the formulation will be needed to give a set dose.78 The 
loading efficiency however describes how much of the initial drug that was put in will 
remain in the final formulation. Poor loading efficiency is not necessarily a barrier to 
high drug loading, but is an important consideration in manufacturing.  
Loading of a drug through physical and electrostatic ab/adsorption, either into a 
polymer matrix or particle surface often gives poor loading efficiency, as the amount 
of drug that will enter into the nanomedicine is dictated by the partition coefficient 
between it and the solvent (usually water). As such, loading efficiencies of below 10% 
are common in the literature.79, 80 This poses issues with the large volume/mass of 
particle carrier that consequently has to be administered to achieve a therapeutic 
concentration of drug, raising questions surrounding toxicity and pharmacokinetic 
properties. The simple absorption of a drug is however an attractive method of particle 
loading due to its simplicity and broad applicability. Methods have been explored to 
improve the loading achievable; for liposomal formulations specifically, increasing the 
surfactant concentration, and incorporating other molecules such as cholesterol into 
the structure have been established to improve loading.81, 82 Work from Taylor et al. 
in the 1990’s demonstrated the benefit of incorporating cholesterol in the 
encapsulation of sodium cromoglycate.83 They showed a drug loading of 30.7% after 
50% cholesterol was added to the liposome particle. This was an increase of 112.7% 
compared to without the cholesterol. More generally, improving the solubility of the 
drug in the nanoparticle also enhances the drug loading: charge, pH and co-solvents 
(subsequently evaporated away) have all been employed in such a manner.81, 84, 85 To 
use such a method for the loading of a macromolecule, it has been shown by Calvo et 
al. that encapsulating the macromolecules at their isoelectric point provides for the 
greatest loading percent.86 Furthermore highly porous inorganic nanoparticles have 
been shown to be able to exploit ab/adsorptive methods of drug loading, due to their 
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extremely large surface area to volume ratio, being able to achieve a drug loading of 
between 30-60%.78, 87-89 One recent report from Jiang et al. showed quite remarkable 
drug loading to mesoporous glass.90 In this study, the mesoporous glass was 
functionalised with amino groups and subsequently loaded with gentamicin sulfate, 
the amino functionalisation increasing loading from 49% to 63% when compared to 
the non-functional equivalent. 
In an incorporative method of loading, the drug is added during the particle formation 
process. This can result in higher loading concentrations through matrix entrapment, 
and the homogeneous distribution of drug through the carrier also reduces the 
incidence of burst release.77 However, depending on the method of particle production, 
the stability of the drug or drug-conjugate must be considered during the synthetic 
method, particularly for biomolecules such as proteins that will denature when taken 
too far out of their natural conditions.91, 92 Spray drying has been used as a method for 
producing nano and microparticles where there are sensitive components, due to the 
short time an elevated temperature is required for solvent evaporation.93, 94  
Drugs loaded into nanoparticles using the previously described methods, typically 
suffer from poor spatiotemporal control over drug release, relying on desorption or 
matrix erosion as release mechanisms. These suffer from being dependant on relative 
solubility and diffusion rates in various body compartments, and can lead to 
inappropriate burst release of a drug.77, 78  
An effective strategy for gaining control over drug release, and retaining high drug 
loading, is to use a covalent linker to bind a drug to a polymer or particle.78 The bond 
used must however be able to break upon a stimulus relevant to the drug target 
environment, making their use less universal as a loading and release mechanism. The 
most common of those stimuli is pH, this is partly due to the convenient pH drop found 
in the cellular lysosome after endocytosis and the number of pH responsive bonds such 
as: acetals, imines, oximes and hydrazones to name a few.95, 96 One notable example 
of a pH responsive release was from Bae et al. who demonstrated the targeted delivery 
of adriamycin to cancer cells using a folate targeted polymeric micelles.97 Adriamycin 
was released upon a relevant drop in pH hydrolysing a hydrazone linker. Disulphide 
bridges have also been explored as covalent linkers for drugs, able to be broken upon 
exposure to a reducing environment, such as that found in the glutathione rich 
environment of a cancer cell.98-100  
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Figure 1.4: Graphical representation of the PEG-disulphide-camptothecin linked vesicles prepared by Shen et al. 
co-loaded with doxorubicin, providing a reductive responsive drug delivery agent. Image adapted from original 
paper.101 
A good example of a disulphide being used effectively in controlled nanoparticle 
release is that of Shen et al.101 Either one or two camptothecin moieties were linked to 
a short PEG chain via a disulphide bridge with drug loading of camptothecin up to 
58%, and self-assembled into vesicles (Figure 1.4). The vesicles were further loaded 
with doxorubicin via encapsulation up 18.5% w/w. Vesicles with camptothecin alone 
were shown equivalent to free camptothecin in vitro. With co-loaded doxorubicin 
however a vastly improved cytotoxic effect on ovarian and breast cancer cells was 
demonstrated.  This study showed the potential for efficient drug loading and release 
using a responsive covalent linker, it further showed in vitro the potential to use two 
different drug loading methods effectively to produce a synergistic biological 
response.   
In summary, the method of loading and release of a drug in a nanoparticle must be 
considered on a case by case basis. If a prolonged systemic release is desired, then 
simple ab/adsorption and desorption methods may be best where solubility allows, due 
to their simplicity and non-specific release profiles. If, however a specific site of 
release is required, a responsive release may be preferred where there is a stimulus 
specific to the site of action that can be exploited to cause drug release.  
1.2 Biological Influence of Nanoparticle Properties  
One of the major benefits to using nanoparticles for biomedical applications, is the 
wide variety of physical properties it is possible to modify on them. Each of these can 
be used to tailor a nanoparticulate system for a specific use, and an understanding of 
their biological impact is crucial in designing a successful drug delivery agent.   
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1.2.1 Particle Size  
The size of a particle can greatly influence its biological effect, this is most obvious in 
a simple example such as that of an eye drop. Particles under 10 μm in diameter are 
not detectable, whilst over that a gritty uncomfortable sensation will be felt on the 
eye.102 Particle size is also known to have an influence on deposition in the lungs, with 
smaller particles being able to deposit further towards the alveoli.103 Reducing the size 
of particles has been shown in liposomes and gold nanoparticles (< 10 nm) to increase 
the efficacy in crossing the blood brain barrier.104, 105 Moreover, particle size can be 
changed to modify the bio distribution across all organs and tissues after injection. 
With particle sizes under 5 nm showing renal clearance, inflamed tissues retaining 
particles over 80 nm, and ultimately most particles showing accumulation in the liver, 
spleen and lungs (Figure 1.5).106-109  
 
Figure 1.5: Representation of the effect particle size has on the biodistribution of a nanoparticle, showing 
accumulation in certain pathologies/tissues 
The influence of particle size on cellular uptake has also been extensively investigated, 
it is however difficult to come to many firm conclusions regarding the influence of 
size alone on endocytosis, as the results show great variation between studies and 
uptake mechanism.110, 111 Some size limits do recur in the literature, for example 
immune cell lines have been shown to endocytose larger particles more efficiently 
(diameter > 100 nm), whereas studies in various non-immune cells (e.g. HeLa) have 
shown a diameter of 50 nm to be optimal for cell uptake.110, 112-114 To fully understand 
the influence of particle size however, it must be considered with particle morphology.  
1.2.2 Particle Morphology  
Nanoparticles are also produced in a variety of different morphologies, including: 
spheres, vesicles, rods and worms.115 Non-spherical morphologies, with a high aspect 
ratio have been shown to exhibit prolonged circulation times. One widely cited study 
by Geng et al. shows the circulation of filamentous particles to be up to a week, 
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compared to a vesicular equivalent of only two days.116 They further report enhanced 
anti-tumour activity when loaded with paclitaxel. One extensive study by Decuzzi et 
al. used spherical, quasi hemi-spherical, discoid and cylindrical silica nanoparticles in 
mice, and determined the accumulation in various organs.117 Spheres above 700 nm in 
diameter were shown to have reduced accumulation with increasing size, interestingly 
disc shaped particles were shown to have in increased accumulation in all organs 
except the liver, a phenomenon the authors attribute to the differing rotational inertia 
and increased adhesion in most organs except to Kupffer cells in the liver. Cylindrical 
particles were also shown to have the largest increase in deposition in the liver, which 
may also partly explain the prolonged half-life of cylinders seen in vivo. Furthermore, 
cylindrical nanoparticles may have an advantage in tumour accumulation, due to 
tumbling in blood flow pushing them towards the blood vessel walls. This results in 
increased extravasation at sites of increased permeability, such as a tumour.118, 119 
Morphology has also been shown to influence interaction with cells and 
internalisation.111 A spherical morphology has been shown optimal for immune cell 
uptake, providing further reasons for the increased circulation time that non-spherical 
morphologies exhibit compared to spherical equivalents.120, 121 In non-immune cells 
above 100 nm in diameter, a non-spherical morphology (higher aspect ratio) has been 
shown to cause an increased cellular uptake. Gratton et al. reported that with increasing 
aspect ratio a corresponding acceleration in particle uptake was seen in HeLa cells.122  
Conversely Qiu et al. and Chithrani et al. both report that in gold nanoparticles under 
100 nm a spherical morphology becomes optimal.116, 120, 122-124   
1.2.3 Particle Surface Charge  
The surface charge of nanoparticles has also been widely studied, generally dividing 
particles into: anionic, neutral and cationic. Broadly speaking cationic particles have 
been shown by many studies to be internalised into various cell lines to a greater extent 
than a neutral or anionic equivalent.125 110 Perumal et al. demonstrated this effect well 
using poly(amidoamine) dendrimers with different surface functionality, providing 
positive, neutral and negative charge (amines, hydroxyls and carboxylic acids 
respectively).126 The dendrimers were shown, in A549 (lung epithelial carcinoma) 
cells, to be taken up by distinctly different mechanisms, with anionic dendrimers 
mainly being internalised via clathrin mediated endocytosis and neutral and cationic 
counterparts via non-specific direct interactions. In the case of positive dendrimers and 
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more generally particles, the increase in uptake is presumed to be due to electrostatic 
interactions between the cationic particle surface and the anionic cell surface.127 This 
same interaction is also responsible however for the widely reported increase in 
cytotoxicity of cationic nanoparticles (Figure 1.6).128, 129   
 
Figure 1.6: Graphical representation of the major effects of particle surface charge: neutral and anionic particles 
with reduced uptake but improved toxicity profiles, cationic particles with increased uptake but poor toxicity 
profiles 
1.2.4 “Stealth” Particle Coatings 
After administration a nanoparticle must avoid excretion and evade immune clearance, 
the surface functionalisation of a nanoparticle is an important property in achieving 
this. Indeed most efforts to evade recognition and capture by the immune system focus 
on the use of “stealth” polymers.130-132 First introduced in the 90’s, the typical 
protective or “stealth” polymer that is approved for use is PEG, used coupled to a 
protein to prolong circulation time (PEGylation) and as a coating for many 
nanoparticles.133-136 A study from the Müller group on the effect of the PEG corona 
thickness and density found that increasing the molecular weight and density of PEG 
at the particle surface reduced protein adsorption. They further found that they could 
not completely stop adsorption up to the maximum size and density of PEG tested.131 
More recently, concerns have been raised about the immunogenicity of PEG, with 
many studies including those from the Kiwada group showing the production of anti-
PEG antibodies after injection of PEGylated liposomes.69, 137, 138 Despite recent 
concerns, PEG remains the polymer of choice of pharmaceutical companies to produce 
a “stealth” coating and prolong in vivo circulation time of a therapeutic. However, one 
candidate group of polymers to replace it is poly(2-oxazolines) (POx).139-144 Research 
from the Hoogenboom group recently demonstrated the comparative pharmacokinetic 
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behaviour of radioactively labelled PEG and POx of various molar masses in mice.145 
POx showed similar pharmacokinetic properties, with a cut off for renal clearance at a 
polymer size of around 40 kDa. It was further shown that polymer chain length was 
the dominant property affecting biodistribution over polymer molecular weight. Han 
et al. reported the ability of POx based micelles to solubilise a wide range of 
chemotherapeutics (pactitaxel, docetaxel, 17-allylamino-17-demethoxygeldanamycin, 
etoposide, and bortezomib) up to 50% w/w drug loading and the enhancement of 
cytotoxic effect in vitro.146 Studies on POx in vivo are still few, He et al. published the 
use of triblock POx based micelles (P((MeOx)33-b-(BuOx)26-b-(MeOx)45) to solubilise 
and successfully deliver a variety of taxoids, to nude mice.147 The study reported 
modest improvements in reducing tumour growth on current chemotherapeutic 
formulations, but importantly that the POx polymer was non-toxic.  
Even with the concerns over immunogenicity, particle surface functionalisation with 
PEG represents one of the most successful nanoparticle strategies in biomedicine. It is 
unlikely to be replaced as a technology until a potential replacement such as POx can 
show superiority in in vivo tests.  
1.3 Targeted Nanoparticles   
Often the rationale for using a nanoparticulate drug delivery agent is to increase the 
concentration of an active pharmaceutical ingredient (API) at the site of action, relative 
to the rest of the body. In doing so the API’s clinical effect is designed to be increased 
whilst minimising systemic side effects and overall dose. To do this the API loaded 
nanoparticle must be able to reach the site of action in a high concentration. As 
previously explained, a particle system may be coated such that it is protected from 
clearance to help achieve this. However a particle may also be targeted to direct it to a 
site of action either through active or passive mechanisms.148-150  
1.3.1 Passive Targeting  
The targeting of a site of action with a nanoparticle need not always be an active 
process, passive targeting mechanisms may first be exploited.77, 151 Certain disease 
states lend themselves to the use of nanoparticulate therapy. As previously stated, 
when injected most nanoparticles will eventually accumulate in the liver.152, 153 Whilst 
this is a problem for targeting elsewhere in the body, for delivery of drugs for hepatic 
disease states such as cirrhosis or cancerous metastases, this is a fortunate 
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accumulation that has been widely exploited.154, 155 One example by Canup et al. 
delivered CD98 siRNA to the liver in a simple poly(lactic acid) (PLA)/poly(vinyl 
alcohol) (PVA) nanoparticle, prepared by a solvent evaporation technique.156 In this 
study particle accumulation in the liver led to an in vivo reduction in all biomarkers for 
non-alcoholic fatty liver disease, such as pro-inflammatory cytokines. Another widely 
discussed and potentially controversial effect nanoparticles can take advantage of for 
passive targeting is the enhanced permeability and retention (EPR) effect displayed by 
solid tumours.31, 157-159 The theory of the EPR effect suggests that fast growing tumours 
with increased metabolism depletes the surrounding tissue of oxygen. This stimulates 
the release of growth factors such as vascular endothelial growth factor (VEGF), 
causing the local over production of blood vessels. The vessels produced have thin 
walls without the tight endothelial junctions usually seen, and thus provide a sieve that 
allows the escape of nanoparticles under 100 nm into the tumour environment where 
they can accumulate (Figure 1.7).157, 160  
  
 
Figure 1.7: Graphical representation of the increased tumour vasculature and loose endothelial junctions, causing 
the EPR effect and the retention of nanomaterials in the tumour environment 
The EPR effect had been heralded as a silver bullet for all solid tumours, it now appears 
however that the benefits of this effect are less pronounced than had been hoped. 
Indeed work by Chauhan et al. showed that repairing the poor tumour vasculature 
improved the accumulation of nanoparticles under 12 nm in diameter, however 
reduced the accumulation of 125 nm particles.161 The effect still holds promise for 
Chapter 1 
Andrew Lunn                                                                                                                   16 
 
certain tumour types such as carcinomas, in particular the passive targeting of the EPR 
effect may be effectively coupled with an active targeting ligand.157, 162, 163  
1.3.2 Active Targeting 
Active targeting is often achieved by decorating the surface of a particle with a 
targeting ligand. The ligand may be specific for a receptor that is either exclusively 
expressed, or overexpressed at a site of interest.164, 165 The targeting groups possible 
are diverse, including: small molecules and short peptides, to larger targeting groups 
such as immunoglobulins.166-172  
The earliest reports of targeted nanomedicines were in 1980 and used monoclonal 
antibody (mAb) functionalised liposomes.173, 174 The first, by Heath et al. conjugated 
a mAb to a liposome surface, through an imine bond between primary amines on the 
mAb and aldehydes on the vesicle.175 Using these liposomes an 80% association of 
liposomes to erythrocytes was achieved. Since then mAb’s have been licenced in 
dozens of formulations, perhaps most notably rituximab, targeting CD20 in the 
treatment of non-Hodgkin’s lymphoma, which has gone on to revolutionise other 
disease states such as rheumatoid arthritis.176 Monoclonal antibodies are still widely 
used in research, such as in the recent article from Gu et al. who reported the use of a 
mAb functionalised chitosan nanoparticle to deliver siRNA for the inhibition of HIV 
replication in astrocytes.177 This work showed a significant increase in the level of 
internalised siRNA in relevant astrocytes and blood brain barrier cells, however did 
not describe any in vivo tests to confirm the ability of the particle to cross the blood 
brain barrier. Nevertheless it shows the continuing potential of mAb’s in targeted 
therapy.  
The use of mAb’s is not without its drawbacks however, they are large proteins (ca 
150 kDa and 15 nm diameter) that can be difficult to use in manufacturing processes 
due to stability issues, and can pose immunogenic issues.178  
Short peptide sequences, typically 10-15 amino acids in length have been explored as 
alternative targeting agents, to retain the specificity of mAb’s and also address the 
manufacturing and stability issues.165 The use of combinatorial libraries has led to the 
discovery of many peptide sequences that can effectively target specific sites in the 
body.179 The most widely reported peptide used for targeting, is arginylglycylaspartic 
acid (RGD), which binds to αv integrin receptors.180  There are various types of αv 
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receptor to which RGD will bind, however αvβ6 and αvβ8 that specifically activate 
the TGFβ1 pathway have been shown to be upregulated in aggressive cancerous 
cells.181-183 Gray et al. exploited this over-expression by coating liposomes with the 
αvβ6 specific peptide H2009.1, and showed a six fold increase in affinity of a tetramer 
bearing liposome over a monomeric equivalent.184 Various other targeting peptides 
have shown promise, one of which is Cys-Arg-Glu-Lys-Ala (CREKA). Zhao et al. 
showed the potential of CREKA, using it to functionalise a polyamidoamine 
dendrimer, showing enhanced glioblastoma targeting in the brains of nude mice.185  
Small molecules have also widely been studied for their ability to produce targeted 
nanoparticles due to their: convenient manufacture and handling, wide range of 
efficient conjugation chemistries and favourable immunological properties.165, 186 The 
most widely used small molecule used for nanoparticle targeting is folic acid and its 
derivatives.187 The cell surface folate receptor is an attractive target, as from circulation 
it is not accessible to targeting ligands, except in certain tumour types such as those in 
the ovary, kidney and lung.188, 189 Work from Muraldiharan et al. showed the efficient 
delivery and increased cytotoxic effect of siRNA acting on “human antigen R” in 
folate receptor overexpressing lung cancer cells, delivered in a folate functionalised 
liposome.190 More recently Alibolandi et al. reported the dual delivery of doxorubicin 
and cadmium quantum dots (QD) in the hydrophobic bilayer and aqueous core 
respectively of a folate conjugated PEG-Poly(lactic-co-glycolic acid) polymersome.191 
This study demonstrated the sustained release of doxorubicin and QD’s over 12 days 
and the ability to deliver both an imaging and therapeutic agent together in vitro. 
Further in vivo studies however showed only a modest increase in tumour targeting 
compared to a non-folate equivalent polymersome, with accumulation in multiple 
organs magnitudes higher than that seen in the tumour.  
The other main class of targeting small molecules used is sugars, which are known to 
be endocytosed after preferential binding to specific cell surface lectins (or 
carbohydrate binding proteins).54, 192-194 The presentation of particular sugars or sugar 
sequences has been shown able to target various disease states including cancer and 
infection.195-197 The individual binding of a sugar to a lectin is weak, but the 
presentation of sugars on a nanoparticle as targeting agents enables them to take 
advantage of the “cluster glycoside effect” whereby a high density of ligands increases 
the overall binding affinity.198 To take advantage of this effect, and for ease of 
synthesis, sugars are often used as glycopolymers.199, 200 Ting et al. demonstrated the 
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ability of a glucose functionalised glycopolymer to aggregate with the tetravalent plant 
lectin concanavalin A.195 Furthermore the glycoparticles were shown to increase 
Escherichia coli aggregation through interactions with fimH when compared to the 
linear counterpart, showing the potential to target infective bacteria using 
glycoparticles (Figure 1.8). 
 
Figure 1.8: Graphical abstract showing the aggregation of poly(2-(methylacrylamido)glucopyranose) coated 
nanoparticles made via RAFT emulsion polymerisation with concanvalin A and E. coli. Image adapted from 
original publication by Ting et al.195 
There are various reports of the in vitro delivery of small molecules such as 
doxorubicin and proteins such as insulin using glyconanoparticles.201-205 Importantly 
though the presence of sugars at the surface of nanoparticles has been shown to 
enhance in vivo targeting, typically to cancerous or immune cells with mannose, 
galactose and glucose.206-214 One study of particular interest when considering the 
design of a targeted glyconanoparticle is that of Wijagkanalan et al. who demonstrated 
the in vitro and in vivo effect of varying the density of mannose presented on 
macrophage cellular uptake.215 Crucially they showed a statistically relevant increase 
in macrophage uptake of mannose decorated liposomes over bare liposomes in a 
concentration and time dependant manner both in vitro and in vivo. They further show 
a positive correlation between mannose functionalisation and cellular uptake. 
Interestingly, there was no statistical difference between bare liposomes and those with 
only 2.5% mannose functionalisation. This has implications on the design of targeted 
nanocarriers in general, and more specifically highlights the importance of the cluster 
glycoside effect in efficient lectin targeting.  
In summary, nanoparticles are of considerable interest for a variety of biomedical 
applications. There remain many issues with their use, particularly in translation from 
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the lab to the clinic, with toxicity, accumulation and cost issues hampering their 
progress. Further fundamental studies on the biological effect of different types of 
nanoparticle are required, and cheaper manufacturing methods, particularly for 
functional polymeric nanoparticles to progress beyond the simple PEGylation of 
biomolecules and liposomes. 
1.4 Emulsion Polymerisation  
A simple way of synthesising a variety of nanoparticles and allowing modification of 
many of the properties previously discussed is via emulsion polymerisation. Emulsion 
polymerisation is a heterogeneous radical polymerisation that is usually performed in 
water, producing a polymeric latex, and is the most widely used disperse 
polymerisation technique.216, 217 
 
Figure 1.9: Example kinetics of a classic emulsion polymerisation, cartoons within depict the major component of 
each stage. Stage I: particle nucleation, Stage II: polymer and particle growth, Stage III: consumption of remaining 
monomer and production of final latex 
A standard phase emulsion polymerisation takes place with water as the continuous 
phase and an “oil” as the suspended phase. In the case of an emulsion polymerisation 
the oil phase will be a liquid monomer that is immiscible with water. Typically the 
monomer will be suspended through the water with an excess of a surfactant such as 
sodium dodecyl sulphate (SDS), with only a small concentration of monomer being 
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dissolved in the aqueous phase. The excess surfactant will self-assemble, usually into 
a micellar form and crucially, due to their abundance and size, have a surface area far 
larger than that of the stabilised monomer droplets. A water soluble initiator is also 
introduced, such as potassium persulphate (KPS). The reaction mix is, under an inert 
atmosphere and with efficient stirring, heated to produce radicals (Figure 1.9).218  
1.4.1 Emulsion Polymerisation Kinetics  
The idea that polymer growth could occur within a growing latex particle was first 
introduced in the 1940’s by Harkins.219 This was later developed by Smith and Ewart 
into the eponymously named “Smith-Ewart” theory, which has formed the basis for 
most mechanistic understandings of emulsion polymerisation ever since.220-222 Based 
on this theory, an emulsion polymerisation may be thought of in three stages. 
In stage I of the emulsion process, particle nucleation occurs. The aqueous radicals 
polymerise with the small concentration of dissolved monomer, the growing oligomer 
may terminate in the aqueous phase as a surfactant or grow until it reaches a critical 
length known as a Z-mer. The Z-mer is surface active and will insert into a hydrophobic 
phase usually a surfactant micelle. The Z-mer may continue growing in the aqueous 
phase and reach a length where it will collapse in on itself like a surfactant (self-
nucleation) this is a J-mer. This is more typical of less hydrophobic monomers. To 
produce particles with a narrow and monodisperse distribution of diameters, this stage 
of the emulsion polymerisation is critical, and particle nucleation must be fast, with all 
particles starting growth at around the same time.216  
Stage II of the emulsion polymerisation is where there is linear growth of particles as 
monomer in the nucleated particles is consumed by the growing polymer and 
replenished from the large monomer droplets by diffusion through the aqueous phase. 
This gives an emulsion polymerisation one of its benefits, the compartmentalisation of 
the radicals. This allows for a locally high concentration of monomer, producing a 
pseudo-bulk reaction and a very fast rate of polymerisation. In some systems where 
the kp is high and/or the particles very small, the kinetics can be thought of as 
“one/zero”, statistically meaning that half of all particles are growing at any one time. 
Butyl acrylate typically shows this “on/off” kinetics, where it is only likely for there 
to be one propagating radical per particle, as upon the insertion of another radical they 
are in such close proximity they will almost immediately terminate each other. 
Depending on the system, particles may also grow in this stage by coagulative 
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nucleation, where primary growing particles aggregate together to form larger 
secondary particles. If the monomer is too hydrophobic and cannot diffuse fast enough 
through the water to match the rate of polymerisation, this slows the polymerisation 
and is deemed “diffusion limited”.216 
The rate of polymerisation per particle at this stage can be determined by Equation 1.3. 
This assuming that the polymerisation is not diffusion limited where ?̅? is the average 
number of radicals per latex particle.223 
𝑅𝑝 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 =  𝑘𝑝 ∙ [𝑀]𝑝 ∙ (
?̅?
𝑁𝐴
) 
Equation 1.3: Average rate of polymerisation per particle in an emulsion polymerisation. kp = rate of 
polymerisation coefficient, [M]p = Concentration of monomer in a particle, ?̅? = average number of radicals per 
particle and NA = Avagadro’s number 
From this equation the average rate of polymerisation at stage II for the whole system 
may be determined by multiplying by the number of particles in the system.223 
(Equation 1.4) 
𝑅𝑝 =  𝑘𝑝 ∙ [𝑀]𝑝 ∙ (
?̅?
𝑁𝐴
) ∙ 𝑁𝑝 
Equation 1.4: Average rate of polymerisation in an emulsion polymerisation. kp = rate of polymerisation 
coefficient, [M]p = Concentration of monomer in a particle, ?̅? = average number of radicals per particle, NA = 
Avagadro’s number and Np = number of particles 
Although these equations would hold for stage I and III of an emulsion polymerisation, 
in practice, due to nucleation, changes in the number of particles and decreasing [M]p, 
it is difficult to apply them in stage III. Many other factors will also affect the kinetics 
even in stage II, such as desorption and chain transfer. However if Smith-Ewart case 
2 conditions and “on/off” kinetics are assumed, the rate of polymerisation may be re-
arranged to Equation 1.5.223  
𝑅𝑝 =  
𝑘𝑝 ∙ [𝑀]𝑝 ∙ 𝑁𝑝
2𝑁𝐴
 
Equation 1.5: Average rate of polymerisation in an emulsion polymerisation. kp = rate of polymerisation 
coefficient, [M]p = Concentration of monomer in a particle, NA = Avagadro’s number and Np = number of particles 
If the rate of radical formation in moles is known (ρi) then the average rate of entry to 
a particle is determined by Equation 1.6.223 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡𝑖𝑜𝑛 = 𝑁𝑝/𝜌𝑖𝑁𝐴 
Equation 1.6: Average rate of radical insertion in an emulsion polymerisation. Np = number of particles, ρi = molar 
radical formation and NA = Avagadro’s number 
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As the rate of monomer addition to a propagating radical is determined by kp[M]p, this 
may be combined with Equation 4 to determine the number average degree of 
polymerisation (?̅?𝑛). This assumes negligible chain transfer and that the radical 
insertion species is smaller than the existing propagating radical in a particle (Equation 
1.7).223 
?̅?𝑛 =  𝑘𝑝 ∙ [𝑀]𝑝(𝑁𝑝/𝜌𝑖𝑁𝐴) 
Equation 1.7: Number average degree of polymerisation in an emulsion polymerisation (?̅?𝑛). kp = rate of 
polymerisation coefficient, [M]p = concentration of monomer in particle, Np = number of particles, ρi = molar rate 
of radical formation and NA = Avagadro’s number 
Looking at Equation 1.6 and 1.7 the only common factor that can be readily 
manipulated to change both the rate of polymerisation and number average degree of 
polymerisation is the number of particles. By increasing the number of particles 
(typically by increasing surfactant concentration) the growing radicals are further 
compartmentalised reducing the chance of interaction. This both increases the 
polymerisation rate and the molecular weight of the final polymer.   
Stage III of an emulsion polymerisation occurs when the monomer droplets have been 
exhausted and only the monomer that is swelling the particles remains. Further, 
undesirable particle growth may happen as the remaining monomer is polymerised and 
coagulation between particles continues to occur, causing a slight drop in number of 
particles. The polymerisation rate typically plateaus at this stage, particle diameter may 
show a final rapid increase however, with increased coagulation. The end of this stage 
results in the final latex.  
This technique is widely used on a multi tonne scale across industry and on a smaller 
scale in many labs. Due to the compartmentalisation of radicals, emulsion 
polymerisation benefits from fast kinetics and can produce high molecular weight 
polymers with short reaction times, typically 2-3 hours.224 One of the other features 
that makes emulsion polymerisation an attractive process is that it is performed in 
water. Not only is this cheap and non-toxic, it has a high specific heat capacity making 
the reactions safer. As the product is dispersed through water, the final product will 
still have the viscosity of water regardless of polymer chain length (providing that the 
total solids contents do not exceed 55-60%).225 The final latex may be used without 
further modification for many applications, or the water evaporated to obtain the bulk 
polymer.220, 226 
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However for applications in the medical field the presence of a surfactant such as SDS 
is undesirable and must be removed, a task that is arduous and requires extensive 
dialysis. The use of particles made in such a way is also limited, as their surface 
properties are only modifiable by the initiator used. With the goal of overcoming these 
issues of surfactant and surface properties, a number of controlled radical emulsion 
polymerisation techniques have been researched. Controlled radical polymerisation, 
producing a “pseudo-surfactant free” emulsion system, has been at the forefront of 
what can be achieved with an emulsion polymerisation. The first instance of a 
controlled radical emulsion polymerisation utilised nitroxide mediated polymerisation 
(NMP), more recent efforts however have focussed on the use of reversible addition 
fragmentation chain-transfer (RAFT) polymerisation.216, 227-231 Before considering 
RAFT emulsion polymerisation, RAFT polymerisation will be introduced in more 
general terms.  
1.4.2 Reversible Addition Fragmentation Chain-Transfer Polymerisation  
Reversible addition-fragmentation chain-transfer (RAFT) polymerisation is a 
reversible deactivation radical polymerisation (RDRP) technique, developed at the 
Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia, 
which uses a thioester based CTA known as a RAFT agent, of the general structure 
shown in Scheme 1.1, which are typically dithioesters, trithiocarbonates or 
xanthates.232 
 
Scheme 1.1: The general structure of a RAFT agent, showing stabilising Z-group and re-initiating R-group. 
RAFT polymerisation is a standard free radical polymerisation undertaken in presence 
of a CTA, which can reversibly transfer between growing chains and provide excellent 
control of polymer dispersity. The degenerative chain transfer process of RAFT agent 
from chain to chain permits to keep a majority of chains living, with the number of 
terminated chains, which cannot further chain-extend, being directly linked to the 
number of initial radicals produced during polymerisation. To ensure optimal 
polymerisation, producing a polymer with a narrow molecular weight distribution and 
high chain end fidelity, the choice of RAFT agent is key. The R-group must be a good 
leaving group able to fragment and re-initiate polymerisation at a similar rate to the 
monomer being used and as such often resembles the structure of a monomer. The Z-
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group is chosen for its ability to stabilise the RAFT intermediate adduct. The RAFT 
polymerisation process consists of initiation, propagation, chain transfer (as pre-
equilibrium, re-initiation and main equilibrium) and minimised termination. The full 
RAFT reaction scheme is shown in Scheme 1.2.  
Initiation, propagation and termination proceed as in a standard free radical 
polymerisation. During the pre-equilibrium a growing polymer radical reacts with a 
RAFT agent forming an intermediate adduct, which may fragment towards the original 
polymer or R-group. If the adduct fragments towards the R-group, this is deemed the 
re-initiation step, and the R-group will then initiate monomer polymerisation. Once all 
of the RAFT agent has re-initiated and been consumed, the main equilibrium occurs. 
All of the growing chains rapidly interchange with the RAFT agents, and spread evenly 
amongst them, statistically facilitating even chain growth and a narrow molecular 
weight distribution.232  
 
Scheme 1.2: General RAFT mechanism, termination shown as bimolecular termination, however 
disproportionation is also possible 
One of the major benefits of RAFT polymerisation, is that it follows kinetics similar 
to free radical polymerisation, including a relatively fast rate of polymerisation. RAFT 
polymerisation is also a favoured technique due to its versatility. Polymerisations may 
be performed in a wide range of solvents, with many vinyl monomer types and it is 
tolerant to many functional groups. However to minimise termination events the 
amount of initiator used is reduced as low as is possible without causing excessive 
slowing the rate of polymerisation. Other considerations when using RAFT 
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polymerisation include that no one RAFT agent is able to polymerise all monomers 
and must be carefully matched to the monomer used. Furthermore the resulting 
polymers contain a RAFT end group that may be undesirable for various applications. 
It is no surprise then, that various methods for RAFT end group removal have been 
developed. These have been widely reviewed and include: aminolysis, thermolysis, 
radical removal and hetero Diels-Alder reactions.233, 234 
1.4.3 RAFT Emulsion Polymerisation  
RAFT Emulsion Polymerisation, takes a standard RAFT polymerisation, with its 
associated benefits, and performs it within the mechanism of an emulsion 
polymerisation, (Figure 1.10) and was first proposed by Hawket et al.235   
In this technique, a small amphiphilic di-block copolymer, typically less than 30 
monomer units long is synthesised via RAFT solution polymerisation.236 The 
synthesised di-block copolymer after purification is suspended in water, whereupon 
(due to its amphiphilic nature) it forms micelles with RAFT CTA’s embedded within 
them.237  
 
Figure 1.10: Simplified representation of RAFT emulsion polymerisation 
With the appropriate hydrophilic initiator and hydrophobic monomer, these can then 
be chain extended using an emulsion polymerization. This results in a colloidally 
stable particle formation, which can be used as a latex, if desired, or further processed 
to leave the bulk polymer. Latexes synthesised in this way, should not only have a 
narrow particle size distribution, but the constituent polymers will also benefit from 
having controlled molecular weights and a low dispersity (Đ), having undergone 
degenerative chain transfer. As the RAFT di-block acts as the stabilising surfactant, 
when it is chain extended during the polymerisation it is covalently bound to the 
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resulting particles.238, 239 Not only does this eliminate the need to use a charged free 
surfactant like SDS, it also imparts any functionality from the hydrophilic block of the 
original di-block onto the surface of the final particles. This allows for modification of 
the particle shell with any hydrophilic monomer suitable for RAFT polymerisation, 
and the particle core to be tuned with any monomer suitable for RAFT emulsion 
polymerisation. A good example of this was shown by Ting et al, where a nanoparticle 
with a glucose shell was produced using a RAFT emulsion polymerisation.195 
As with any technique, RAFT emulsion polymerisation has its drawbacks.240 The 
synthesis of each individual di-block copolymer is relatively time consuming and 
expensive. This may be improved by starting the emulsion polymerisation from a 
hydrophilic polymer, forming the di-block in-situ, making the reaction one pot and 
removing intermediate purification. The resulting particle will also have the RAFT 
agent embedded within its core, something that may pose licencing issues for 
biomedical applications. On top of these drawbacks, few RAFT agents are being 
produced in large enough volumes to make a product using them commercially viable. 
The last of these issues may well change soon with the expiration of many RAFT 
patents.240, 241 Strategies to produce controllable and functionalised polymeric 
nanoparticles in a cheap and scalable way though, still remain a useful area of research. 
1.4.4 Surfactant Free Emulsion Polymerisation   
It is known that if an emulsion polymerisation monomer is hydrophilic enough, it may 
grow past the length of a Z-mer to a J-mer.223 At this increased length the oligomer 
may act as a surfactant like molecule in its own right with the initiator head group 
providing the hydrophilic part, and one or many of these chains may self-nucleate 
without the need for additional surfactant. Work in the 1970’s focussing on styrene, 
before the advent of controlled radical polymerisation techniques, particularly from 
Goodall, Wilkinson, Hearne and Roe exploited this in what was commonly deemed 
then “soap free” emulsion polymerisation.242-244 In this work a classic emulsion 
polymerisation system was used, however the surfactant was not added, leading to a 
self-nucleating system of J-mers. It was found that the self-nucleation of particles with 
a sufficiently charged initator head group, such as potassium persulfate, was able to 
stabilise growing polymer particles. In these surfactant free emulsion polymerisations, 
particle growth was observed to proceed to a large extent by coagulative nucleation as 
well as internal polymer growth.245 The initiators used in this technique to be able to 
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access particle diameters below 100 nm typically have a very strong charge to improve 
stability, there may still be concerns surrounding the biocompatibility of these head 
groups.246-248 Attempts to use this technique with a less charged initiator typically 
result in particles over 100 nm up to microns in diameter.249, 250 Limited work has 
focussed on using a surfactant free technique with a hydrophilic co-monomer such as 
acrylic acid to help access sub-100 nm particle diameters.245, 251-253 The potential for 
the hydrophilic co-monomer to be incorporated into the final latex particle, potentially 
providing a facile route to functionalisation remains underexplored, a proposed 
mechanism for this is summarised in Figure 1.11. 
 
Figure 1.11: Proposed emulsion polymerisation mechanism in a free radical surfactant free emulsion 
polymerisation, including a hydrophilic co-monomer 
Given the benefits of functionalised nanoparticles, it is unsurprising that there has been 
a plethora of research into their use as both diagnostic and drug delivery agents as 
previously discussed. Most of the nanoparticle based products that are actually being 
used in a clinical setting are still liposomal formulations.35 However with the right 
fundamental study, addressing of current limitations and realistic translation of 
synthetic techniques, polymeric nanoparticles could still have a positive impact on 
therapeutics. 
1.5 Motivation 
Nanoparticles represent an interesting avenue of biomedical research, particularly as 
drug delivery agents. Strategies to synthesise clinically viable polymeric nanoparticles 
however are still in need of full development. Emulsion polymerisation represents one 
potential way of addressing that need, as a versatile technique with the potential to 
produce complex systems to an industrially relevant scale. 
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Existing strategies to produce functional nanoparticles with controllable size have 
focussed on controlled radical polymerisation techniques such as RAFT in an emulsion 
system. These systems are of great use in understanding fundamental properties of 
nanoparticles, such as the influence of core and shell characteristics on the biological 
properties of a particle. They are however potentially limited in scale and applicability 
by cost and challenges in gaining medical approval. Surfactant free emulsion 
polymerisation techniques may provide a solution to this issue. As a technique 
however it has until now, mainly been shown to be able to reliably control the size and 
charge of latex particles, with some reports of their surface functionality. 
There is therefore still a need for cheap and scalable techniques to produce functional 
nanoparticles for a variety of uses. The work presented in this thesis will first focus on 
the preparation of glycosylated nanoparticles via RAFT emulsion polymerisation and 
use them to develop a DLS based technique to study lectin induced aggregation. 
Similar particles will be produced via a free radical surfactant free emulsion 
polymerisation, initially to establish if this technique can produce surface 
functionalised particles with the addition of a functional hydrophilic glycomonomer. 
The resulting glycoparticles will then be used to investigate the effect of particle core 
glass transition temperature on lectin induced aggregation. Finally the same surfactant 
free technique will be used to prepare a macrophage targeted, drug loaded nanoparticle 
system for the intracellular delivery of isoniazid, and investigated for its ability to kill 
intracellular mycobacteria as a mimic for Mycobacteria tuberculosis.  
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2 Chapter 2 
Synthesis of Glycosylated Nanoparticles via RAFT Seeded Emulsion 
Polymerisation and Investigations into Their Aggregation with 
Online DLS Measurements 
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2.2 Abstract 
This chapter will explore the use of Dynamic Light Scattering (DLS) as a technique to 
analyse particle aggregation. Polymeric nanoparticles can be prepared by a variety of 
techniques, with varied and interesting surface functionality now available. One useful 
technique for preparing polymeric nanoparticles with highly tuneable surfaces is 
RAFT emulsion polymerisation. Using this technique a range of poly(α-D-
mannopyran-1-oxyethyl acrylamide) coated nanoparticles of varying sizes were 
prepared. The particles were used, along with the lectin concanavalin A, to develop a 
DLS based system for tracking particle aggregation in real time. The system was 
validated by equivalent experiments analysed using a standard UV-Vis spectroscopic 
analysis and was shown to be reliable and robust up to an aggregate diameter of ca 
500 nm. This system was further used to study the effect of particle size on lectin 
binding and final aggregate size. Larger particles were found to have a qualitatively 
enhanced aggregation response by both UV-vis and DLS techniques. The DLS 
technique however, was able to provide quantitative data on the number of particles 
per aggregate produced. 
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2.3 Introduction 
Within various disciplines, polymeric nanoparticles have found uses that require them 
to be well defined with reliable size control.1-3 The most prevalent of these fields, as 
discussed in Chapter One, is as drug delivery agents, used to improve the performance 
of a drug that may have an unfavourable absorption metabolism degradation and 
excretion (ADME) profile.4-10 In efforts to address these issues for both existing and 
novel therapeutics, smart drug delivery vectors of various forms have been researched, 
including the use of polymeric nanoparticles.5, 11-16  
Many nanoparticle systems for drug delivery currently being researched are polymeric 
in nature. These systems may be synthesised with a range of functional monomers 
using techniques such as emulsion polymerisation.17-20 Emulsion polymerisation 
provides an industrially applicable and easy way of generating polymeric 
nanoparticles with narrow size distributions, down to diameters of tens of 
nanometres.21, 22 To access small diameters with a narrow particle size distribution, a 
classical emulsion polymerisation typically requires the addition of a surfactant such 
as sodium dodecyl sulphate (SDS), resulting in particles that may show poor 
biocompatibility.23 In an effort to avoid this toxicity, emulsion polymerisations have 
been combined with controlled radical polymerisation (CRP) techniques, using a short 
polymer to provide micelles and particle stabilisation, subsequently becoming 
covalently bound to the resulting latex.24-26 Synthesising particles with these methods 
also allows control of polymer molar mass and architecture, polymer end group, and 
therefore particle surface functionality.27 One such method is that of reversible 
addition-fragmentation chain transfer (RAFT) emulsion polymerisation. In one 
specific use of this method, a suitable hydrophilic monomer and RAFT agent are 
polymerised to a low degree of polymerisation (typically under 30 monomer units) and 
then chain extended with a hydrophobic monomer to produce a short di-block 
amphiphilic macroRAFT agent. Upon suspension in water these form micelles, and 
can subsequently be chain extended following an emulsion polymerisation method.  
RAFT emulsion may also be performed directly from the hydrophilic block, rather 
than chain extending with a hydrophobic monomer before the emulsion, as initially 
proposed by Hawkett et al.27 In 2010, Stenzel et al.29 published a paper using this 
technique to produce nanoparticles with a glycopolymer shell of glucose, and the 
technique as a whole has been subject to wide study.24, 28-31 
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The ability to functionalise the surface of nanoparticles with moieties such as sugars, 
opens possibilities for targeting specific receptors in the body directing nanoparticles 
to a specific site of action. Sugars specifically are able to target lectins on cells 
including: malignancies, specific tissues, or pathogenic bacteria.29, 32 Lectins are 
carbohydrate binding proteins, that are not enzymes or antibodies.33 They contain 
carbohydrate recognition domains (CRD’s), which show preferential binding to 
specific carbohydrates or carbohydrate sequences. Lectins can be further divided into 
types including (although not limited to): C-type, Galectins, Calnexins, L-type, P-type 
etc. The function of lectins varies between types, for example: C-type lectins are 
involved in cell adhesion, glycoprotein clearance and innate immunity, whereas 
galectins are involved in glycan cross linking in the extra cellular matrix.34, 35 Lectins 
form a complex with carbohydrates via a combination of hydrogen bonding, 
hydrophobic interactions and (with the involvement of water bridges) co-ordination to 
a metal ion. Binding may also involve electrostatic interactions in some cases.2 The 
process and specificity of lectin-carbohydrate interaction is complex, with many other 
factors such as: depth of CRD pocket and ability of the lectin structure to deform, 
enabling lectins to bind to carbohydrate sequences that they are not specific to. The 
binding then may be thought of as a preference to a certain sequence, with the ability 
to form a weaker complex with other carbohydrates.36  
The ability of lectins to show reduced binding to other sugars is important when 
considering using them as a targeting agent, that even with a specific sequence of 
sugars, complete specificity may not be achieved. Single interactions between a sugar 
and a lectin are relatively weak, however it has been shown that where there is a high 
density of carbohydrates present, the culmination of all of the interactions acts in a 
non-linear way and results in a strong binding, this is known as the “cluster glycoside 
effect”.37 Having a high concentration of sugar moieties allows an increased binding 
as when one interaction breaks, it is highly likely that a proximal sugar will take its 
place in the binding domain, which can be thought of as a “bind and slide” 
mechanism.38, 39 Due to these factors, how the sugar moieties are presented is crucial 
for lectin binding. Recent work from the Becer group has again highlighted the 
importance of this, with a system showing improved lectin binding in an assembled 
state when compared to the same glycopolymer in a linear state.40 
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Functionalised nanoparticles therefore represent a good platform to take advantage of 
the “cluster glycoside effect”, as they are able to present a very high local concentration 
of a sugar on their surface when engineered properly.37, 41-44 
Different cell and tissue types are known to express different lectins with a particular 
specificity. The plant lectin concanavalin A (ConA) is known to bind majorly to alpha 
mannose and glucose residues (less so to beta), and ricinus communis agglutinin 120 
(RCA120) to beta galactose residues. The same diversity is found in the mammalian 
body too, for example some melanoma cell lines have shown increased binding to 
galactose functional nanoparticles.45 In rats, galactose has been shown to target the 
proximal gastro-intestinal (GI) tract, whilst fucose targets the distal GI tract.46, 47 
Furthermore, dendritic cells and macrophages of the human immune system have been 
shown to express lectins such as dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) that exhibit preferential binding to 
mannose.48-51  
Various research groups have used glyconanoparticles of many types to probe the 
ability of lectins for use as diagnostic and targeting agents.1, 32, 52-54 The ubiquity and 
specificity of receptors with such a preference for binding to specific carbohydrates 
therefore represents an attractive target to distinguish between and target different cells 
and disease states.2, 55, 56  
Once a targeted latex with a moiety like a sugar has been synthesised, it is important 
to be able to assess its ability to be recognised and effectively bind to the corresponding 
receptor, in this case a lectin. One method that is commonly used to study the ability 
of particles to bind to proteins, and in particular to lectins is turbidimetric UV-Vis 
analysis, together with a multivalent lectin in solution such as the tetravalent lectin 
ConA, isolated from the jack bean plant.57, 58 These tests, that simply require the 
mixing of two solutions, are quick and easy to perform; typically a lectin in solution 
will be placed in a UV-Vis spectrometer monitoring absorbance as the particle of 
interest is added. An increase in absorbance greater than the particles alone would 
produce indicates aggregation of particles through lectin binding, producing larger 
particle aggregates with a greater ability to scatter light.  Whilst this is a useful tool for 
quickly determining qualitatively if there is a particle-lectin interaction, without in 
depth mathematical analysis it does not give any quantitative information. The analysis 
needed makes many assumptions and does not fully take into account the light 
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scattering properties of particles, or the dilution effect seen when mixing two solutions 
together. Another technique used to determine particle size and aggregation is dynamic 
light scattering (DLS) analysis. Time dependant DLS has been used in determining the 
thermal stability of metal nanoparticles, but is far less common when applied to 
particle-lectin binding, as the former simply involves the heating of a sample in situ, 
whereas the latter would require full mixing of lectin and particle during DLS 
measurements.22, 54, 59-66 Mixing solutions during DLS measurements is not trivial, due 
to the nature of DLS analysis, and the practicalities of not being able to open the 
machine during measurement runs. Online (real time) aggregation analysis however, 
presents an interesting way of monitoring the lectin binding properties of glyco-
nanoparticles, not being affected by dilution effects or particle light scattering 
properties, but indeed taking advantage of them. As DLS relies as a technique on the 
Brownian motion of particles in solution, it requires all analysis to be performed on 
colloidally stable particles and aggregates below a critical size, at which they would 
sediment out of solution.67 If DLS is to be used to study glycoparticle-lectin 
interactions then: the particles analysed must be well defined, with a known amount 
of sugar residues on their surface and be of a size and at a concentration such as to 
limit aggregate size and sedimentation out of solution when a lectin is introduced.  
With its ability to synthesise well defined particles below 100 nm in diameter, RAFT 
emulsion polymerisation represents a good method for producing particles to 
investigate the use of DLS as a technique to study glycoparticle-lectin interactions. It 
is with this motivation that this chapter will present the synthesis and characterisation 
of mannosylated glyco-nanoparticles with well controlled diameters, and subsequently 
use them to precisely investigate and trial the use of real time “online” DLS to track 
particle-lectin interactions. The same technique will further be used to determine the 
effect of particle size on lectin binding.   
2.4 Results and Discussion 
2.4.1 α-D-Mannopyran-1-oxyethyl Acrylamide Monomer Synthesis 
In order to produce a macro-chain transfer agent (CTA) suitable for producing 
mannosylated nanoparticles via RAFT emulsion polymerisation, a monomer suitable 
for RAFT polymerisation that could be either post functionalised with mannose, or 
that already bore a mannose moiety was required. It was desirable to have a mannose 
functionalised monomer before polymerisation, this way it could be ensured that all 
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monomer units in the polymer chain bore a mannose residue and that the exact 
mannose concentration was known. Previous research carried out by Cameron et al. 
has shown the synthesis of  monosaccharide monomers via a coupling reaction of an 
acetate protected sugar to hydroxyethyl acrylamide (HEAm), and a modification of 
this method was used to synthesise a α-D-mannopyran-1-oxyethyl acrylamide 
(ManAm) monomer (Scheme 2.1).68 Briefly: α-D-mannose pentaacetate underwent a 
nucleophilic substitution with HEAm at the anomeric carbon using boron trifluoride 
diethyl etherate (BF3) as a Lewis acid to act as an activating agent. Due to neighbouring 
group participation from the adjacent acetate protecting group with the anomeric 
carbon, the resulting monomer produced will majorly be in the α isomer form.69 This 
protected sugar monomer was subsequently de-protected with potassium carbonate in 
methanol and purified by column chromatography with a yield of ca 60%. The 
molecule structure was confirmed by 1H and 13C NMR spectroscopy, IR spectroscopy, 
and mass spectrometry (Section 1.5.1.1).  
 
Scheme 2.1: Synthetic scheme for α-D-mannopyran-1-oxyethyl acrylamide monomer   
2.4.2 Synthesis of Poly(α-D-mannopyran-1-oxyethyl acrylamide)10-b-Poly(n-
Butyl Acrylate)15 
 
Scheme 2.2: Synthetic scheme for RAFT emulsion mediated particle synthesis via a poly(α-D-mannopyran-1-
oxyethyl acrylamide)10-b-poly(n-butyl acrylate)15 di-block copolymer 
Previous research has indicated that short chain polymeric oligomers of an amphiphilic 
nature self-assembled in water act as a sufficient nucleation site and stabiliser for the 
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formation and growth of polymeric latex particles.70 By using RAFT polymerisation 
to synthesise short oligomers of this nature from ManAm and butyl acrylate (BA), an 
amphiphilic macro-CTA suitable for aqueous self-assembly, and undergoing chain 
extension in a RAFT emulsion polymerisation was produced (Scheme 2.2). Using a 
solvent of DMF/Water (70/30 % v/v) to ensure solubility of all monomers at all 
temperatures, a P(ManAm)10-b-P(BA)15 polymer was synthesised. The addition of 
water to the DMF solvent was required as α-D-mannopyran-1-oxyethyl acrylamide 
was found to be thermoresponsive, with lower critical solution temperature (LCST) 
like behaviour in DMF, precipitating at around 50 °C.  2-(n-
butyltrithiocarbonylthio)propionic acid (PABTC) was selected to use as the CTA for 
this polymerisation as previous work has shown it to be an excellent RAFT agent for 
both acrylamides and acrylates.71, 72 In addition to its ability to act as a chain transfer 
agent for both acrylates and acrylamides, PABTC also possesses a carboxylic acid 
moiety on its R group, improving aqueous solubility and imparting electrostatic 
stabilization to the surface of the growing particle thus increasing colloidal stability. 
α-D-mannopyran-1-oxyethyl acrylamide was polymerised at 70 °C for seven hours at 
pH 7 using the thermal initiator 4,4’-azobis (4-cyanovaleric acid) (ACVA) as a radical 
source with >99% conversion of monomer to polymer confirmed by 1H NMR 
spectroscopy. After this seven hour polymerisation only 43% of the ACVA initiator 
had been consumed, and as the first block had polymerised to completion, the 
polymerisation of the second block of the polymer was performed without purification. 
Butyl acrylate, purged of oxygen, was therefore directly added to the reaction vessel 
to the required concentration, which was then heated to 70 °C again and left stirring 
for a further seven hours, allowing 97% conversion of butyl acrylate from monomer 
to polymer. Analysis by 1H NMR spectroscopy of side chain protons compared to 
protons from the CH3 present on the butyl Z-group of PABTC confirmed the polymer 
structure to be P(ManAm)10-b-P(BA)15 (Section 2.5.1.2). Chromatographic analysis of 
the polymer using size exclusion chromatography (SEC) indicated a monomodal 
molecular weight distribution of Mn = 4600 g mol 
-1 (Đ = 1.14) (Section 2.5.1.2). 
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Figure 2.1: DLS traces of particles formed from (a)  P(ManAm)10-b-P(BA)15  (b)  P(ManAm)10-b-P(BA)15-b-
P(BA)25  (c)  P(ManAm)10-b-P(BA)15-b-P(BA)75  (d)  P(ManAm)10-b-P(BA)15-b-P(BA)100  (e)  P(ManAm)10-b-
P(BA)15-b-P(BA)154  (f)  P(ManAm)10-b-P(BA)15-b-P(BA)200  (g)  P(ManAm)10-b-P(BA)15-b-
P(BA)300  (h)  P(ManAm)10-b-P(BA)15-b-P(BA)400. 
To confirm the ability of this di-block to form micelles in water, an aqueous solution 
of the purified polymer was prepared at a concentration of 15 mg mL-1 and the resulting 
micelle size determined by DLS measurement, displaying a mean hydrodynamic 
diameter of 10 nm (Pdi 0.06) and a zeta potential of -20 mV (Table 2.1, Figure 2.1).  
2.4.3 Synthesis of Mannosylated Nanoparticles 
 
Figure 2.2: DMF SEC traces of (a)  P(ManAm)10-b-P(BA)15  (b)  P(ManAm)10-b-P(BA)15-b-
P(BA)25  (c)  P(ManAm)10-b-P(BA)15-b-P(BA)75  (d)  P(ManAm)10-b-P(BA)15-b-P(BA)100  (e)  P(ManAm)10-b-
P(BA)15-b-P(BA)154  (f)  P(ManAm)10-b-P(BA)15-b-P(BA)200  (g)  P(ManAm)10-b-P(BA)15-b-
P(BA)300  (h)  P(ManAm)10-b-P(BA)15-b-P(BA)400.   
Multiple emulsion polymerisations were performed, using the synthesised 
P(ManAm)10-b-P(BA)15 macro-CTA following a modified literature procedure 
(Figure 2).73 Typically: in a 7 mL vial with a 1 cm magnetic stirrer, P(ManAm)10-b-
P(BA)15 was suspended in deionised (DI) water at a concentration of 23 mg mL
-1 to 
which a previously prepared solution of ACVA in DI water at a concentration of 5 mg 
mL-1 with 2 eq. of sodium hydroxide was added. The vial was then sealed and the 
Chapter 2 
Andrew Lunn                                                                                                                   54 
 
solution purged of oxygen with nitrogen flow for 10 minutes, following which the 
required volume of butyl acrylate was added in with a gas tight glass syringe, before 
heating the reaction to 70 °C and stirring for three hours. In all cases this resulted in 
the formation of well-defined monodisperse latex particles, with butyl acrylate cores 
ranging in diameter from 82-180 nm (Pdi ≤0.1) (Figure 2.1, Table 1). To ensure that 
monomer to polymer conversion was complete (> 99%) 1H NMR spectroscopy was 
performed using a mixed solvent of d6-DMSO/ CDCl3 (80/20 % v/v). No single 
common deuterated solvent was found to be able to adequately dissolve both the 
mannose monomer and butyl acrylate parts of the polymer, and the mix of deuterated 
DMSO and chloroform was found to be the best solvent mix. In all cases tested, 
monomer to polymer conversion was determined to be >99%, confirming that the 
emulsion polymerisation was complete after three hours.  
 
Table 2.1: Synthetic results for mannosylated nanoparticles with butyl acrylate core synthesised via RAFT 
emulsion polymerisation, and the constituent polymers. a determined by DLS (number distribution), b Pdi values 
calculated using Equation 2, c determined by DMF-SEC analysis with PMMA standard d dispersity values are for 
all populations in chromatogram 
As observed with the block copolymer micelles in solution, the resulting glycoparticles 
all had negative zeta potentials around -32 mV, due to the carboxylic acid present on 
the R group from the very first polymerisation on the PABTC RAFT agent. The 
polymer particles were disassembled into their particle forming polymer unimers by 
addition of an excess of DMF, and SEC chromatography performed to determine the 
unimer molecular weight distribution (Figure 2.2). Control of the unimer dispersity 
can be seen for the smaller particles where the target degree of polymerisation (DP) 
was lower. However, as the target DP increases a corresponding increase in polymer 
dispersity can be seen, indicating a loss of control over the chain extension in the 
growing polymer particle. This is presumably due a large number of initiator derived 
or “dead” chains that can no longer be chain extended, and RAFT end groups not being 
readily available in the larger particle due to diffusion limitation, allowing for free 
radical polymerisation to occur without RAFT group involvement.  
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2.4.4 Size Control of Mannosylated Nanoparticles   
 
Figure 2.3: Size calibration of particles synthesised from:  poly(α-D-mannopyran-1-oxyethyl acrylamide)10-b-
poly(n-butyl acrylate)15 plotting unimer Mn against the resulting particle volume of particles A, B, C and E, F and 
G. A near linear relationship can be seen with a linear regression p-value of 0.93   
It is important that particle size can be reliably and reproducibly controlled using the 
RAFT emulsion polymerisation mechanism over a range of sizes. To test this, multiple 
RAFT emulsion polymerisations were carried out following the same method as in 
Section 2.4.3 with varying concentrations of butyl acrylate to target a range of degrees 
of polymerisation to control the final resulting particle size (Table 2.1). The theoretical 
molecular weight of particle constituent unimers was then plotted against the resulting 
particle volume for particles A, B, C, E, F and G (Figure 2.3). As expected, a linear 
relationship can be seen indicating that any particle diameter between 80 and 180 nm 
can be targeted with a Pdi ≤0.1. To then determine if the particle size was reproducible 
and produce a particle with a diameter between 100-154 nm (filling a gap in the size 
calibration between particle C and E), the plot of Mn~particle volume was used as a 
calibration to determine a target DP for a particle 123 nm in diameter. By back 
calculating from the Mn suggested, a target DP of 154 was then targeted (Table 2.1 
particle D).  This resulted in a particle with a diameter by DLS of 127 nm, confirming 
that the calibration produced by these experiments is reliable and that the RAFT 
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emulsion polymerisation method can reliably be used to target a reproducible range of 
particle sizes. Such batch to batch consistency is an important factor when considering 
these particles for biomedical applications, as to be considered for formulation a 
synthesis method would have to be validated for such parameters.  
2.4.5 Aggregation Studies  
Having synthesised a range of well-defined glyco-nanoparticles with mannosylated 
shells and shown them to be stable, these could then be taken forward and used in 
lectin binding studies. Such binding studies are typically carried out in a predominantly 
qualitative way using UV-vis turbidimetric studies, wherein the absorbance (typically 
at a wavelength of 500 nm) of a lectin solution is monitored over time after the addition 
of sugar moieties.58, 74 This allows for the monitoring of particle aggregation in a 
straight forward manner, giving information about the time dependant nature of sugar-
lectin binding based on the increase in absorbance resulting from aggregation of 
particles causing turbidity in the solution. In their most simple format, these studies 
can be used to confirm the presence of a particular moiety at the surface of a particle, 
or to investigate the colloidal stability of a latex. UV-Vis is not appropriate as a method 
of determining the relative level of aggregation or stability between particles however 
due to the nature of light scattering. This is because the change in apparent absorbance 
between different particle sizes or aggregation over time is non-linear in relation to 
size.21 Building on previous work in the field of thermal stability of metal nanoparticles 
the use of DLS to monitor particle-lectin aggregation was compared to that of UV-Vis. 
2.4.6 UV-Vis Method Optimisation  
UV-Vis studies were performed as an initial test to confirm the presence of mannose 
on the surface of the latex particles and optimise conditions for the aggregation studies. 
To probe the effect of order of addition of lectin and sugar, the UV-vis aggregation 
study was performed adding the particles to a lectin solution and again, with the lectin 
to a particle solution, with the hypothesis that the order of addition would have no 
overall effect on the lectin binding. Due to coagulum certain latexes were also found 
to block the cannula used in the DLS studies, so it was beneficial for future studies that 
the order of addition did not affect the particle lectin binding, to avoid this issue. This 
same test was also performed with and without stirring, to determine the effect, if any, 
this would have on the particle-lectin binding; this was important as for further study 
by DLS as here the samples could not be mixed.  
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Figure 2.4: Effect of stirring and order of addition. a) Stirring UV-Vis (normalised), b) not stirring UV-Vis 
(normalised), c) not stirring DLS. Hollow circles denote particle solution added into ConA solution, filled circles 
denote ConA solution into particle solution. 
The UV-Vis studies were carried out using an 82 nm α-mannose coated particle with 
concanavalin A as an alpha mannose and glucose specific lectin. A cuvette loaded with 
particle solution was loaded into a UV-Vis spectrometer and an absorbance reading 
was taken every second at 500 nm. After one minute the ConA solution was added 
using an autopipette. This was repeated with the addition of particle to lectin solution 
both with and without stirring (Figure 2.4).  
The order of addition was shown to have a small effect on final solution turbidity, with 
particle into lectin solution resulting in a slightly higher absorbance reading than lectin 
into particles solution, the difference was minimal however, and the aggregation trend 
for both mixed and non-mixed samples remained unchanged by order of addition.  
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Figure 2.5: Showing particle-lectin aggregate sedimentation after stirring. A) α-mannose particle-ConA lectin 
aggregation stable in solution before mixing, B) five minutes after stirring, showing extensive sedimentation 
This difference may be attributed to a slower diffusion of particles through lectin 
solution, than would be seen from ConA lectin through particle solution. The effect of 
stirring was however far more pronounced and consistent regardless of order of 
addition. For both experiments, stirred and not stirred, a sharp increase in absorbance 
can be seen upon solution mixing due to sugar-lectin interaction. In those experiments 
without stirring, this then plateaus to an absorbance reading between 0.8-1. With 
stirring however, the initial sharp increase in absorbance is followed by a subsequent 
decrease and plateau to a much lower final absorbance value of 0.6. A potential 
explanation for this phenomenon is that stirring introduces kinetic energy, increasing 
particle movement, and hence particle-lectin collisions, and thus the chances of a 
successful binding event between them. This higher successful collision rate may 
result in larger aggregates to form reaching a critical size, resulting in sedimentation 
out of solution and a lower absorbance. This hypothesis was supported further visually, 
by observing the resulting solutions. Those that were stirred were observed to 
completely sediment from solution after five minutes, whereas those without stirring 
were stable up to 24 hours. If solutions that were not stirred were later subject to 
stirring, they were also found to completely sediment from solution after five minutes. 
(Figure 2.5). Based on these results, if was concluded that aggregation could 
potentially be monitored by DLS, as when not stirred, successful aggregation occurred 
and a stable aggregate solution was obtained. 
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2.4.7 DLS Method Development 
After optimising test conditions using UV-Vis aggregation the same experiment was 
performed using DLS to optimise the experimental setup such that real time (online) 
DLS measurements could be performed to track particle-lectin aggregation.  
To enable real time information to be obtained, a setup where solutions could be mixed 
without interrupting the normal running of the DLS machine was required; to achieve 
this a cannula injection system was developed. A 4.5 mL plastic cuvette was charged 
with 1.25 mL of the required solution (particle or lectin) and fitted with a size 23 
septum, which was pierced with a cannula attached to a 250 μL glass Hamilton syringe. 
The cannula was manipulated in such a way that any solution injected through it would 
flow down the side of the cuvette, rather than being squirted directly into the solution 
below, this was to minimise interference with Brownian motion and prevent air bubble 
formation. The cuvette was loaded into the DLS with the cannula exiting through a slit 
in the side of the sample chamber (Figure 2.6).  The software was set up to take a size 
reading every 10 seconds (each reading actually taking 11.6 s) for one hour. After six 
readings (69.9 s) had taken place, the required solution of lectin or particles was then 
injected into the cuvette through the Hamilton syringe. This interrupted only one 
measurement, recording an artificially low diameter as the particles are induced to 
move faster than under Brownian motion alone. This allowed real time analysis of the 
particle aggregates being formed and also allowed the addition of further solutions for 
later experiments. All experiments were performed at the same concentration of lectin 
and mannose. In later analysis, particle size for the initial solution was measured by 
number distribution so as to minimise the influence of any large particles in solution. 
For clarity of presentation however, and to give an idea of every distribution in the 
sample, z-average was used for aggregate analysis and is plotted in figures. 
As the effect of order of addition was still not clear, initially both orders were trialled 
to determine any effect and plotted as Z-average diameter for each individual 10 s 
measurement over time (Figure 2.4). Here, the order of addition was shown to have no 
effect on final particle aggregate size, with both average aggregate sizes increasing at 
the same rate and reaching the same final size of ca 2400 nm.  
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Figure 2.6: Pictures showing the setup of the DLS with a cannula injection system into the sealed sample holder, 
allowing injection of solution during measurements 
This result confirmed that aggregation experiments could be conducted adding lectin 
solution to a particle solution without stirring. Having confirmed this, further study 
into the suitability of DLS for tracking particle-lectin aggregation and in obtaining 
quantitative information about the aggregation was possible. 
2.4.8 Effect of Particle Size on Lectin Binding  
Having established experimental parameters for UV-Vis and DLS suitable for real 
time tracking of particle aggregation, the effect of glycoparticle diameter on lectin 
aggregation was investigated. The hypothesis being that increasing the diameter of the 
particle would increase the ability for aggregation, producing larger aggregates, 
formed of more particles. By comparing the same experiment performed by both UV-
Vis and DLS, direct comparisons of the two techniques could be made, and 
conclusions as to the benefits and limitations of each drawn.    
Using the previously synthesised nanoparticles, identical aggregation experiments 
were performed using UV-Vis and DLS measurements. All conditions were kept 
consistent between different experiments, with a 12.5 μL of latex solution being 
diluted to 1.25 mL in phosphate buffer (PB) (all latexes at a mannose concentration of 
2.608 x10-4 M) and 250 μL of 3.125 x10-5 M ConA in PB solution mixed either via 
pipetting in the case of UV-Vis, or cannula injection system, for DLS, to induce 
particle aggregation. An equivalent PEG coated nanoparticle (synthesised by another 
member of the group) was also tested as a control particle that should not aggregate in 
the presence of concanavalin A (Figure 2.7).  
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Figure 2.7: Nanoparticle-lectin aggregation with both turbidimetric absorbance (filled circles) and DLS Z-average 
diameter (hollow circles) measurements for P(ManAm) particles (a) 82 nm (b) 94 nm (c) 100 nm (d) 127 nm (e) 
146 nm (f) 153 nm (g) 176 nm, and P(PEGA) particle (h) 130 nm. Arrows indicate time of injection for Con A and 
mannose solutions. 
All mannose coated particles resulted in a large increase in diameter and absorbance 
by DLS and UV-Vis upon the addition of ConA. Subsequent addition of α-mannose 
(375 mg mL-1 in PB) resulted in a drop in aggregate size by DLS to the original particle 
diameter and a sharp reduction in absorbance by UV-Vis. This was caused by the 
break-up of aggregates due to competitive inhibition on the ConA binding sites.  No 
response was observed for the PEG control from lectin or sugar addition, confirming 
the aggregation of mannose particles was due to interaction between the sugar residues 
and binding sites on the lectin. This control also confirmed that the addition of ConA 
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does not interfere with DLS measurements, as no size deviation or dilution effect was 
observed. However, a characteristic drop in absorbance can be seen in the UV-Vis 
data, due to the dilution effect, reducing the concentration of particles in solution.  
The conclusions from the data presented to this point between UV-Vis and DLS 
studies are broadly similar, showing qualitatively that all mannose coated particles 
reversibly formed aggregates upon the addition of ConA, and subsequently broke up 
with the addition of an excess of free α-D-mannose. However, by further analysing the 
data obtained from DLS it is possible to quantify the results further than is possible 
with UV-Vis. Firstly, after the initial sharp increase in z-average diameter a second 
distinct phase of slower aggregation can be seen.  
This is particularly visible as a shift to larger diameters for smaller particles (a, b, c, 
and d) and indicates the slow formation of larger aggregates formed through aggregate-
aggregate interaction. This secondary phase of aggregation, though visible in UV-Vis 
studies, is not able to be quantified as a specific increase in aggregate size.  
𝑝𝑝𝑎 = (
𝑎𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
) × 0.74 
Equation 2.1: Estimation of number of particles forming final particle-lectin aggregate, final aggregate volume 
divided by the average volume of a single constituent particle, then multiplied by 0.74 as the maximum packing 
parameter for hard spheres. Aggregate and particle volume determined from radius by DLS 
Using the DLS data, an estimation of particles per aggregate (ppa) may be made. To 
determine this, the average final aggregate volume is divided by the volume of the 
initial particles forming the aggregate and then multiplied by the maximum packing 
parameter for hard spheres (0.74) (Equation 2.1).75 This information can also be 
compared to a theoretical maximum number of aggregation, a value past which 
sedimentation would occur. A diameter of over 500 nm, is recognised as an 
approximate diameter past which polymeric particles start to lose colloidal stability in 
water and as such was used to determine a theoretical maximum number of 
aggregation for particle-lectin aggregates (Table 2.2).58 Aggregate size was 
determined by taking a mean average diameter after the initial phase of aggregation 
had completed. A clear increase in aggregate size can be seen as the particle size 
increases, this could of course simply be due to the aggregates being composed of 
larger particles. However, by taking the original particle size into account, and 
determining the number of particles required to form each aggregate, an increase in 
aggregation number can be seen from 3.6 ppa for 82 nm particles to 30 ppa for particles 
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146 nm in diameter. Particles above this diameter (153 and 176 nm) were not able to 
accurately be analysed as they exhibited a large amount of sedimentation. This further 
supports the previous assertions that for this DLS aggregation analysis to provide 
quantitative data, aggregates must remain stable in solution, and that a diameter of 500 
nm represents a good upper limit for aggregate diameter. It is hypothesised that the 
observed increase in particle aggregation is related to the surface area of the original 
particle, containing more mannose residues and therefore more lectins, increasing the 
chances of a second successful interaction with a mannose residue on another particle. 
In addition to this, the contact angle between two particles will decrease as particle 
size increases leading to a corresponding increase in the potential area of interaction 
where a ConA molecule will be able to bind to residues on both particles. 
Particle 
Diameter 
(nm)a 
Particle Vol 
(nm3) 
Aggregate 
Diameter 
(nm) 
Aggregate Vol 
(nm3)b 
Nagg Max Nagg Th 
82 290,000 138 1,400,000 3.6 167 
94 430,000 206 4,600,000 7.9 113 
100 520,000 214 5,100,000 7.3 93 
127 1,100,000 390 31,00,000 20.9 44 
146 1,600,000 496 64,000,000 29.6 30 
153 1,900,000 589 107,000,000 41.7 25 
176 2,900,000 591 108,000,000 27.6 17 
 
Table 2.2: Analysis of final particle aggregate, compared to original particle diameter.  a- measured by DLS, b- 
determined using aggregate diameter and formula for the volume of a sphere 
The data presented shows that DLS may be used a technique analogous to UV-Vis in 
the qualitative data obtained for particle aggregation studies. It has also been shown 
that further quantitative analysis determining the aggregate size and estimating the 
number of particles forming each aggregate is possible. However, this is only possible 
where aggregation conditions are controlled such that colloidal stability is maintained, 
and aggregates formed are small enough to remain governed by Brownian motion.   
2.5 Conclusions 
In conclusion, this chapter has focussed on the preparation of glycosylated 
nanoparticles by the method of RAFT emulsion polymerisation, and the development 
of a quantitative DLS based technique for studying particle-lectin aggregation.  
Particles of a range of sizes were synthesised from a short amphiphilic di-block 
copolymer. These particles were further shown to be surface functionalised with 
mannose from the hydrophilic part of the di-block copolymer. 
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These particles then had their aggregation properties with ConA studied using UV-Vis 
and a developed DLS system. Online aggregation measurements using a cannula 
injection system were shown to be comparable to UV-Vis studies The DLS system 
was further shown however, to not be affected by the dilution effect and, rather than 
be hindered by light scattering changes, take advantage of them to provide quantitative 
information on particle aggregate size and composition.  
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2.6 Experimental  
2.6.5 Materials  
Poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 480 g mol
-1), n-
butyl acrylate (nBA, >99), and N-hydroxyethyl acrylamide were obtained from Sigma-
Aldrich and all monomers above were passed through basic aluminium oxide to 
remove inhibitor before use. 1,2,3,4,6-penta-O-acetyl-D-mannopyranose was obtained 
from Carbosynth Ltd and used as received. Concanavalin A was bought from MP 
Biomedical SAS. All solvents were bought from commercial sources and were used 
as received. Dimethyl sulfoxide-d6 (99.9% D atom), chloroform-d3 (99.8% D atom) 
and deuterium oxide-d2 (99.9% D atom), were obtained from Sigma Aldrich and used 
for NMR spectroscopy. Thermal initiator 4,4′-azobis(4-cyanovaleric acid) (ACVA) 
(>98%, Aldrich) was used as received. 0.45 μm syringe filters were obtained from 
Alpha Laboratories Ltd. 
2.6.6 Analysis  
2.6.6.1 NMR Spectroscopy  
1H NMR spectra were recorded on a Bruker DPX-300 spectrometer using deuterated 
solvent (materials section). Each sample was run with a decay time of 2 s with 16 
repeats. 
2.6.6.2 Mass Spectrometry  
Mass spectrometry measurements were performed on an Agilent 6130B Single Quad 
for ESI, with a methanol solvent in positive mode. 
2.6.6.3 Infrared Spectroscopy  
Fourier Transform Infrared Spectroscopy (FTIR) spectra were recorded using a Bruker 
Vector 22. The contact sampler was a horizontal diamond accessory (ATR) with a 
resolution of 4 cm-1. Scan speed was set at 0.5 cm s-1 with 120 scans performed per 
sample and performed on a dry solid sample. 
2.6.6.4 Size Exclusion Chromatography  
Chromatograms were performed using an Agilent 390-LC MDS instrument equipped 
with differential refractive index (DRI), viscometry, dual angle light scatter and dual 
wavelength UV detectors. The system was equipped with 2 x PLgel Mixed D columns 
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(300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent was DMF with 5 mmol 
NH4BF4 additive. Samples were run at 1 ml min
-1 at 50°C. Poly(methyl methacrylate) 
standards (Agilent EasyVials) were used for calibration. Analyte samples were filtered 
through a nylon membrane with 0.22 μm pore size before injection. Experimental 
molar mass (Mn,SEC) and dispersity (Đ) values of synthesised polymers were 
determined by conventional calibration using Agilent SEC software. 
2.6.6.5 Dynamic light scattering, size and ζ-potential  
Size and ζ-potential measurements were carried out using a Malvern Zetasizer Nano-
ZS at 25°C with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back 
scattering).  Measurements were taken assuming the refractive index of 
hydroxyethylacrylamide for P(ManAm)10-b-P(BA)15 and the refractive index of n-
butyl acrylate for latex particles. DLS samples of latex particles were prepared by 
diluting 1000-fold with 1 mL of water filtered through a 0.45 µm RC syringe filter and 
measured in 1.5 mL polystyrene cuvettes for measuring size and a Malvern DTS-1070 
cuvette for ζ-potential. Di-block copolymer samples were measured at the 
concentration of a typical RAFT emulsion polymerisation. Samples were incubated 
for 60 seconds at 25°C prior to measurement. Measurements were repeated three times 
with automatic attenuation selection and measurement position. Results were analysed 
using Malvern DTS 6.20 software. Pdi values were calculated using the following 
equation. Measurements of ζ-potential were modelled with the Smoluchowski theory. 
Number distributions are reported for initial particle size, as previously in the group 
they have been found to match most closely the diameters obtained through electron 
microscopy.       
𝑃𝑑𝑖 =  
𝜎2
𝑑2
 
Equation 2.2: Equation to calculate Pdi from standard deviation (σ), and diameter (d). 
2.6.7 Synthetic Procedures 
2.6.7.1   Synthesis of α-D-mannopyran-1-oxyethyl acrylamide 
7.5 g (0.0192 mol, 1.13 eq) of α-D-mannopyran-1-oxyethyl acrylamide and 2.01 g 
(0.017 mol, 1 eq) of hydroxyl ethyl acrylamide were dissolved in 77 mL of anhydrous 
DCM in a 250 mL round bottomed flask (RBF) equipped with a magnetic stirrer and 
an appropriately sized rubber septum. The reaction mixture was purged with nitrogen 
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gas and 13.33 g of boron trifluoride diethyl etherate (0.044 mol, 11.6 mL) was 
transferred using a gas-tight Hamilton syringe charged with nitrogen. The reaction 
mixture was consequently subjected to four cycles of 10 min sonication and 5 min rest 
prior to stirring at ambient temperature for 48 h. The progress of the reaction was 
monitored with thin layer chromatography (TLC) using a 9:1 chloroform:methanol 
mixture (v/v), and stained with 5% sulfuric acid in ethanol. Once complete, the 
reaction mixture was then diluted with two parts DCM and washed thoroughly with 
brine three times then water in an appropriately sized separating funnel. The organic 
phase was dried over magnesium sulfate, filtered via vacuum filtration and the solvent 
removed under reduced pressure at a temperature no higher than 30 °C leaving an 
orange brown viscous liquid. This was dissolved in 40 mL of potassium carbonate in 
methanol, purged with nitrogen gas and stirred at ambient temperature for 24 h. The 
pH was adjusted to pH 7 with a Dowex 50WX4 hydrogen form exchange resin and 
stirred until the pH was fully adjusted. The Dowex resin was removed with vacuum 
filtration and solvent removed under reduced pressure at a temperature no higher than 
30 °C. The crude product was purified via column chromatography on an 80 g silica 
column and eluted with a 2:8 methanol: chloroform mixture at a flow rate of 1 mL 
min-1, on an auto-column equipped with a UV-Vis detector set to 308 nm. The product 
was found to elute at around 15 min. Product fractions were combined, the solvent 
evaporated to less than 10 mL under reduced pressure and subsequently freeze dried 
to yield the pure monomer as a white powder.  
 
Scheme 2.3: Structure of α-D-mannopyran-1-oxyethyl acrylamide 
1H NMR spectroscopy (D2O, 400 MHz) δH: 6.13 (dt, J = 31.0, 13.5 Hz, 2H, CH2CH), 
5.65 (d, J = 10.0 Hz, 1H, CH2CH), 4.74 (s, J = 16.2 Hz, 1H, CHO2CH), 3.80 (s, J = 
122.4 Hz, 1H, CH2OH), 3.76 – 3.28 (m, 9H). 13C NMR spectroscopy (D2O, 400 MHz): 
δ 129.75 (s) (CHCH2), 121.41 (m) (CH2CH), 99.61 (s) (CH2OH), 72.71 (s) (CHO), 
70.39 (s) (CHO), 69.92 (s) (CHO), 66.52 (s) (CHO), 65.69 (s) (CHO), 60.76 (m) 
(CH2O), 37.77 (m) (CH2NC). (Figures 2.8 and 2.9) 
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MS m/z [M+Na]+: 300.1 (MSth: 300.9)  
IR spectroscopy (cm-1): 3275 (b), 2928 (b), 1656 (n), 1624 (m), 1548 (b), 1409 (m), 
1317 (w), 1249 (m), 1131 (m), 1089 (m), 1051 (s), 1023 (s).  
 
Figure 2.8: α-D-mannopyran-1-oxyethyl acrylamide monomer 1H NMR spectrum, solvent D2O 
  
 
Figure 2.9: α-D-mannopyran-1-oxyethyl acrylamide monomer 13C NMR spectrum, solvent D2O 
4 
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2.6.7.2 Poly (α-D-Mannopyran-1-oxyethyl Acrylamide)10-b-Poly(n-Butyl 
Acrylate)15 Synthesis  
 
Scheme 2.10: Structure of poly(α-D-mannopyran-1-oxyethyl acrylamide)10-b-poly(n-butyl acrylate)15 
α-D-mannopyran-1-oxyethyl acrylamide (1g, 3.62 mmol, 10 eq.), 2-((butylthio) 
carbonothioyl) thio)propanoic acid (0.0864g, 3.62x10-4 mol, 1 eq.), and ACVA (from 
a pre-made stock solution of 10mg mL-1 in DMF:water (70:30) mix) (0.0508g, 
1.81x10-4 mol) were dissolved in a mixture of DMF:water (70:30) to a total volume of 
10.8 mL in a 25 mL round bottomed flask with a magnetic stirrer bar. The flask was 
sealed with an appropriate rubber septum and purged of oxygen with nitrogen gas for 
ten minutes before immersing it into a preheated oil bath at 70°C and stirred for seven 
hours. Monomer conversion was determined by 1H NMR spectroscopy in D2O, by 
comparison of the ratio of the vinyl peak (δ=6.08) and RAFT agent CH3 z-group butyl 
chain end group peak (δ=0.78). The polymer was analysed by SEC with a DMF eluent 
at 30ᵒC (Mn SEC=2450 g mol
-1 Đ=1.27) (Mn th = 3008 g mol-1). To chain extend the 
synthesized P(ManAm)10 macro-RAFT agent,  n-butyl acrylate was purged of oxygen 
with nitrogen for ten minutes, and 1.3g (1.01x10-2 mol, 1.45mL) was injected into the 
25 mL round bottomed flask using a dry Hamilton syringe, purged with nitrogen. The 
round bottomed flask was then immersed in an oil bath set to 70ᵒC and stirred for seven 
hours. Monomer conversion was determined by 1H NMR spectroscopy in d6-DMSO, 
by comparison of the ratio of vinyl peak (δ=5.94) and RAFT agent/ n-BA CH3 z-group 
butyl chain end group peak (δ=0.83). Polymers were analysed by SEC with a DMF 
eluent (Figures 2.10 and 2.11). 
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Figure 2.11: SEC traces for: red) poly(α-D-mannopyran-1-oxyethyl acrylamide))10 Mn= 2450 g mol-1, Đ=1.27; 
black)  of poly(α-D-mannopyran-1-oxyethyl acrylamide)10-b-poly(n-butyl acrylate)15 Mn= 4600 g mol-1, Đ=1.14 
 
Figure 2.11: 1H NMR spectrum of P(ManAm)10-b-P(BA)15  in D2O 
2.6.7.3 General Method for RAFT-Mediated Emulsion Polymerisation  
 Nanoparticles of different sizes were prepared by altering the ratio of di-block macro-
RAFT agent to monomer in an emulsion polymerisation. As an example, 
P(ManAm)10-b-P(BA)15-b-P(BA)400 was prepared as follows. NaOH (14.3 mg, 3.6 x 
10-4 mol) was added to a suspension of ACVA (50 mg, 1.8 x 10-4 mol) in water (10 
mL) to ensure full solubility. P(ManAm)10-b-P(BA)15 (0.015 g, 3.13 x 10
-6 mol) was 
dissolved in 0.645 mL of water, in a 2mL vial fitted with a cap incorporating a rubber 
septum and equipped with an appropriate magnetic stirrer. 0.175 mL of the above 
ACVA stock solution was added, and the solution was deoxygenated with nitrogen gas 
for 20 minutes. A stock of n-BA was separately deoxygenated in a vial for 10 minutes. 
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The macro-RAFT agent solution was immersed in an oil bath set to 70°C, n-BA (0.160 
g, 1.25 x10-3 mol) was injected immediately and the RAFT-emulsion polymerisation 
was stirred for 3 h at 70°C at 400 rpm. After approximately 10 min, the emulsion 
turned a milky white as the polymerisation proceeded. Conversion of monomer to 
polymer was found to be >99% by 1H NMR spectroscopy in a mixed solvent of d6-
DMSO/ CDCl3 (80/20 % v/v), by comparison of the ratio of vinyl peak (δ=6.14) and 
CH3 butyl chain end group peak (δ=0.88) (Figure 2.12). The polymer was analysed by 
SEC with a DMF eluent at 30ᵒC (Mn SEC= 61000 g mol
-1 Đ=1.27) (Figure 2.13), and by 
DLS to determine particle size (Figure 2.14).  
  
Figure 2.12: 1H NMR spectrum of P(ManAm)10-b-P(BA)15-b-P(BA)400 showing no residual monomer 
 
Figure 2.13: SEC trace of P(ManAm)10-b-P(BA)15-b-P(BA)400 using DMF as an eluent, Mn= 61000 g mol-1 Đ = 
1.9 
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Figure 2.14: DLS trace of P(ManAm)10-b-P(BA)15-b-P(BA)400 in water Diameter = 176 nm, Pdi= 0.1 
2.6.8 General Method for UV-Vis Aggregation Studies  
Turbdimertric studies were conducted by diluting 12.5 μL of undiluted particle 
solution with 1.3 mL of 10 mM phosphate buffer in a 4.5 mL polystyrene cuvette and 
placed in a UV-Vis spectrometer. In a separate 4.5 mL polystyrene cuvette a stock 
solution of 2.027x10-5 M Con A in 10mM phosphate buffer was prepared for use. 
Absorbance readings were taken every second at 500 nm, after 60 seconds 250 µL of 
Con A in phosphate buffer (2.027x10-5 M) was added with an Eppendorf pipette and 
mixed twice to induce aggregation. After a further 9 minutes 50 µL of α-mannose in 
phosphate buffer (375 mg mL-1) was added with an Eppendorf pipette and mixed twice 
to induce competitive binding with the glycosylated nanoparticles. The absorbance 
was monitored for a further 10 minutes. Readings were taken using an Agilent Carey 
60 UV-Vis machine with Agilent software and analysed using Origin. 
2.6.9 DLS Aggregation 
DLS measurements were taken using a Malvern instruments Zetasizer Nano at 25 °C 
with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back scattering). For 
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P(ManAm) particle DLS aggregation studies, 12.5 μL of particle solution was diluted 
with 1.24 mL of 10 mM phosphate buffer to make a total of 1.25 mL in a 4.5 mL 
polystyrene cuvette. The cuvette was fitted with a size 23 septum, which was pierced 
with a cannula attached to a 250 μL Hamilton glass syringe. The cannula was 
positioned such that, solution ejected through it would run down the side of the cuvette.  
This prevented the creation of any air bubbles that may have interfered with 
measurements. The cuvette was placed into the Zetasizer, and the lid closed with the 
syringe exiting through a slit at the side of the instrument. In a separate 4.5 mL 
polystyrene cuvette a stock solution of 2.027x10-5 M Concanavalin A in 10 mM 
phosphate buffer was prepared for use with P(ManAm) particles. The Zetasizer was 
set to take a size reading every 10 seconds for 1 hour, however a delay of 1.66 seconds 
was recorded between each reading, adding 598 seconds to each hour, for which the 
results have been amended. After the sixth reading, 250 μL of 2.027x10-5 M Con A 
stock solution was injected via the cannula giving a final volume of 1.5 mL. The final 
concentration of Con A and mannose residues was 3.125x10-5 M and 2.608x10-4 M 
respectively. The same technique was then repeated with the addition of 250 μL of 75 
mg mL-1 α-mannose in phosphate buffer being injected via the syringe cannula after 
10 minutes (to allow full de-aggregation). This was performed as a competitive 
binding assay, to show reversible lectin binding. 
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3 Chapter 3 
Synthesis of Glyconanoparticles via a Free Radical and Surfactant 
Free Emulsion Polymerisation Technique, and Investigations into the 
Effect of Glass Transition Temperature on Lectin Induced 
Aggregation. 
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3.2 Abstract 
Functional nanoparticles with diameters below 100 nm are desirable for biomedical 
applications and emulsion polymerisation represents an attractive pathway for their 
synthesis. To access sub-100 nm particles however, traditional emulsion 
polymerisation strategies rely on the addition of a surfactant that must subsequently be 
removed. Pseudo-surfactant free emulsion polymerisations, utilising controlled radical 
polymerisation techniques also provide access to: low diameters, controlled molecular 
weights and functionalised surfaces. These techniques however are often time 
consuming and expensive.  This chapter will therefore investigate the synthesis of sub-
100 nm glyconanoparticles via a one step, free radical and surfactant free emulsion 
polymerization. It is shown that by using sterically large, hydrophilic glycomonomers 
such as β-D-lactose-1-oxyethyl acrylamide with the charged azo initiator 4,4’-
azobis(4-cyanovaleric acid), particles are stabilized sufficiently to reproducibly result 
in well defined (Pdi ≤ 0.1) glycoparticles with diameters below 100 nm. This technique 
is further used to synthesise a series of “soft” and “hard” glyconanoparticles to probe 
the effect of changing the particle core glass transition temperature (Tg) on lectin 
induced aggregation. It is shown that “soft” particles, above their Tg, form larger 
aggregates than “hard” equivalents below the core Tg. This effect is hypothesised to be 
due to the ability of the “soft” particles to deform on close packing and form more 
sugar-lectin interactions, evidence for which is provided using cryo-TEM microscopy.   
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3.3 Introduction  
Emulsion polymerisation is an industrially favoured technique for polymer and 
particle synthesis, with existing infrastructure for manufacture on a multi-ton scale in 
industries as diverse as glove production to paints.1 A standard emulsion 
polymerisation, using water as the solvent phase, is particularly favoured because of 
its high specific heat capacity, favourable kinetics and low viscosity.2, 3 These factors 
make emulsion polymerisation a safe, cheap and easy to process way of producing 
both bulk polymers and more specialised particles and is explored fully in Chapter 
One.2 
A classic emulsion polymerisation utilises a surfactant, which typically is charged, 
such as sodium dodecyl sulfate to form micelles. The micelles provide nucleation sites 
of insertion for growing “z-mer” polymer chains and stabilisation to the growing 
particles, keeping them in suspension.4 This allows for the synthesis of polymer 
particles at a high weight percentage with small diameters, routinely below 100 nm. 
The presence of such a surfactant, though advantageous during the polymerisation, is 
detrimental for many uses such as in electronics or medicine, and may require 
extensive purification to be removed; which is typically achieved by extensive 
dialysis.5-7 Avoiding the need for surfactant removal is one motivating factor behind 
the development of “pseudo-surfactant free” controlled radical polymerisation 
techniques, as outlined and utilised in Chapter Two.8-13 As the original amphiphilic 
polymer is bound to the resulting particle, any functionality present is retained by the 
final product.14, 15 “Pseudo surfactant free” techniques are also advantageous as they 
are able to access diameters down to tens of nanometres.16-19 Such techniques, whilst 
promising, and incredibly useful for mechanistic studies as demonstrated in Chapter 
Two, suffer from having a relatively high associated material cost, and in the case of 
RAFT emulsion, result in particles with an embedded RAFT Z-group.20, 21  
A technique to produce functional polymer particles without the use of a controlled 
polymer precursor or surfactant, would then be of interest to produce cheap particles 
without the need for extensive purification. Research conducted in the 1970’s before 
the advent of controlled radical polymerisation techniques, investigated the use of a 
classical emulsion polymerisation without the addition of a surfactant to the system.22-
25 This created a self-nucleating “free radical surfactant free” emulsion polymerisation. 
In such a system one or many of the growing “z-mer” chains nucleate a growing 
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polymer particle by collapsing in on themselves out of solution, and are stabilised by 
the water soluble initiator head groups. This produces both polymer in solution, and 
suspended polymer particles with diameters typically in the hundreds of nanometers 
to micrometers.26 It is desirable for applications such as drug delivery however to be 
able to produce particles with diameters below 100 nm.7, 27-30 Particles below 100 nm 
in diameter may be achieved via a free radical surfactant free emulsion polymerisation, 
by using a strongly charged initiator such as potassium persulfate.31-37 This technique 
has however not previously been explored for producing functional polymer particles 
such as glycopolymer particles, nor the influence of co-polymerising them with a 
hydrophilic monomer on the resulting particle size fully explored.38  
The biological influence of a number of nanoparticle properties such as surface 
functionalisation, particle size, shape and charge have been widely studied as 
discussed in Chapter One.39-50 The biological influence of the particle core properties 
however has been less well studied. In particular particle core rigidity, and the 
biological effects that may have. Some reports have focussed on endocytosis, 
producing conflicting results, with some studies suggesting that a more fluid particle 
increases cell uptake and others suggesting a rigid particle is superior.51-54  
One potential source of the discrepancy seen in these studies, other than the different 
cell lines used, is the variability in the techniques used to vary particle rigidity. For 
example: colloidal hydrogels will have their rigidity modified with varying degrees of 
cross linking.55-57 This has direct influences on the hydration of the gel and the surface 
hydrophobicity.  
One alternative way of tuning polymer rigidity is by influencing the core polymer glass 
transition temperature (Tg), the temperature at which a polymer changes from glassy 
and hard to a soft, more liquid state.58 This physical transition occurs due to changes 
in the mobility of polymer chains past one another. This approach has been used before 
by Lorenz et al.59 In this work the Tg of nanoparticles synthesised via mini-emulsion 
polymerisation was modified by changing the polymeric side chain from one carbon 
to 16 (poly(methyl methacrylate) to poly(stearyl methacrylate)). The results showed 
that a decrease in Tg and rigidity corresponded to an increased endocytosis in a variety 
of cell lines. This work again however cannot control against the change in 
hydrophobicity caused.  
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The current reported work on the biological influence of particle core Tg leaves various 
effects unexplored, such as the influence on particle-particle interaction and 
aggregation, induced by lectins. Neither have previous studies fully negated the effect 
of changing hydrophobicity. The use of a surface functionalised nanoparticle with 
varying core properties could potentially overcome some of these issues. By having 
the same shell chemistry, the differing hydrophobicities of the particle cores should be 
shielded from influencing results.    
This chapter will therefore build on the RAFT emulsion polymerisation synthetic work 
in Chapter Two, and focus on the synthesis of glyconanoparticles via a free radical 
surfactant free emulsion polymerisation method. The use of a highly charged initiator 
head group has previously been shown to enable access to particle diameters below 
100 nm. To develop this, initiators bearing a carboxylic acid will be investigated for 
their ability to stabilise the growing latex. Furthermore, the use of a hydrophilic co-
monomer in the polymerisation will be investigated, initially to establish if the 
hydrophilic monomer will be incorporated onto the resulting particle surface, 
providing a way of simply producing functionalised glyconanoparticles; and the 
subsequent influence the hydrophilic monomer has on the final particle size. In 
addition to this, particles made using a free radical and surfactant free emulsion method 
will be used to investigate the influence of particle core glass transition temperature 
on lectin binding, using the DLS based aggregation tracking system developed in 
Chapter Two.   
3.4 Results and Discussion  
3.4.1 Free Radical Surfactant Free Emulsion Polymerisation  
3.4.1.1 Synthesis of β-D-Lactose-1-oxyethyl Acrylamide 
 
Scheme 3.1: Synthesis of β-D-lactose-1-oxyethyl acrylamide via a nucleophilic substitution between lactose 
octoacetate and hydroxyethyl acrylamide using boron trifluoride di-ethyl etherate as a leaving group. Monomer 
subsequently de-protected by removal of acetyl groups with potassium carbonate in methanol. 
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In order to determine the influence of a range of hydrophilic monomers on the free 
radical and surfactant free emulsion polymerisation method, a disaccharide 
glycomonomer was synthesised for comparison to the mono-saccharide 
glycomonomer, mannose acrylamide, described in Chapter Two. For this purpose, β-
D-lactose-1-oxyethyl acrylamide was selected, as a readily available acetyl protected 
disaccharide suitable for modification to an acrylamide monomer via a coupling 
reaction with Hydroxy Ethyl Acrylamide (HEAm) (Scheme 3.1). As for the synthesis 
of mannose acrylamide, a modification of a method originally published by Cameron 
et al. was used.60 Briefly: Octa-O-acetyl-β-D-lactose (lactose octaaetate) was subject 
to a nucleophilic substitution reaction with HEAm at the anomeric carbon of the 
glucose residue, using boron trifluoride diethyl etherate as a Lewis acid to act as an 
activating agent. The protected sugar monomer was subsequently de-protected by 
removal of the acetyl groups with potassium carbonate in methanol. The pure product, 
free of all acetyl protecting groups was found to precipitate out of the methanol 
solutions and was easily recovered by filtration, and was further purified by washing 
with methanol. The monomer structure and purity was confirmed by 1H NMR 
spectroscopy, mass spectroscopy and elemental analysis. (Section 3.5.1.1)  
3.4.1.2 Particle Synthesis and Size Control Using a Free Radical and 
Surfactant Free Emulsion Polymerisation  
It has previously been established in the literature that it is possible to make polymeric 
nanoparticles simply with the use of a charged initiator and a suitable hydrophobic 
monomer, such as styrene, in water.  
 
Table 3.1: Synthetic results for nanoparticles synthesised via a free radical surfactant free emulsion polymerisation, 
diameters by DLS reported are number distributions a Pdi values calculated using eq. 3.2, b diameter determined 
from an average of a minimum of 20 particles imaged by SEM 
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Less is known however about the influence of adding a hydrophilic co-monomer into 
the reaction, specifically: if the hydrophilic monomer will be incorporated onto the 
surface of resulting particles and the influence of the hydrophilic monomer on particle 
size. In order to understand this, surfactant free emulsion polymerisations were 
performed with various hydrophilic monomers. Initially a series of polymerisations 
were carried out using the same LactAm monomer concentration, whilst varying the 
concentration of hydrophobic butyl acrylate (BA) monomer, effectively changing the 
ratio of hydrophilic to hydrophobic monomer used. This was to establish whether or 
not the surfactant free technique would work and if reliable size control could be 
achieved. The general procedure was typically: LactAm monomer (228 μ mol) and 
initiator (3.13 μM) were dissolved in water (to a volume such that on addition of BA 
a total of 2 mL was achieved) in a 7 mL glass vial, charged with a magnetic follower 
and fitted with a rubber septum. The reaction vessel was purged of oxygen for ten 
minutes, after which the required volume of BA was injected through the septum using 
a gas tight syringe purged of oxygen. The reaction was then heated to 70 °C and stirred 
at 800 rpm for three hours. In all cases this resulted in the formation of monodisperse 
polymer latexes (Pdi ≤ 0.1).  
 
Figure 3.1: DLS traces by number for P(LactAm-co-nBA) particles at the different ratios indicated, used in 
determining a size calibration and establishing particle size control using a free radical and surfactant free synthetic 
technique. An expected increase in particle diameter can be observed as the concentration of BA increases, and 
thus the ratio of BA to LactAm, is also increased.  
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By varying the ratio of LactAm:BA from 1:5 to 1:50, particles with cores ranging in 
diameter from 85 - 348 nm were achieved (Table 3.1, A-E, Figures 3.1, 3.2). When 
the particle volume (derived from the radius by DLS), is plotted against the ratio of 
BA to LactAm (Figure 3.2), a linear relationship can be seen with a fitted R2 value of 
0.963. This confirms that by adjusting the ratio of hydrophilic to hydrophobic 
monomer in the emulsion a predictable change in diameter can be achieved. This result 
also confirms that the particles synthesised are reproducible. 
All particles also exhibited a zeta potential of between -31 to -43 mV. Whilst this 
cannot be taken as a quantitative measure of the surface charge of the particle (rather 
at the slipping plane), this result did show that the surface of the particles was 
negatively charged from, and stabilised by, the de-protonated carboxylic acid group 
on the ACVA initiator, confirming it as a suitably charged initiator for use in a 
surfactant free emulsion polymerisation. All latexes were found to have a pH of circa 
7 both before and after reaction. A representative sample, when broken up into 
constituent polymeric unimers by drying and mixing with DMF, along with linear 
polymer formed in solution, showed a dispersity by SEC of 1.56 (Mw/Mn) (Figure 3.2). 
This figure is consistent with those that would be expected from a free radical 
polymerisation of this sort in emulsion.61, 62 Samples were also analysed by 1H NMR 
spectroscopy to ensure complete conversion of monomer to polymer. A mixed solvent 
of 4 parts d-DMSO to 1 part d-CHCl3 was used to allow full solubility of all parts, 
polymerisations were found to go to >99% conversion confirming complete reaction 
(Section 3.5.1.2). 
  
Figure 3.2: A) SEC Analysis performed using a DMF eluent , P(LactAm-co-nBA) latex particle “A” (Table 1) 
Mn= 175000 g mol-1 Đ=1.56, B) Particle size calibration with varying molar ratios of hydrophobic butyl acrylate 
monomer to hydrophilic β-D-lactose-1-oxyethyl acrylamide monomer, plotted against the resulting particle 
volume.  
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3.4.1.3 Incorporation of Hydrophilic Polymer onto Latex Particle  
In order to use a free radical surfactant free emulsion polymerisation technique for 
producing surface functionalised particles, it was necessary to establish if the 
hydrophilic monomer would successfully be incorporated onto the resulting latex 
particles. As the focus of this study was to determine the influence of the hydrophilic 
monomer on the latex and ultimately to produce glycoparticles, a simple turbidimetric 
experiment was designed to confirm the particle incorporation of the hydrophilic 
monomer. A particle was synthesised using the previously described method with: 
mannose acrylamide (ManAm) as the hydrophilic part and styrene as the hydrophobic 
part in a ratio of 5:1 styrene to ManAm (Particle H, Table 3.1). This resulted in a 
particle with a diameter of 88 nm (DLS number distribution). Following a procedure 
described initially in Chapter Two, turbidimetric studies were then performed on the 
potentially mannosylated latex using Con A, a tetravalent lectin specific for glucose 
and mannose, as a cross linker to induce aggregation.63 Initially the latex was purified 
of any P(ManAm) not bound to the particles by repeated cycles of particle 
sedimentation via centrifugation at 13,500 rpm for ten minutes. After each cycle the 
supernatant was removed and the particle pellet re-suspended with clean deionised 
water, thus removing any free polymer in solution. This purification technique was 
preferred to dialysis, as it has no upper molecular weight cut off unlike a dialysis 
membrane that does. This was in efforts to ensure that even the longest polymer not 
anchored to the particle was removed, which was important, as free radical 
polymerisation produces polymers of a very high molar mass. Turbidimetric 
aggregation studies were then performed on both the pure and impure latexes, the latex 
was diluted with tri(hydroxymethyl) aminomethane (TRIS) buffer (pH 7) in a cuvette 
and placed within a UV-Vis sprectrometer. The instrument was blanked and reading 
taken every second at 500 nm, and Con A in TRIS buffer was added (Figure 3.3). The 
results show that for both the pure and impure latex, aggregation with the Con A 
occurs, as an increase in turbidity is seen after Con A addition in both cases. The 
impure latex shows a slow and steady increase in absorbance, due to slow aggregation 
over 30 minutes. The purified latex however, shows a much faster increase in 
absorbance from increased aggregation, reaching its maximum in four minutes.  
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Figure 3.3: UV-Vis turbidimetric aggregation tests between mannose coated particles and Con A. a) raw latex with 
free P(ManAm) in solution, b) purified latex with free P(ManAm) removed from solution via centrifugation  
After five minutes, the absorbance in the pure latex can also be seen to quickly reduce 
again, this is hypothesised to be due to the presence of large particulate aggregates 
sedimenting out of solution, dramatically reducing the suspended particle 
concentration. This result confirmed that the particles did have a mannose shell, and 
that the surfactant free emulsion technique successfully incorporated the hydrophilic 
monomer into the particle structure. It is hypothesised that the difference in 
aggregation profile between the pure and impure latexes is due to free P(ManAm) 
homopolymer, present in the impure latex, competing for binding sites on the Con A 
with the mannosylated particles. Free P(ManAm) is not present in the pure latex and 
therefore the mannosylated particles have no competition for binding, and can exhibit 
the faster response seen. A modified turbidimetric test was also performed with the 
addition of free mannose post aggregation in excess to compete for Con A binding 
sites and induce aggregate break up, confirming that aggregation was due to sugar-
lectin binding (Figure 3.4).  
It was not clear however from turbidimetry alone, the extent to which the hydrophilic 
monomer was incorporated into the particle structure. To quantify the amount of 
hydrophilic glycopolymer bound to the particles, a simple gravimetric study was 
performed. The mass of 1 mL of raw latex was compared to the mass of 1 mL of the 
purified latex, after drying both in solutions in a vacuum oven at 40 °C for 16 hours. 
The average mass difference after three repeats represented the mass of polymer and 
initiator in solution. As the mass of initiator was negligible compared to the polymer, 
the mass difference was used to differentially calculate the amount of polymer bound 
to the particles, and determined to be 41% incorporation.  
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Figure 3.4: UV-Vis absorbance trace of P(ManAm)-co-P(BA) particles initially aggregated with Con A lectin, 
causing an increase in absorbance. Aggregation subsequently reversed with the addition of free β-D-lactose sugar, 
causing a corresponding reduction in absorbance 
3.4.1.4 Effect of Hydrophilic Monomer on Resulting Particle Size 
Having established that the hydrophilic monomer used in the surfactant free emulsion 
system was successfully incorporated into the particle structure, the influence the 
hydrophilic monomer has on the resulting particle size was investigated. The accepted 
mechanism by which particles are formed in a surfactant free emulsion polymerisation 
is with the initial polymerisation of small amounts of hydrophobic monomer in the 
aqueous phase, reaching a critical length (J-crit) and then self-nucleating either as 
single or multiple chains, stabilised by the water soluble initiator head group. These 
particles then continue as in a standard emulsion polymerisation, growing by internal 
polymerisation and particle aggregation. It was hypothesised that in the initial phase 
of polymerisation hydrophilic homopolymer is predominantly formed (as it is fully 
soluble in the water phase with this initiator), followed by co-polymers of the 
hydrophilic and hydrophobic monomers. This would form an in-situ surfactant like 
polymer that, upon reaching the J-crit would nucleate into particles, driving an 
emulsion mechanism. The nucleated particles would be stabilised not only by the 
initiator head group, but also the hydrophilic component of the polymer. The ability of 
the hydrophilic monomer to stabilise a particle, would therefore have a large impact 
on the resulting particle size. A monomer with more steric bulk, charge or ability to 
hydrogen bond would theoretically be better stabiliser, producing a lower apparent 
number of aggregation and resulting in smaller particles. To test this hypothesis 
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surfactant free emulsion polymerisations were performed using a variety of 
hydrophilic vinyl monomers, whilst keeping all other conditions the same. Styrene was 
used as the hydrophobic part as it is one of the most studied monomers in free radical 
emulsion polymerisation, and, owing to the high glass transition temperature (Tg) of 
poly(styrene), will produce particles suitable for analysis by electron microscopy. For 
the hydrophilic part: LactAm, ManAm, hydroxyethyl acrylamide (HEAm) and 
poly(ethylene glycol) methyl ether acrylate (PEGA) were employed, in order to assess 
the effect of monomer size and hydrophilicity. The same synthesis was also repeated 
without the inclusion of any hydrophilic monomer, but with the negatively charged: 
4,4′-azobis(4-cyanovaleric acid) (ACVA) initiator as the sole hydrophilic component. 
The polymerizations all resulted in monodisperse polymer latexes, bearing a negative 
zeta potential from the inclusion of ACVA as the initiator head group, with a typical 
polymer displaying an Mn of 74632 g mol
-1 and a dispersity of 1.78 by DMF SEC 
(Figure 3.5). Varying the hydrophilic monomer led to a range of particles which size 
varied from largest to smallest in the order: HEAm ≥ ACVA > ManAm > PEGA > 
LactAm (Table 3.1 F-J; and Figure 3.6).  
 
Figure 3.5: DMF SEC trace for particle “F” (Table 1), P(LactAm)1-co-(sty)5  Mn= 74600 g mol-1 Đ= 1.78 
This result primarily confirmed that the hydrophilic monomer used plays a large part 
in the stabilization of this emulsion system and can be used to influence the size of any 
resulting particle. This further adds evidence towards confirming the inclusion of the 
hydrophilic part in the resulting particle structure. The trend in diameter change 
between the monomers further supports the hypothesis that those monomers with a 
larger steric bulk stabilise the resulting particles more efficiently than a smaller 
monomer, producing the smallest particles. The number of hydroxyl groups on the 
hydrophilic monomer, and the ability to hydrogen bond with water can also be seen to 
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have an influence on particle size and stabilisation, shown when LactAm and PEGA 
particles are compared directly. Both monomers LactAm and PEGA monomers are of 
a similar molecular weight (439 and 480 g mol-1 respectively), however LactAm has 
seven free hydroxyl groups and is able to form more hydrogen bonds with water than 
PEGA. Consequently LactAm is able to stabilise a growing particle more efficiently 
than with steric bulk alone, and produced particles 55 nm in diameter compared to 
PEGA, which produced particles 70 nm in diameter. A similar trend is also seen when 
comparing ManAm to HEAm, with ManAm producing a diameter of 88 nm and 
HEAm 112 nm. This direct comparison is less valid however due to the difference in 
molecular weight (277 and 115 g mol-1 for ManAm and HEAm respectively).  
 
Figure 3.6: Particle diameter by DLS with varying hydrophilic monomer: Normalised DLS traces by number for 
particles F-J (Table 1) showing A) number average particle diameter (normalised) B) intensity average 
(normalised). Traces F-J represent: LactAm, PEGA, ManAm, HEAm, ACVA respectively 
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It is also noteworthy that the emulsion polymerisation using only the ACVA initiator 
as the hydrophilic component, produced well-defined particles of 108 nm in diameter. 
The stabilisation in this case is solely due to the charged carboxylic acid group of 
ACVA, having been deprotonated by sodium hydroxide used to ensure complete 
dissolution of ACVA in water. That such a small, well defined particle was achieved 
with only the head group shows the importance of charge, and the initiator choice, in 
stabilising the growing particles. In the case of HEAm particles, the ACVA potentially 
provided the majority of stabilisation, as both particles stabilised by HEAm and ACVA 
alone showed equivalent sizes and zeta potentials (c. 110 nm and -37 to -39 mV 
respectively). The diameters and morphology of the particles was also confirmed by 
scanning electron microscopy (SEM) and was broadly found to be in agreement with 
the number distribution determined by DLS (Figure 3.7, Table 3.1). 
 
Figure 3.7: SEM images showing particle size and morphology. Pictures a, b, c, d and e correspond to styrene 
particles with shells of β-D-lactose-1-oxyethyl acrylamide, PEGA, mannose acrylamide, hydroxyethyl acrylamide 
and no hydrophilic monomer respectively. Average diameter for each can be found in Table 3.1 
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SEM analysis also showed evidence on the mechanism of particle growth in a free 
radical surfactant free emulsion polymerisation. In images a, b, c, and d of Figure 3.7, 
a smaller population of proto-particles can be seen in addition to the larger particle 
population, indicating the inclusion of multiple particles. These findings suggest that 
proto-particle aggregation is a significant means of growth, along with the accepted 
particle size increase through radical insertion and internal polymer growth. The 
smallest particles produced were those using LactAm as the hydrophilic monomer, 
resulting in a diameter of 55 nm (determined by DLS and confirmed by scanning 
electron microscopy (SEM), giving an average size of 54 nm). This suggested that the 
lactose monomer provides superior stabilization when compared to all other 
hydrophilic co-monomers tested. The improved stabilisation is hypothesised to be due 
to its seven hydroxyl groups, which increase the number of potential hydrogen bonds 
and thus its number of hydration and water solubility, as well as good steric 
stabilization from its bulky disaccharide structure. These results are remarkable as 
surfactant free polymerization does not typically provide access to particle diameters 
under 100 nm, due to insufficient stabilization causing particle aggregation. Indeed, 
most examples to date use the initiator potassium persulfate (KPS) to provide sufficient 
stabilization, e.g., in the emulsion polymerization of styrene and methyl 
methacrylate.23, 32 This work however, has shown that styrene particles made with 
ACVA initiator and either lactose monomer, PEGA, or mannose acrylamide as a 
hydrophilic co-monomer provide access to particles of diameter 55, 70, and 88 nm, 
respectively. Being able to reliably produce particles under 100 nm in diameter without 
the use of a surfactant or initial polymer di-block shows the potential for using a 
charged initiator with sterically large or charged monomers, particularly 
glycomonomers, for their ability at stabilizing a latex and to produce functional 
nanoparticles.  
3.4.1.5 Maximum Weight Percentage  
One major drawback to a surfactant free system, relying on in situ stabilisation is the 
low weight percentage of polymer that can be used, typically around 5%, if a particle 
diameter below 100 nm is desired.  To further explore the limits of the surfactant free 
system described here, we experimentally determined the maximum particle 
concentration possible by repeating an emulsion polymerisation of LactAm and 
styrene at a ratio of 1:10 at varying weight percentages of: 10, 15, 20 and 30 wt% 
(Figure 3.8).  
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Figure 3.8: DLS traces by number of LactAm:Styrene 1:10 particles at both 10 and 15 wt%. 10% diameter = 230 
nm Pdi = 0.062, 15% diameter = 210 nm, Pdi = 0.048 
The maximum solids percent was determined to be <20 wt% of monomer, as well-
defined particles were produced up to 15 wt%. At 20 wt% and above, defined particles 
were not obtained and aggregated to such an extent that a reliable size could not be 
obtained by DLS.  
3.4.2 Effect of Particle Core Tg on Lectin Binding 
Having shown the potential for synthesising surface functionalised particles using a 
free radical surfactant free emulsion polymerisation, and for DLS to be used in real 
time qualitative analysis of particle-lectin aggregation, the two techniques were used 
together to determine the effect of particle core glass transition temperature (Tg) on 
lectin induced particle aggregation. When particles aggregate, they are brought into 
very close proximity to each other by multiple lectin-sugar interactions, the force of 
which individually may be small, but cumulatively may be enough to deform particles, 
if the constituent polymer is above its Tg and able to flow. Conversely a particle in 
which the core forming polymer is below the Tg and hard, particle deformation would 
be less likely to occur, requiring far larger forces. For this reason it is hypothesised 
that those particles below their Tg will be able to deform, increasing their packing 
density above the maximum for a hard sphere (74%), and the area and number of 
particle-lectin interactions, resulting in larger aggregates, when compared to an 
equivalent particle below its Tg.  
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3.4.2.1 Synthesis of “Soft” and “Hard” Particles with Varying Core Glass 
Transition Temperatures  
To investigate the effect of particle core Tg a series of lactose and mannose coated 
particles with equivalent butyl acrylate or styrene cores were synthesised, representing 
particles with a low and high Tg (ca -30 °C and 100 °C respectively). Using the 
developed surfactant free emulsion polymerisation was of benefit here, as each particle 
could be made readily from the monomers alone, with no need for separate polymer 
di-block synthesis of each particle composition. As the DLS aggregation tracking 
technique is limited by the colloidal stability of the final particle aggregate, smaller 
particles that were able to be aggregated in a controlled way were required. For this 
reason LactAm coated particles were chosen to study using the DLS aggregation 
method, as LactAm produced the smallest particles using a surfactant free emulsion 
polymerisation. Lactose coated particles were also able to be aggregated using the 
bivalent lectin ricinus communis rgglutinin (RCA)120, which is known to bind 
specifically to β-galactose terminal residues.64 This is in preference to the tetravalent 
Con A, preferential towards mannose and glucose), as the interactions from a bivalent 
lectin were hypothesised to be fewer and thus produce a smaller aggregate. Conversely 
for analysis by cryo-Transmission Electron Microscopy (TEM) larger particles and 
aggregates are easier to analyse. For this purpose P(ManAm) coated particles were 
synthesised to be larger in diameter, and form larger aggregates with the tetravalent 
lectin Con A. 
 Particle Composition Hydrophilic 
(μmol) 
Hydrophobic 
(μmol) 
Tg (°C) Diameter by 
DLS (nm) 
PDia 
A P(LactAm)1-co-(Sty)5 47 235 103 55 0.1 
B P(LactAm)1-co-(BA)4.5 47 212 -42 60 0.058 
C P(ManAm)1-co-(Sty)5 55 275 103 145 0.1 
D P(ManAm)1-co-(BA)2.8 55 154 -42 150 0.09 
 
Table 3.2: Synthetic results for nanoparticles synthesised via a free radical surfactant free emulsion polymerisation, 
for use in determining the effect of particle core Tg on lectin induced aggregation a Pdi values calculated using 
Equation 3.2 
Initially equivalent particles with a LactAm shell were synthesised, using the 
previously described surfactant free emulsion polymerisation method, with poly(butyl 
acrylate) (BA) and poly(styrene) (Sty) cores producing diameters of 60 and 55 nm 
respectively (Table 3.2). Differential scanning calorimetry (DSC) was performed on 
the particles, and revealed a core Tg of -42 °C for P(BA) and 103 °C for P(Sty); 
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confirming that in the bulk phase at least, particles with P(BA) cores are above their 
Tg and can be considered “soft” and fluid at room temperature, whereas P(Sty) particles 
are not and can be considered as “hard” spheres at room temperature. (Figure 3.9) 
Particles with a P(ManAm) shell and equivalent P(BA) and P(Sty) cores were then 
synthesised using the same synthetic method, producing particles with diameters of 
150 and 145 nm, and core Tg’s of -42 and 102 °C respectively (Table 3.2, Figure 3.10). 
LactAm coated particles were then purified by dialysis against deionised water using 
a membrane with a 100 kD molecular weight cut off (efficient centrifugation was not 
possible due to the small particle size), and filtration through a 200 nm syringe filter. 
This was to remove free P(LactAm) in solution and any large particles. ManAm coated 
particles were purified by three cycles of centrifugation and particle re-suspension in 
clean de-ionised water to remove P(ManAm) homopolymer.  
  
Figure 3.9: DSC traces for P(LactAm) coated particles with: A) poly(butyl acrylate) and B) poly(styrene) core, 
synthesised via a free radical surfactant free emulsion polymerisation showing glass transition temperatures of -42 
and 103 °C for butyl acrylate and styrene respectively. 
3.4.2.2 Particle-Lectin DLS Aggregation Determining Effect of Glass 
Transition Temperature 
In order to determine the effect, if any, of changing the particle core Tg on lectin 
induced aggregation, the P(BA) and P(Sty) particles had their lectin induced 
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aggregation analysed by the real time DLS technique outlined in Chapter Two. This 
was to reveal any difference in apparent number of particles per aggregate, with the 
hypothesis that P(BA) particles will form larger aggregates than equivalent P(Sty) 
particles, comprising more particles due to deformation allowing more simultaneous 
sugar-lectin interactions. Both the impure and purified P(LactAm) coated particles 
were analysed using the bivalent lectin RCA120, following a modified protocol 
described in Chapter Two (Section 2.3.7). Briefly, each latex was diluted with TRIS 
buffer, and placed into a cuvette in the DLS instrument, having been fitted with a 
septum and cannula to a glass syringe. A series of consecutive ten second 
measurements were performed for an hour, and after 60 s, RCA120 in TRIS buffer was 
injected to induce aggregation. After 40 minutes 75 mg mL-1 β-D-lactose in TRIS 
buffer was injected to competitively inhibit aggregation and induce aggregate break 
up (Figure 3.11). Particle aggregation can be seen in all cases as an increase in Z-
average diameter after the injection of RCA120.  
 
Figure 3.10: DSC traces of P(ManAm) coated particles with: A) P(BA) core showing a major Tg of -42 °C, B) 
P(Sty) core showing a major Tg of 102 °C 
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Figure 3.11: Results for lectin induced aggregation of lactose coated particles with the lectin RCA120, showing 
differences between particles with a “hard” P(Sty) core in black and a “soft” P(BA) in red. Initial increase in 
diameter where lectin introduced, subsequent reduction in aggregate size induced by free β-D-lactose sugar. A) 
Aggregation of raw latexes followed in DLS showing larger aggregate size for P(BA) particles, B) experiment “A” 
repeated with a purified latex, removing free P(LactAm) from solution, thus increasing the aggregation response, 
C) number of particles per aggregate determined using Equation 1, D) Mean count rate for all experiments, showing 
a steady increase suggesting no major sedimentation of aggregates from solution.  
Furthermore, this aggregation was confirmed as being due to reversible sugar-lectin 
interactions by the fast reversal of aggregation induced by the introduction of an excess 
of free β-D-lactose, seen as a return to the original Z-average diameter.  The increase 
in aggregate diameter was reduced when using impure particle latexes with both P(BA) 
and P(Sty) aggregates showing a lower number of aggregation when impure. This 
reduced aggregation is due to competition for lectin binding sites from free P(LactAm) 
homopolymer in solution. In the pure particles, where free P(LactAm) has been 
removed by dialysis, a much larger number of particles per final aggregate can be seen. 
In both cases (pure and impure) latexes composing a “soft” core of P(BA) showed an 
increased aggregate size, in the case of the pure particles, P(BA) showing a number of 
aggregation of 6439, compared to P(Sty) showing 2134 particles per aggregate when 
determined using Equation 3.1, dividing the aggregate by the particle volume and 
multiplying by the ideal packing parameter of hard spheres, 0.7404. 
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𝑝𝑝𝑎 = (
𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒 𝑉𝑜𝑙.
𝑃𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑉𝑜𝑙.⁄ ) × 0.74 
Equation 3.1: Used to determine number of particles per aggregate from DLS 
As both P(Sty) and P(BA) possess the same P(LactAm) concentration (before 
purification) and similar particle diameter, this increase in aggregate size may be 
attributed to the difference in particle core Tg. Suggesting that a particle with a “soft” 
core is able to form larger particle aggregates than a “hard” equivalent, which is 
hypothesised to be due to the ability of its core to deform, packing above the hard 
sphere limit of 74% and creating more simultaneous sugar-lectin interactions. In order 
for the data revealed by aggregation in DLS to be reliable, it is important that the 
aggregates formed are colloidally stable in solution and do not sediment. In order to 
track this the mean count rate was also monitored over time (Figure 3.11). An increase 
in count rate can be seen upon introducing the lectin to the latex, due to increased light 
scattering from particle aggregates. The intensity does not decrease again until the 
injection of free β-D-lactose sugar, suggesting that the aggregates formed are not 
growing large enough to sediment out of solution, thus validating the results obtained 
in this part.  
Having shown that the particles above their core Tg have an increased lectin induced 
aggregation, a cryo-Transmission Electron Microscopy (TEM) experiment was 
designed to try and elucidate the mechanism by which increased aggregation occurred. 
Images were obtained by the University of Warwick Advanced Bioimaging Research 
Technology Platform. It was hypothesised that the increased aggregation was due to 
the ability of the “soft” particles being able to deform and pack closer together, 
forming more simultaneous sugar-lectin interactions. In order to be visualised by cryo-
TEM it was necessary to perform the aggregation experiment at a far higher 
concentration.  
Therefore the aggregation experiment was repeated at the same particle to lectin ratio, 
however with the concentrated latex solution. At this high concentration, particle 
aggregation was immediate, therefore 20 μL of the aggregated solution was 
immediately placed onto a lacey carbon TEM grid after mixing and flash frozen in 
liquid ethane before being imaged (Figure 3.12).  The results from this test were 
inconclusive, with potential deformation being seen in the P(BA) particles, however 
this was not clear.  
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In order to try and improve the resolution of the microscopy, and the extent to which 
the particles may deform, a larger particle system with higher valence lectin was 
required.  
 
Figure 3.12: Cryo-TEM images of P(LactAm) coated particles with “soft” P(BA) and “hard” P(Sty) cores, a) 
P(BA) particles before aggregation, b) P(BA) after lectin induced aggregation with RCA120, c) P(Sty) particles 
before aggregation, d) P(Sty) after lectin induced aggregation with RCA120. All samples were flash frozen before 
imaging, in the case of aggregated samples, this was done immediately after lectin aggregation of concentrated 
latex   
For this purpose P(ManAm) coated P(BA) and P(Sty) cored particles were used. 
Purified particles were initially analysed by DLS aggregation with the tetravalent 
lectin Con A, to confirm that they aggregated as expected before performing cryo-
TEM. Both particles showed an expected increase in diameter after Con A injection, 
with the “soft” P(BA) particles showing a limited increase in aggregate size compared 
to the equivalent P(Sty) particles, showing 170 and 51 particles per aggregate 
respectively; this confirmed them as suitable for subsequent cryo-TEM experiments. 
The results from this DLS experiment alone were however not reliable for confirming 
that particles with a “soft” core aggregate more than “hard” equivalents, due to 
sedimentation of aggregates out of solution in both cases, shown in the reduced count 
rates over time after Con A addition (Figure 3.13).  
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Figure 3.13: Results for lectin induced aggregation of mannose coated particles with the lectin Con A showing 
differences between particles with a “hard” P(Sty) core in black and a “soft” P(BA) in red, initial increase in 
diameter where lectin introduced. A) Aggregation of purified latexes followed in DLS showing larger aggregate 
size for P(BA) particles, B) mean count rate for all experiments, showing an initial increase and subsequent drop, 
suggesting sedimentation of aggregates from solution, C) number of particles per aggregate determined using 
Equation 3.1 
This sedimentation was however expected, due to the large particle size and increased 
interaction with the tetravalent Con A. When the same experiment was performed on 
the concentrated latex and analysed using cryo-TEM a clear difference between the 
“soft” P(BA) and the “hard” P(Sty) particles was seen (Figure 3.14).  P(BA) particles 
could be seen to show significant deformation only when aggregated, conversely no 
deformation could be seen at all with the P(Sty) particles either before or after 
aggregation. This result, taken together with the increase in apparent aggregate size 
when analysed by DLS, provides evidence for the hypothesis that particles with a 
“soft” core undergo increased lectin induced aggregation, where the polymer is above 
its Tg. The appearance of visual particle deformation after aggregation seen in P(BA) 
particles suggests that the reason for this may be the ability of the core forming “soft” 
polymer being able to flow. This enables the particles to deform and pack above the 
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theoretical limit for a hard sphere (74%), allowing more simultaneous sugar-lectin 
interactions and thus the formation of larger aggregates.  
 
Figure 3.14: Cryo-TEM images of P(ManAm) coated particles with “soft” P(BA) and “hard” P(Sty) cores, a) 
P(BA) particles before aggregation, b) P(BA) after lectin induced aggregation with ConA showing deformation 
and close packing, c) P(Sty) particles before aggregation, d) P(Sty) after lectin induced aggregation with ConA 
showing no deformation and loose packing. All samples were flash frozen before imaging, in the case of aggregated 
samples, this was done immediately after lectin aggregation of concentrated latex   
3.5 Conclusions 
In this chapter it has been shown that a surfactant free emulsion polymerisation method 
can reliably produce nanoparticles between 50 and 350 nm in diameter in a one-step 
synthesis, with little or no purification necessary. The use of a hydrophilic co-
monomer has been shown to influence the resulting particle size through improved 
particle stabilisation, and shown to be incorporated into the final particle structure. The 
initiator ACVA and glycomonomers, particularly disaccharide monomers with a large 
number of hydration such as β-D-lactose-1-oxyethyl acrylamide, have been shown to 
be extremely good at stabilizing emulsion polymerizations; and provide a useful tool 
for synthesizing low diameter, well-defined carbohydrate coated nanoparticles suitable 
for biological use. The versatility and reproducibility of this technique has also been 
shown by synthesising a range of P(LactAm) and P(ManAm) particles with “soft” and 
“hard” cores of P(BA) and P(Sty) respectively of equivalent diameter. Furthermore 
these particles were used to study the effect of particle core forming polymer Tg on 
lectin induced aggregation using both DLS and cryo-TEM techniques. Particles with 
a “soft” core above the Tg, of P(BA) were shown to form larger aggregates than a 
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“hard” P(Sty) equivalent when aggregated using identical conditions, showing a larger 
number of particles per aggregate. Cryo-TEM experiments, visualising the particle-
lectin aggregates and showing only P(BA) particles deforming from spherical after 
lectin induced aggregation were also performed. These provided evidence to support 
the hypothesis that the increase in aggregation shown by P(BA) particles over a P(Sty) 
equivalent was due to the ability of the P(BA) particle to deform above its Tg, packing 
closer than the theoretical maximum for a hard sphere (74%), and being able to form 
more simultaneous sugar-lectin interactions.   
Chapter 3 
Andrew Lunn                                                                                                                   104 
 
3.6 Experimental  
3.6.1 Materials  
Poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 480 g mol
-1), n-
butyl acrylate (BA, >99%), bromo-propionic acid (>99%), 1-butanethiol (99%) and 
carbon disulphide (>99%), and N-hydroxyethyl acrylamide were obtained from 
Sigma-Aldrich and all monomers above were passed through basic aluminium oxide 
to remove inhibitor before use. 1,2,3,4,6-penta-O-acetyl-D-mannopyranose and β-D-
lactose octaacetate was obtained from Carbosynth Ltd and used as received. 
concanavalin A and RCA120 was bought from MP Biomedical SAS. All solvents were 
bought from commercial sources and were used as received. Dimethyl sulfoxide-d6 
(99.9% D atom), chloroform-d3 (99.8% D atom) and deuterium oxide-d2 (99.9% D 
atom), were obtained from Sigma Aldrich and used for 1H NMR spectroscopy. 
Thermal initiator 4,4′-azobis(4-cyanovaleric acid) (ACVA, >98%, Aldrich) was used 
as received. 0.45 μm syringe filters were obtained from Alpha Laboratories Ltd. Super 
smooth silicon wafers and lacey carbon (on copper) TEM grids were purchased from 
Agar Scientific and used as received.  
3.6.2 Analysis  
3.6.2.1 NMR Spectroscopy  
1H NMR spectra were recorded on a Bruker DPX-300 spectrometer using a mixed 
deuterated solvent of 4 parts d-DMSO to 1 part d-CHCl3. Each sample was run with a 
decay time of 2 s with 16 repeats. 
3.6.2.2 Mass Spectrometry  
Mass spectrometry measurements were performed on an Agilent 6130B Single Quad 
for ESI, with a methanol solvent. 
3.6.2.3 Elemental Analysis 
Samples were sent to Warwick Analytical Services (WAS) for analysis, all values are 
reported as received from WAS. 
3.6.2.4 Scanning Electron Microscopy (SEM)  
Polymer latex particles were first synthesised as described above. Raw latex was 
diluted by a factor of 500 with filtered de-ionised water, 5 μL was spotted onto a super 
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smooth silicon wafer and left to dry overnight in a laminar flow cabinet to ensure no 
sample contamination. Acheson silver DAG 1415M was painted onto the corners of 
each silicon wafer to as electrostatic screening. Samples were visualised using a Zeiss 
Gemini SEM- field emission scanning electron microscope. Particle diameter was 
determined using images obtained from SEM using Image J software with the FIJI 
macro. A minimum of 20 particles for each sample were manually measured and a 
mean average taken of the resulting diameters. 
3.6.2.5 Cryo-Transmission Electron Microscopy (TEM) 
Cryo-TEM samples were analysed by the Warwick Advanced Bioimaging Research 
Technology Platform (RTP). Samples were prepared by mixing the required amount 
of lectin-buffer solution with concentrated particle latex. 20 μL of the particle-lectin 
solution was immediately placed onto a lacey carbon TEM grid (on mesh copper) 
using an autopipette, and flash frozen by submerging in liquid ethanol. Images were 
then acquired by Warwick RTP using a Jeol 2200FS and processed using ImageJ 
software. The University of Warwick Advanced Bioimaging Research Technology 
Platform supported by BBSRC ALERT14 award BB/M01228X/1 are acknowledged 
for help with obtaining these images.   
3.6.2.6 Differential Scanning Calorimetry  
Glass transition temperatures were determined by differential scanning colorimetry 
using a Mettler-Toledo DSC1 with autosampler under nitrogen at a heating rate of two 
degrees per minute in capped 40 µL aluminium crucibles, with pierced lids.   
3.6.2.7 Size Exclusion Chromatography  
Chromatograms were recorded using an agilent 390-LC MDS instrument equipped 
with differential refractive index (DRI), viscometry (VS), dual angle light scatter (LS) 
and UV detectors. The system was equipped with 2 x PLgel Mixed D columns (300 x 
7.5 mm) and a PLgel 5 µm guard column. The eluent is DMF with 5 mmol NH4BF4 
additive. Samples were run at 1ml min-1 at 50’C. Poly(methyl methacrylate) standards 
(Agilent EasyVials) were used for calibration between 955,000 – 550 gmol-1. 
Experimental molar mass (Mn,SEC) and dispersity (Đ) values of synthesized polymers 
were determined by conventional calibration and universal calibration using Agilent 
GPC/SEC software.  
3.6.2.8 Dynamic light scattering, size and ζ-potential  
Chapter 3 
Andrew Lunn                                                                                                                   106 
 
Size and ζ-potential measurements were carried out using a Malvern Zetasizer Nano-
ZS at 25°C with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back 
scattering).  Pdi values were calculated using Equation 3.2.  
 
𝑃𝑑𝑖 =  
𝜎2
𝑑2
 
Equation 3.2: Equation to calculate Pdi from standard deviation (σ), and diameter (d). 
3.6.3 Synthetic Procedures  
3.6.3.1 Synthesis of β-D-Lactose-1-oxyethyl Acrylamide  
β-D-lactose-1-oxyethyl acrylamide monomer was synthesised following modification 
of the same procedure used to synthesise α-D-mannose-1-oxyethyl acrylamide in 
Chapter Two (Section 2.3.1). However, column chromatography was not utilised for 
the final purification of the monomer. Removal of the acetyl protecting groups was 
performed by evaporating DCM from the crude protected monomer and dissolving in 
250 mL of 0.3 M potassium carbonate in dry methanol in a 500 mL round bottom 
flask, which was charged with a 2.5 cm magnetic stirrer and sealed with a size 49 
septum. The flask was then purged of oxygen by bubbling nitrogen through it for 20 
minutes. This was then stirred at 400 rpm for 2 hours. The fully de-protected β-D-
lactose-1-oxyethyl acrylamide precipitated out of solution and was isolated by 
Buchner filtration, removing the excess solvent through a 2 μM filter. The resulting 
crude product was then washed with an excess of dry methanol under vacuum 
pumping. The structure of the monomer was confirmed by 1H NMR spectroscopy, 
Mass Spectroscopy and elemental analysis. (Table 3.3, Figure 3.15) 
  
Table 3.3: Elemental analysis for β-D-lactose-1-oxyethyl acrylamide monomer, showing theoretical and observed 
(analysed) percentage. 
MS m/z [M+Na]+: 462 (MSth:462.16), [M+K]+:478 (MSth:478.13)  
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1H NMR spectroscopy (400 MHz, D2O) δ 6.29 – 5.99 (m, 2H), 5.69 (d, J = 9.9 Hz, 
1H), 4.45 – 4.34 (m, 2H), 4.02 – 3.35 (m, 23H), 3.31 – 3.20 (m, 1H). 
 
Figure 3.15: 1H NMR spectrum for β-D-lactose-1-oxyethyl acrylamide monomer 
3.6.3.2 General Method for Free Radical Surfactant Free Emulsion 
Polymerisation  
Nanoparticles of various sizes (diameters between 50-500 nm) were synthesised by 
varying the ratio of hydrophilic to hydrophobic monomer in the reaction mixture. The 
general method by which nanoparticles were prepared is represented by the following: 
14.3 mg NaOH (3.6 x 10-4 mol) was added to 10 mL of deionised water, into which 50 
mg of ACVA (1.8 x 10-4 mol) was dissolved, the 2 eq. of NaOH is to ensure full 
solubility of ACVA in water. 10 mg of β-D-lactose acrylamide powder (2.276 x10-4 
M) was weighed into a tared 7.5 mL glass vial, 1.6327 mL of deionised water was then 
added into the glass vial using an auto-pipette, to which 0.351 mL of the previously 
described stock solution of ACVA was added. The glass vial was then charged with a 
1 cm magnetic stirrer bar, sealed with a size 21 septum and purged of oxygen by 
bubbling nitrogen through the solution for 10 minutes. In a separate 20 mL glass vial, 
sealed with a size 33 septum, n-butyl acrylate was purged of oxygen by bubbling 
nitrogen through the liquid monomer for 10 minutes. After both solutions had been 
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purged, 0.01459 mg of BA (1.139x10-3 moles, 0.0163 mL)) was transferred into the 
7.5 mL glass vial using a gas tight Hamilton syringe that has been purged of oxygen. 
The 7.5 mL vial was placed into an oil bath set to 70 °C and stirred at a rate of 800 
rpm for three hours. After approximately 5-10 minutes the reaction mixture turned a 
uniform white milky colour as the particles nucleated and the polymerisation 
proceeded.  At the end of three hours the reaction was quenched by removing the vial 
from the oil bath and exposing it to oxygen by removing the septum. The latex was 
analysed by 1H NMR spectroscopy to confirm complete conversion of monomer to 
polymer (>99%) (Figure 3.16), SEC to determine polymer molecular weight and 
dispersity (Mn = 174608 g mol
-1, Đ= 1.56, Figure 3.17), and DLS to determine particle 
diameter (Figure 3.18)  
 
Figure 3.16: 1H NMR spectrum for particle “A” (Table 3.1), P(LactAm)1-co-(BA)5 showing no residual monomer 
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Figure 3.17: DMF SEC trace for particle “A” (Table 3.1), P(LactAm)1-co-(BA)5 Mn= 174600 g mol-1, Đ= 1.56 
 
Figure 3.18: DLS number distribution for particle “A” (Table 1), P(LactAm)1-co-(BA)5 Diameter = 85 nm Pdi= 
0.1  
3.6.3.3 General Method for UV-Vis Aggregation Studies 
Turbidimetric studies were conducted by diluting 12.5 μL of undiluted particle 
solution with 1.25mL of 10 mM TRIS buffer in a 4.5 mL polystyrene cuvette, and 
placed in the UV-Vis spectrometer. In a separate 4.5 mL polystyrene cuvette, a stock 
solution of 2.027x10-5 M Con A in 10 mM TRIS buffer was prepared for use with 
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P(ManAm), P(LactAm) and P(GalAm) particles. Absorbance readings were taken 
every second at 500 nm, with 185.5 μL of Con A stock solution being added after 60 
seconds at which point 250 µL of Con A in TRIS buffer (2.027x10-5 M) was added 
with an Eppendorf pipette, and mixed twice to induce aggregation. In the case of de-
aggregation experiments the same protocol was followed with the following 
modifications: the initial 12.5 μL particle solution was diluted with 2.5 mL of 10 mM 
TRIS buffer (rather than 1.25 mL) and a further 9 minutes after Con A solution 
addition, 250 µL of mannose in phosphate buffer (150 mg mL-1) was added with an 
Eppendorf pipette and mixed twice to induce competitive binding with the 
glycosylated nanoparticles. The absorbance was monitored for a further 10 minutes. 
Readings were taken using an Agilent Cary 60 UV-Vis machine with Agilent software 
and analysed using Origin. 
3.6.3.4 General Method for DLS Aggregation Studies 
DLS measurements were taken using a Malvern instruments Zetasizer Nano at 25°C 
with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back scattering). For 
P(LactAm) particle DLS aggregation studies, 10 μL of particle solution was diluted 
with 1.24 mL of 0.1 mM TRIS buffer in a 4.5 mL polystyrene cuvette. The cuvette 
was fitted with a size 23 septum, which was pierced with a cannula attached to a 250 
μL Hamilton glass syringe. The cannula was positioned such that, solution ejected 
through it would run down the side of the cuvette.  This prevented the creation of any 
air bubbles that may have interfered with measurements. The cuvette was placed into 
the Zetasizer, and the lid closed with the syringe exiting through a slit at the side of 
the instrument. In a separate 4.5 mL polystyrene cuvette a stock solution of 15 μg mL-
1 RCA120 in 0.1 mM TRIS buffer was prepared. The Zetasizer was set to take a size 
reading every 10 seconds for 1 hour, however a delay of 1.66 seconds was recorded 
between each reading, adding 598 seconds to each hour, for which the results have 
been amended. After the sixth reading, 250 μL of 15 μg mL-1 RCA120 stock solution 
was injected via the cannula giving a final volume of 1.5 mL. The final concentration 
of RCA120 and side chain sugar residue was 3 μg mL-1 and 1.14x10-4M respectively. 
The same technique was then repeated with the addition of 250 μL of 75 mg mL-1 β-
D-lactose in TRIS buffer being injected via the syringe cannula after 40 minutes (to 
allow full aggregation). This was performed as a competitive binding assay, to show 
reversible lectin binding. The same technique was repeated for P(ManAm) particles 
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using 5 μL of particle latex with a stock solution of 2.027x10-5 M ConA in 0.1 mM 
TRIS buffer. This gave a final concentration of Con A and side chain residue of 
3.125x10-5M and 1.37x10-4M respectively.  
An estimation of aggregate volume was made by using the average final aggregate 
radius obtained by DLS in the formula for the volume of a sphere. Further, by dividing 
this by the initial volume of particles forming the aggregate multiplied by 0.74 (the 
ideal packing parameter of spheres) an estimation of aggregation number as particles 
per aggregate (ppa) was be made, summarised in Equation 3.1. 
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4.1 Abstract 
Tuberculosis (TB) is a global epidemic, killing 1.7 million people in 2016 alone, 
particularly those in poorer communities. Mycobacterium tuberculosis, the most 
common causative bacteria of TB, is difficult to treat due in part to its ability to survive 
and replicate within the host macrophage. New treatment options leading to better 
tolerated, shorter antibiotic courses targeting intracellular bacteria are of great interest. 
The development of a novel, pH responsive, mannosylated nanoparticle, covalently 
loaded with isoniazid, a first line TB antibiotic, is presented. This nanoparticle drug 
delivery agent is shown to have an increased macrophage uptake and, upon exposure 
to the acidic phagolysosome, release isoniazid through hydrolysis of a hydrazone 
bond, and disintegrate into linear polymer. Full antibiotic activity is shown to be 
retained in cell tests, with mannosylated isoniazid particles being the only treatment 
exhibiting complete bacterial eradication of intracellular bacteria, compared to an 
equivalent PEGylated system and free isoniazid. 
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4.2 Introduction  
Tuberculosis (TB), a bacterial infection mainly caused by Mycobacterium 
tuberculosis, is a global epidemic, being one of the top 10 causes of death in the world 
and killing 1.7 million people in 2016 alone.1, 2 Most infections affect the lungs, and it 
is generally contracted via prolonged inhalation of aerosols containing the bacteria 
from a person with an active infection coughing or sneezing. Infection typically occurs 
whilst living in close quarters, with the majority of deaths associated with TB occur in 
people who live in countries with low or middle incomes.3,4  
One of the most widely used and important antibiotics in the treatment of TB is 
isoniazid, which is commonly in combination with: rifampicin, pyrazinamide or 
ethambutol for a minimum of six months.5-7 Such long drug regimens are required 
partly as TB is a slowly dividing bacteria that is able to survive and grow inside 
immune macrophage cells.8-12 It is difficult to target and eradicate the bacteria that are 
able to survive in immune cells, this coupled with antibiotic courses not being finished 
contribute to ineffective therapy.13, 14 New therapeutics, capable of targeting 
intracellular bacteria would therefore be an invaluable weapon in combatting 
tuberculosis.  
Many strategies exist to improve tuberculosis therapy, including the development of 
new small molecule antibiotics such as bedaquiline.15-18 Another strategy, with 
potential to quickly improve the efficacy and longevity of current antibiotics, is to 
deliver them to the site of action bound to a targeted nanocarrier, the use of which is 
fully explored in Chapter One.19-21 In this manner an increased concentration of 
antibiotic may be achieved at the infection site, in this case the macrophage, from a 
smaller overall administered dose, potentially reducing systemic exposure and 
minimising associated side effects. The nanocarrier must be able to be effectively 
loaded with a drug and release it intracellularly in the macrophage. Covalently loading 
a drug to a nanocarrier is one way of ensuring high drug loading with minimal 
unwanted release. If this strategy is employed, the drug must either remain active when 
tethered to the nanocarrier or the covalent bond must be cleavable at the site of action. 
A release trigger of considerable interest is pH, particularly when targeting the 
macrophage. Upon phagocytosis any carrier would experience an acidic shift of 
environment from extracellular pH 7 to lysosomal pH 5.22, 23 This change would 
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quickly hydrolyse a bond such as an imine, oxime or hydrazone, and consequently 
release any drug tethered by it e.g. isoniazid.24-26  
Such a change in pH could also be used to address one further issue when using 
polymeric nanoparticles as drug delivery agents, the accumulation of the injected 
particles in organs such as the liver and spleen.27 Particles that are able to break up into 
their constituent polymers upon a stimulus would be able to be cleared thus avoiding 
accumulation, pH is a good candidate stimulus for producing such a response.28, 29 A 
pH change, such as that experienced when moving from the extracellular to the 
phagolysosomal environment, can be used to induce assembly or disassembly through 
modified polymer solubility.30-32 Both Sun et al. and Bütün et al. have shown that 
Poly(2-(Dimethylamino)ethyl methacrylate) (P(DMAEMA)) exhibits a change from 
hydrophobic to hydrophilic upon pH reduction, due to protonation of the tertiary 
amine.33-35 It is reasonable to assume that similar polymers such as poly(2-(di-
isopropylamino)ethyl methacrylate) (P(DPAEMA)) would exhibit similar behaviour. 
If this solubility change could be induced at pH 5, such polymers could be used to 
produce the required particle break-up for clearance upon phagocytosis.  
Another property that can be exploited in improving macrophage targeting is particle 
size. Macrophages are known to preferentially phagocytose particles ≥100 nm in 
diameter, ensuring that any nanocarrier that is over this diameter will further improve 
the macrophage uptake and intracellular concentration of any drug associated with it.36-
39 Macrophages also express certain cell surface lectins such as dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), which bind to 
the sugar mannose, a property that can be taken advantage of by having the surface of 
a nanocarrier functionalised with mannose.40-42 Lectin-sugar interactions have 
previously been shown to be enhanced by the close packing of sugars such as on a 
particle surface, the “cluster glycoside effect”.43-46 Such properties are achievable 
using a nanoparticle system synthesised using techniques such as those demonstrated 
in both Chapter Two and Three. Thus mannose coated polymeric nanoparticles are 
good candidates for targeting the macrophage.  
Using the free-radical surfactant free emulsion polymerisation method for synthesising 
functional nanoparticles developed in Chapter Three as a simple and scalable process; 
this chapter will explore the synthesis of isoniazid loaded nanoparticles with a novel 
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hydrazone linked, pH responsive isoniazid vinyl monomer (DAAm-hydrazone-INH), 
together with DPAEMA and mannose acrylamide (ManAm).47 It is demonstrated that 
particles with a mannose shell are capable of preferential endocytosis into macrophage 
cells, and upon endocytosis, release their antibiotic cargo as a result of acidic 
hydrolysis of the hydrazone linker. Furthermore, to stop bioaccumulation, the same 
reduction in pH causes the particles to break down into their constituent linear 
polymers for clearance. Finally, bacterial killing assays show the retention of full 
antibiotic effect after intracellular release, with full bacterial eradication only being 
achieved by mannose coated pH responsive isoniazid nanocarrier.  
4.3 Results and Discussion  
4.3.1 Monomer Syntheses 
 
Scheme 4.1: Proposed synthetic mechanism for hydrazone formation between diacetone acrylamide and isoniazid 
To achieve intracellular release of isoniazid with a high drug loading and efficiency, a 
responsive monomer was required that was suitable for use during emulsion 
polymerisation, and able to release isoniazid upon phagocytosis. The pH change from 
the extracellular to phagoloysosomal environment is from around pH 7 to 5. As 
isoniazid bears a hydrazine group, a convenient bond that this can form with an 
aldehyde or ketone is a hydrazone, which is stable at pH 7 and hydrolyses around pH 
5. To achieve this hydrazone linked monomer, a condensation reaction was performed 
between the hydrazine group on isoniazid, and the ketone on the commercially 
available monomer, diacetone acrylamide (Scheme 4.1). Using stoichiometric 
conditions, the reaction yielded in full conversion the expected structure of the 
diacetone acrylamide-isoniazid imine linked monomer (DAAm-hydrazone-INH) 
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product. The structure was confirmed by 1H NMR spectroscopy, mass spectrometry 
and elemental analysis (Section 4.5.2).    
 
Scheme 4.2: Proposed synthetic mechanism for urea formation between 2-icocyanatoethyl methacrylate 
and isoniazid 
To assess the pH-responsive isoniazid release of the DAAm-hydrazone-INH 
monomer, a non-responsive control was also synthesised that would not release 
isoniazid at the reduced phagolysosomal pH. This was achieved by coupling the 
hydrazine group on isoniazid with 2-isocyanatoethyl methacrylate, forming a urea 
linked isoniazid monomer (urea-INH). (Scheme 4.2) The pure monomer was found to 
precipitate out of methanol when cooled to 2-8 °C, and was recovered by filtration and 
further purified by recrystallization in methanol. The structure and purity were 
confirmed by 1H NMR spectroscopy, mass spectrometry and elemental analysis. 
(Section 4.5.3). By having both a pH and non-pH responsive monomer, particles could 
then be made that were suitable for assessing the ability of a hydrazone linked isoniazid 
for intracellular release.  
 
Scheme 4.3: Proposed mechanism for the synthesis of cyanine 3 acrylamide, from cyanine 3 amine and acryloyl 
chloride 
In order to determine particle uptake by macrophages however, a fluorescent particle 
analogue was required to track the particles by fluorescence microscopy and using a 
fluorescence plate reader. To produce fluorescent particle analogues, a cyanine 3 
acrylamide (Cy3Am) monomer was synthesised to be used as a co-monomer in a low 
molar percentage during particle synthesis. (Scheme 4.3) To achieve this, cyanine 3 
amine was reacted with acryloyl chloride; mass spectrometry and HPLC analysis 
revealed that this resulted in a pure Cy3Am monomer suitable for use as a hydrophilic 
Chapter 4 
Andrew Lunn                                                                                                                   122 
 
 
co-monomer during emulsion polymerisation. (Section 4.5.4). Having synthesised all 
required monomers, both pH responsive and non-pH responsive isoniazid loaded 
particles could be synthesised with their fluorescent analogues. 
 
Figure 4.1: Graphical representation of the nanoparticle system produced showing the three components: 
poly(mannose acrylamide) in blue, poly(diisopropylamino)ethyl methacrylate)) in red and poly(diacetone 
acrylamide-hydrazone-isoniazid) in green 
4.3.2 Particle Synthesis    
To produce controlled drug delivery to macrophages, nanoparticles around 200 nm in 
diameter and coated in mannose were targeted. This was in order to exploit both the 
propensity of macrophages to phagocytose particles over 100 nm in diameter, and to 
target the cell surface lectins known to preferentially bind to mannose, such as DC-
SIGN.40-42, 48, 49 The particles were synthesised using the free radical surfactant free 
emulsion polymerisation method outlined in Chapter Three.47 In addition to the 
investigative system of mannose coated particles with cleavable isoniazid 
(P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)) (Figure 4.1), control 
particles of: mannose with no antibiotic (P(ManAm)-co-P(DPAEMA)), mannose and 
a non-cleavable isoniazid (P(ManAm)-co-P(urea-INH)-co-P(DPAEMA)), PEGA 
shell with no antibiotic (P(PEGA)-co-P(DPAEMA)), and PEGA with cleavable 
isoniazid   (P(PEGA)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)) were also 
synthesised.  This was to determine the source of any antimicrobial activity. 
Fluorescent analogues of P(ManAm)-co-(DAAm-hydrazone-INH)-co-P(DPAEMA)-
co-P(Cy3Am), P(PEGA)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)-co-
P(Cy3Am) and P(ManAm)-co-P(DPAEMA)-co-P(Cy3Am) particles were also 
synthesised with 1% Cy3Am co-monomer as a molar ratio to DPAEMA content.  
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Table 4.1: Characterisation of all particles synthesised via surfactant free emulsion polymerisation, all reactions 
used a VA-044 initiator at a concentration of 0.75 mg mL-1. a determined using DLS number distribution, b 
determined using SEM with an average of 20 particles measured, c determined using Equation 4.1. Original DLS 
traces see A4.1-4.4, SEM images A4.5-4.7, d determined using Equation 1.1. 
All non-fluorescent latexes were analysed for particle size by DLS. Fluorescent latexes 
were analysed using SEM as DLS was not suitable due to absorption at the wavelength 
of the laser used (633 nm) (Table 4.1). The absorption/emission maxima of the Cy3Am 
particles was determined as 554/565 nm (Figure 4.2). There was some size discrepancy 
between particles, with the majority showing diameters of around 200 nm. Crucially 
the (P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)), (P(ManAm)-co-
P(DPAEMA)), (P(PEGA)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)) and 
(P(PEGA)-co-P(DPAEMA)) particles were all within 15 nm diameter of each other 
(210-225 nm). This is important as these particles will be directly compared to each 
other for their antibiotic activity in cell tests. Using this emulsion polymerisation 
method for isoniazid loading ensured 100% encapsulation efficiency (assuming full 
conversion of monomer to polymer), significantly higher than possible using 
entrapment methods, typically showing 40-80%.50-52 Furthermore the pro-drug loading 
of DAAm-hydrazone-INH achieved in the investigative system of (P(ManAm)-co-
P(DAAm-hydrazone-INH)-co-P(DPAEMA)) was 33 % calculated using eq. 1.1. 
When considered as the total amount of active drug released this reduces to 17% (pro-
drug loading was used for continuity of calculation between systems and to account 
for change in mass of conjugate product). Both of these represent a high percentage of 
drug loading, compared to the commonplace loading percent achieved in the literature 
of around 10%.53 
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Figure 4.2: Fluorescent absorption and emission spectrum of mannose-(DAAm-hydrazone-Iso)-DPAEMA-
Cy3Am particles in water, absorption/emission maxima λ = 554/565 nm 
This produced a latex with a final active isoniazid concentration of 6.5 mg mL-1, which 
is potentially too low for clinical applications, however if the solids content of this 
emulsion were increased to the maximum of 15% (as established in Chapter Three), a 
concentration of 44 mg mL-1 could be achieved whilst still keeping a stable latex. This 
concentration would be clinically relevant for both injectable and inhalable 
formulations with 6.8 mL providing a standard dose of 300 mg isoniazid.54  
4.3.3 Particle Disintegration and Isoniazid Release pH Studies  
 
Figure 4.3: A) Normalised level of isoniazid released from P(ManAm)-co-P(DAAm-hydrazone-INH)-co-
P(DPAEMA) particles over 24 hours at pH 3, 5 and 7, determined using HPLC (Original traces A4.9), B) Average 
diameter by DLS of P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA) particles at pH: 2.1, 2.9, 3.7, 5.3, 
6 and 7.5, showing stability at pH 7 and particle break up as a large drop in diameter below pH 6, count rate data 
A4.8 
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For the synthesised particles to selectively release isoniazid intracellularly, it is 
necessary for the hydrazone bonding the isoniazid to be selectively cleaved, in 
response to a relevant drop in pH. To assess this and the ability of the particles to 
disassemble at reduced pH values, their physical characteristics at a range of pHs were 
first assessed. To determine if isoniazid would be released from the particles at a 
relevant pH, P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA) particles 
were diluted in phosphate buffered saline (PBS) to 1 mg mL-1 at pH: 3, 5 and 7 and 
analysed by HPLC over 24 hours, comparing peak integrations for isoniazid. HPLC 
samples were prepared by centrifugation to remove polymer particles (where still 
present) and filtration to remove as much polymer as possible. This purification was 
necessary as the acidic conditions of the HPLC eluent would cause hydrolytic release 
of isoniazid bound to any polymer left, producing an artificially increased release 
profile (Figure 4.3, A4.9). The results confirmed the release of isoniazid at reduced pH 
values, with the largest release of isoniazid being seen at pH 3, reducing to half at pH 
5. Some limited release can be seen at pH 7; this is believed to be caused by residual 
particles/polymer in solution, releasing isoniazid in the acidic conditions of the HPLC 
eluent. These results confirmed that the DAAm-hydrazone-INH monomer was stable 
at neutral pH, releasing isoniazid via hydrolysis at reduced pH values. These results 
were in line with recent literature: Hwang et al. showed isoniazid release from a silica 
particle using a similar hydrazone linker to be stimulated with reduced pH, and 
minimal release at pH 7. More recently Nkanga et al. showed in two publications, 
nearly full isoniazid release from a hydrazone linker in 12 hours below pH 5.4.55-57  
A 5 mg mL-1 solution of the non-responsive urea-INH monomer was also tested for 
isoniazid release at pH 3 by mass spectrometry to ensure it was hydrolytically stable 
and a suitable control (A4.10). After 24 hours, a characteristic peak for the urea-INH 
monomer at m/z 315.2 [mass + Na]+ was still observed, with no trace of a peak for 
isoniazid. This result confirmed that the non-responsive control monomer did not 
release isoniazid under acidic physiological conditions.   
Due to the tertiary amine becoming protonated in acidic conditions, P(DPAEMA) is 
known to exhibit pH responsive behaviour, switching from hydrophobic to hydrophilic 
in an acidic environment.32, 58, 59 For this reason it was chosen as a co-monomer for 
particle synthesis, in order to cause particle disintegration after endocytosis and avoid 
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particle bioaccumulation. Dilutions of P(ManAm)-co-P(DAAm-hydrazone-INH)-co-
P(DPAEMA) particles were prepared to pHs of: 2.1, 2.9, 3.7, 5.3, 6 and 7.5, and their 
diameter analysed by DLS to determine the pH at which particle break up occurred 
(Figure 4.3). The particles were shown to be stable from pH 7.5-6, below which the 
particles swelled and disintegrated; this can be seen as an increase and subsequent drop 
in diameter by DLS. The point of disassembly at pH 6, which represents the pKb of 
the P(DPAEMA) is a useful value biologically, as the synthesised particles will be 
stable at extracellular pH 7 and break up in phagolysosomal conditions (around pH 5). 
The pH at which these particles break up is as expected and matches that reported by 
Xu et al. who used the same response to trigger the assembly of a polymeric tri-block.58  
These results confirmed the ability of this particle system to both break down into 
linear polymer and release isoniazid in response to a biologically relevant pH drop, 
and thus the suitability of the system for further biological testing as an intracellular 
drug delivery vector for isoniazid. 
4.3.4 Cytotoxicity  
In order for this particle system to be of use in delivering isoniazid to kill infective 
bacteria, it must itself be biocompatible and non-toxic to the host cells. To ensure the 
particles were biocompatible, cell viability tests were performed to determine the 
cytotoxicity of the responsive particles synthesised. The equivalent concentration of 
isoniazid loaded into the particles was used as a control. A 2,3-bis-(2-methoxy-4-nitro-
5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay was performed to 
determine cell viability by mitochondrial activity against a healthy cell control (Figure 
4.4). Particles were tested against a lung epithelial cell line (A549) and PMA activated 
THP-1 macrophages, representative of the typical pulmonary environment. The 
particles were shown to be non-toxic up to 0.5 mg mL-1 of polymer against A549 cells 
and 0.1 mg mL-1 in macrophages. The equivalent dose of isoniazid showed a similar, 
but less pronounced trend in both cell lines; it may then be concluded that any cytotoxic 
effect seen from the isoniazid particles is predominantly due to the presence of 
polymer and partially isoniazid. This matches well with the literature, one useful 
example from Hwang et al. in 2016 tested a range of polymeric nanoparticles against 
A549 and THP-1 cells specifically and also reported significant toxicity above 0.1 mg 
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mL-1.60 Taken together with the previous physical tests, these results suggested that 
the particles were suitable for further biological testing. 
 
Figure 4.4: Cytotoxicity tests, cell viability determined over 24 hours using an XTT assay. P(ManAm)-co-
P(DAAm-hydrazone-INH)-co-P(DPAEMA) particles tested against: A) THP-1 derived macrophages and B) lung 
epithelial (A549) cells. The equivalent concentrations of isoniazid delivered by the particle system tested against: 
C) THP-1 derived macrophages and D) lung epithelial (A549) cells 
4.3.5 Cellular Uptake  
It is important for the mechanism of particle break up and drug release that the particles 
are endocytosed via a lysosomal pathway, exposing the particles to an acidic 
environment. This has been previously demonstrated by Kalluru et al. who showed 
polylactide nanoparticles were trafficked to the phagolysosome of macrophages.61 It 
was also hypothesised that the presence of mannose on the particle surface would 
confer a preferential endocytosis, and demonstrate macrophage targeting. In order to 
test this hypothesis, a fluorescent cell uptake assay was performed using a cytation 3 
plate reader, with equivalent experiments performed using confocal fluorescence 
microscopy. It was first necessary however to ensure that the previously synthesised 
fluorescent particle analogues were purified to ensure they had no free dye present that 
would interfere with the experiment.  
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Figure 4.5: A) Fluorescence spectra of mannose-(DAAm-hydrazone-Iso)-DPAEMA-Cy3Am particle supernatant 
after centrifugation (excitation λ = 554 nm), showing disappearance of fluorescence indicative of all free dye having 
been removed, B) Fluorescence HPLC (absorption/emission λ = 554/565 nm) of mannose-(DAAm-hydrazone-Iso)-
DPAEMA-Cy3Am particles showing disappearance of free fluorescent polymer and monomer in solution 
indicative of complete removal, C) Image showing loss of colour from free Cy3Am and poly(Cy3Am) in the 
supernatants of mannose-(DAAm-hydrazone-Iso)-DPAEMA-Cy3Am 
To achieve this,  P(ManAm)-co-(DAAm-hydrazone-INH)-co-P(DPAEMA)-co-
P(Cy3Am) and P(PEGA)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA)-co-
P(Cy3Am) particles were purified by repeated cycles of centrifugation and 
replacement of supernatant with clean, deionised water. Both visually and using 
fluorescence spectroscopy, the removed supernatants showed an eventual loss of 
fluorescence, and HPLC analysis of the purified particles showed loss of free 
fluorescent polymer and monomer after purification. This confirmed the successful 
removal of all free dye. (Figure 4.5). The purified particles were then used in a 
fluorescence uptake assay. Particles were incubated at 0.1 mg mL-1 with THP-1 
macrophage cells for two, six and 24 hours. The level of intracellular fluorescence was 
analysed on a fluorescent plate reader, taking an average reading of fluorescence per 
cell as an indication of the level of endocytosis (A4.11). The relative fluorescence of 
the two latexes were normalised to each other using the extinction coefficient of each, 
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obtained from calibration curves of fluorescence by concentration (Figure 4.6). The 
results were then analysed by means of a separate Student’s T-test between ManAm 
and PEGA particles at each time point (Figure 4.7). (Normality of distribution was 
verified with a Kolmogorov-Smirnov non-parametrical test). 
  
Figure 4.6: Fluorescence calibration of A) mannose-(DAAm-hydrazone-Iso)-DPAEMA-Cy3Am particles and B) 
PEGA-(DAAm-hydrazone-Iso)-DPAEMA-Cy3Am particles  
The results showed that the particles were taken up in a time dependent manner and 
that, at six and 24 hours, a significantly increased fluorescence was observed for the 
mannose coated particles. This confirmed that a mannose shell conferred a preferential 
endocytosis over PEGA equivalent. These statistical analyses were supplemented with 
confocal microscopy images of the mannose coated particles in THP-1 macrophages, 
showing punctuated fluorescence increasing in intensity over the same two, six and 24 
hour time course. (Figure 4.7). This result is key in providing evidence that the 
presence of a mannosylated shell does confer a preferential uptake into macrophage 
cell lines. The increase, though statistically significant is modest however, as those 
with a PEG shell also show a time dependant increase in uptake. This effect has been 
reviewed in the literature, and the results presented here are broadly in line with 
previously reported data, with mannosylated liposomes having been shown to have an 
increased macrophage uptake when compared to a “bare” liposomal equivalent.62 The 
relative increase in mannosylated particle uptake, compared to a PEG equivalent in the 
environment of a well plate with a cell monolayer, is not surprising however. In this 
artificial environment the macrophages are left with particles simply placed on them 
in a perfect environment for their growth. The situation in vivo though is rather more 
complex, as the targeting of mannose receptors may give a far more pronounced 
increase in macrophage uptake. Reports regarding the in vivo uptake of a mannosylated 
compared to non-mannosylated particles all show an increased macrophage uptake of  
B A 
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Figure 4.7: Cellular uptake of fluorescent analogues of P(ManAm)-co-(DAAm-hydrazone-INH)-co-
P(DPAEMA)-co-P(Cy3Am) particles at 0.1 mg mL-1 by THP-1 derived macrophages tracked in A-D by confocal 
microscopy with particle incubation for B) two hours, C) six hours, D) 24 hours and A) as a control with no 
particles. Particles are shown in green with a Cy3 fluorophore, Actin in red with a DyLight 650 phalloidin stain, 
and the cell nucleus in blue with a DAPI stain. E) Comparative uptake of fluorescent ManAm and PEGA particles. 
Average intracellular fluorescence determined using a fluorescence plate reader as an indicator of endocytosis. 
Error bars show standard error, * = p < 0.05, ** = p < 0.01 determined by a Student’s T-test. Example images taken 
by citation plate reader shown in A4.12. 
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mannosylated particles, although the extent to which that effect is seen varies greatly 
between reports.42, 63, 64 Indeed some studies, such as that from the Hashida group 
report a circa two fold increase in alveolar macrophages,37 with others including those 
from the Morimoto group showing almost a three-fold concentration increase, again 
in macrophages.36, 41  
4.3.6 BCG Invasion and Intracellular Killing  
Mycobacterium tuberculosis is known to enter the macrophage, evading detection, 
replicating and ultimately bursting out of the macrophage cell.8-10 Therapies able to 
target and kill bacteria intracellularly are crucial in improving outcomes for TB 
therapy. Using Mycobacterium bovis Bacilli Calmette Guerin (BCG) as a mimic, 
intracellular killing assays were performed to assess the efficacy of synthesised 
P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA) particles (performed 
without purification). These were  performed against the control of free isoniazid at 
7.2 μg mL-1, Poly(Ethylene Glycol) Acrylate (PEGA) coated particles with cleavable 
isoniazid, mannose coated particles with no isoniazid and mannose coated particles 
with non-cleavable isoniazid: (P(PEGA)-co-P(DAAm-hydrazone-INH)-co-
P(DPAEMA), P(ManAm)-co-P(DPAEMA), and P(ManAm)-co-P(urea-INH)-co-
P(DPAEMA) respectively. An isoniazid concentration of 7.2 μg mL-1 was used as this 
is equivalent to the concentration of particle bound isoniazid at experimental 
concentration. In order to determine the antimicrobial activity, THP-1 macrophages 
were infected with M. bovis BCG by incubation at a multiplicity of infection (MOI) of 
one, with extracellular BCG subsequently washed off and killed. Infected 
macrophages were incubated for 20 hours with treatment or control at 0.1 mg mL-1 
polymer concentration or equivalent isoniazid concentration (7.2 μg mL-1). This 
concentration was selected as it provides an isoniazid concentration within the normal 
therapeutic range in serum (4.3-8.1 μg mL-1).65, 66 After incubation, macrophage cells 
were lysed to release intracellular bacteria and Colony Forming Unit (CFU) counts 
were performed to determine the number of bacteria present in each well. Results were 
analysed for significance using an ANOVA with a post-hoc Tukey’s range test. (Figure 
4.8, A4.12). The results showed that all treatments containing either free isoniazid or 
isoniazid bound by a cleavable hydrazone bond, exhibited significant bacterial killing 
compared to every other treatment group and positive controls. 
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Figure 4.8: Intracellular BCG killing determined as number of viable bacteria via CFU counts after treatment, with 
positive controls of infected cells receiving no treatment at four and 24 hours. A) CFU counts comparing mannose-
(DAAm-hydrazone-INH)-DPAEMA particles against controls of PEGA-(DAAm-hydrazone-INH)-DPAEMA, 
mannose-(DAAm-urea-INH)-DPAEMA and mannose-DPAEMA particles, and equivalent free isoniazid. B) 
Comparing mannose-DPAEMA particles to PEGA-DPAEMA particles and free isoniazid. Error bars show 
standard error, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 (Full statistical analysis A4.12-
4.13) 
Furthermore, delivery via a mannosylated particle improved the activity of the 
delivered dose of isoniazid, with P(ManAm)-co-P(DAAm-hydrazone-INH)-co-
P(DPAEMA) being the only treatment showing complete bacterial eradication. As the 
bacterial level observed for these treatments was so close to the minimum level of 
detection for this method, statistical significance could not be shown between the 
mannosylated particle and the PEG equivalent or free isoniazid. Nevertheless, this 
result was remarkable when compared to similar tests in the literature; with the 
particulate systems retaining as a minimum, full antimicrobial activity, and achieving 
complete bacterial eradication in 20 hours at a typical therapeutic serum 
concentration.61, 65, 66 Studies, such as that from Horvati et al. used a similar analytical 
method and found that isoniazid conjugated poly(lactic-co-glycolic acid) (PLGA) 
particles, whilst having a greater antimicrobial effect than free isoniazid, still showed 
50-100 bacterial colonies per well after three days treatment time.67  
Treatments without isoniazid, or where isoniazid had been introduced via a non-
cleavable linker: P(ManAm)-co-P(DPAEMA) and P(ManAm)-co-P(urea-INH)-co-
P(DPAEMA), showed a far reduced antimicrobial activity, with no statistical 
difference between the two treatments. This revealed that for the isoniazid to be active 
it must first be released from the polymer, and gave further evidence that the 
Chapter 4 
Andrew Lunn                                                                                                                   133 
 
 
responsive systems were effectively releasing isoniazid. Both control particles did 
however show statistically significant antimicrobial activity compared to the 24 hours 
control group. It was not clear though if this activity was an immunological response 
to the mannose present, or antimicrobial activity of the DPAEMA component that has 
recently been reported.68-71 The most relevant of these recent reports being that of 
Phillips et al. who showed that poly(dimethylaminoethyl methacrylate) was active 
against Mycobacterium smegmatis, a bacterium of the same family as tuberculosis and 
BCG, but faster growing.72 This study was limited to extracellular bacteria in MIC 
testing. Interestingly, further work from the same group has revealed the antimicrobial 
effect of a polycation against M. smegmatis is bacteriostatic and not membrane 
lysing.73  
To determine which component was the cause of the activity in this case, intracellular 
bacterial killing assays were performed with the P(ManAm)-co-P(DPAEMA) particle 
against controls of P(PEGA)-co-P(DPAEMA) and isoniazid (Figure 4.8, Table 4.1). 
Again, isoniazid showed good antimicrobial activity, with significantly reduced CFU 
counts against all other treatment groups and controls, validating the experiment. Both 
mannose and PEG coated particles showed limited, but statistically significant 
antimicrobial activity when compared to the 24 hour positive control. There was no 
significant difference shown between mannose and PEG coated particles however; this 
indicates that the antimicrobial activity shown is from the DPAEMA content of the 
particles. Positive polymers are known to exhibit antimicrobial activity, it was 
therefore hypothesised that protonation of the tertiary amine on DPAEMA in the acidic 
environment of the phagolysosome is responsible for the activity shown.74 This 
suggests limited co-localisation within the macrophage between the polymer and 
bacteria, either through lysosomal fusion or escape.   
4.3.7 Particle-Bacteria Co-Localisation Confocal Microscopy 
To test the hypothesis of intracellular co-localisation between particles and bacteria, 
THP-1 macrophages were infected with eGFP fluorescent BCG following the same 
protocol used in the bacterial killing assays. The infected macrophages were then 
treated with a fluorescent P(ManAm)-co-P(DPAEMA)-co-P(Cy3Am) particle, 
bearing no isoniazid so as not to eradicate BCG. Upon imaging using a Zeiss 880 
confocal microscope, limited co-localisation could be seen between BCG (shown in 
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magenta) and polymer (shown in green) (Figure 4.9). This would suggest that there is 
the potential for the now positively charged polymer to directly interact with BCG 
intracellularly, providing a plausible explanation for antimicrobial activity.  
 
Figure 4.9: Confocal microscopy showing co-localisation between investigative ManAm-DPAEMA-Cy3Am 
particle and BCG bacteria, areas of interest denoted by white circle. Green = ManAm-DPAEMA-Cy3Am particles, 
magenta = eGFP BCG, red = DyLight 650 phalloidin stained actin, blue = DAPI stained nucleus. Figures A and B 
show the same image with B only showing channels for particles and BCG for clarity; figures C and D show the 
same image with D only showing channels for particles and BCG for clarity.  
The limited nature of the co-localised fluorescence, together with the likely 
bacteriostatic antimicrobial mechanism would further explain the very modest 
antimicrobial activity that the particles exhibit.73 Where there is fluorescence from 
polymer and bacteria, the polymer fluorescence can be seen to be diffuse, and not 
clearly punctuated, suggesting that interaction is made possible through particle 
lysosomal escape rather than the fusion of separate compartments. Lysosomal escape 
would match with previous findings that nanoparticles and mycobacteria are found in 
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different compartments of the macrophage, the phagosome and phagolysosome 
respectively. The tertiary amine also provides a mechanism by which escape may 
occur, with its buffering capacity potentially triggering the “proton sponge” effect 
causing phagolysosome rupture.75 This provides a reasonable, but not conclusive 
explanation for interaction between bacteria and polymer, and thus the displayed 
antimicrobial activity of the particles not bearing isoniazid. 
4.4 Conclusions 
A novel isoniazid monomer has been described, utilising the hydrazine group of 
isoniazid to form a hydrazone bond with the ketone present on diacetone acrylamide. 
This monomer was shown to be suitable for emulsion polymerisation. The hydrazone 
linker was demonstrated to be cleavable by a biologically relevant drop in pH from 7 
to 5, yielding the active isoniazid compound. This monomer was co-polymerised with 
mannose acrylamide and DPAEMA in a free radical surfactant free emulsion 
polymerisation. Dual pH responsive nanoparticles with diameters of c. 200 nm were 
synthesised, breaking apart and releasing the covalently bound isoniazid at a clinically 
relevant pH of 5 in PBS. Fluorescence uptake studies showed preferential endocytosis 
of mannosylated particles via sugar-lectin interactions, over a PEGylated control. 
These particles were subsequently shown to be effective at killing intracellular M. 
bovis BCG bacteria in THP-1 macrophages, releasing their isoniazid cargo and 
exhibiting at least equivalent activity to free isoniazid in the artificial environment of 
a well plate, with P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA) 
particles being the only treatment to show complete bacterial eradication. This 
improved activity is hypothesised to be due to the increased cellular uptake of mannose 
coated particles, causing a higher intracellular isoniazid concentration compared to the 
controls. Furthermore, limited antimicrobial activity of the DPAEMA component of 
the particle was demonstrated, potentially contributing to the enhanced antimicrobial 
activity of the P(ManAm)-co-P(DAAm-hydrazone-INH)-co-P(DPAEMA) particle.  
Taken together these results show that in vitro, such macrophage targeted particles 
increase intracellular isoniazid concentration, showing an increased antimicrobial 
activity against intracellular mycobacterium, and leave the possibility for an enhanced 
effect in vivo to be studied.     
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4.5 Experimental  
4.5.1 Materials  
Magnesium sulphate, isoniazid (≥ 99%), diacetone acrylamide (99%), poly(ethylene 
glycol) methyl ether acrylate (PEGA, average Mn= 480 g mol
-1), 2-(diisopropylamino) 
ethyl methacrylate (97 %), acryloyl chloride (97%), 2-isocyanatoethyl methacrylate 
(98%), paraformaldehyde powder (95%), sodium hydroxide (≥ 97%), N-
methylmorpholine (99%) phorbol myristate acetate (PMA, ≥ 99%), trifluoro acetic 
acid (>98%), Middlebrook 7H10 agar base, Middlebrook 7H10 broth base, glycerol 
(≥ 99%), hygromycin B from Streptomyces hygroscopius, amikacin (European 
pharmacopoeial standard), phenazine methosulfate (PMS) (≥ 90%) and 2,3-Bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide inner salt (XTT) 
were purchased from Sigma-Aldrich and used as received except for all monomers 
that were passed through basic aluminium oxide to remove inhibitor. Thermal initiator 
VA-044 2,2'-azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride was purchased 
from Alpha Laboratories, Cyanine3 amine (95%) was purchased from Lumiprobe, 
Middlebrook OADC growth supplement was purchased from Agar Scientific, RPMI 
1640 Medium, GlutaMAX™ Supplement, DMEM, Hoechst 33342 and fetal bovine 
serum (FBS) was purchased from ThermoFisher, Phalloidin DyLight 650 Phalloidin 
(300 unit) was purchased from New England Bioloabs, ProLong Gold Antifade 
Reagent with DAPI was purchased from Vector Laboratories, super smooth silicon 
wafers, adhesive copper tape were purchased from Agar Scientific and LabTek II 4-
well microscopy culture slides were purchased from Thermo Scientific and all were 
used as purchased. THP-1 (ATCC® TIB-202™), A549 (ATCC® CCL-185™), 
Mycobacterium bovis Karlson and Lessel (ATCC® 35737™) and cells were taken 
from frozen stocks originally purchased from ATCC, eGFP BCG bacteria was taken 
from stocks previously engineered and used by the group. 
4.5.2 Analysis  
4.5.2.1 NMR Spectroscopy  
1H NMR spectra were recorded on a Bruker DPX-300 spectrometer using deuterated 
solvent (materials section). Each sample was run with a decay time of 2 s with 16 
repeats. 
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4.5.2.2 Mass Spectrometry  
ESI mass spectrometry measurements were performed using an Agilent 6130B single 
quad in methanol as a solvent in positive mode. 
4.5.2.3 Melting Point 
Melting point temperatures were determined using a Stuart SMP10 digital melting 
point apparatus with a small amount of monomer placed into capillary tubing and 
repeated in triplicate, the average of all three readings reported in all cases.  
4.5.2.4 Dynamic Light Scattering  
Size measurements were carried out using a Malvern Zetasizer Nano-ZS at 25°C with 
a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back 
scattering).  Measurements were taken assuming the refractive index of di-isopropyl 
aminoethyl methacrylate. Pdi values were calculated using Equation 4.1. 
Measurements of ζ-potential were modelled with the Smoluchowski theory.      
Pdi= 
σ2
d 2
 
Equation 4.1: Equation to calculate Pdi from standard deviation (σ), and diameter (d).  
4.5.2.5 Scanning Electron Microscopy  
SEM analysis was performed to determine the size and morphology of fluorescent 
particles as the fluorophore absorbed the laser used in DLS. Samples were prepared 
by diluting raw latex by a factor of 500 in previously filtered deionised water. A 5 μL 
drop of this diluted sample was then spotted onto a super smooth silicon wafer and left 
to dry for 12 hours in a laminar flow cabinet to ensure no sample contamination. The 
particles were visualised using a Zeiss Gemini SEM field emission scanning electron 
microscope at an accelerating voltage of 5 keV. Particle size and standard deviation 
was determined by taking an average of 20 particle diameters using Image J software, 
Pdi was determined using Equation 4.1.  
4.5.2.6 High Performance Liquid Chromatography (HPLC)  
HPLC samples were prepared by centrifuging the latex using an Eppendorf 
MiniSpin5452 at 13500 rpm for five minutes. The supernatant was aspirated off and 
filtered using a 0.2 μM PVC syringe filter. The filtered sample was then diluted by a 
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factor of 100 into HPLC water eluent (0.05 TFA) at an injection volume of 100 μL. 
Chromatograms were obtained using an Agilent 1260 Infinity series equipped with an 
Agilent 1260 variable wavelength detector. The HPLC was fitted with a Phenomenex 
Luna® C18 (250 × 4.6 mm) with 5 μm packing (100 Å) column. Mobile phase A: 
water (+0.05 % TFA), mobile phase B: methanol (+0.05 % TFA). The gradient used 
for HPLC analysis was increased from 5% to 95 % B in 30 minutes. Detection for 
isoniazid release was achieved via monitoring at 270 nm. To detect Cy3 or Cy3Am 
the same procedure was carried out, with monitoring of fluorescence at 
excitation/emission wavelengths of 554/565 nm. 
4.5.2.7 Cell Culture 
A549 (lung epithelial carcinoma) cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 2 mM 
of glutamine and pen/strep at 37°C  in a sterile, humid 5% CO2 environment. Tamm-
Horsfall Protein (THP)-1 cells were grown in Roswell Park Memorial Institute (RPMI) 
1640 GlutaMAX Medium supplemented with 20% (v/v) FBS at 37°C in a sterile, 
humid 5% CO2 environment. 
4.5.2.8 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-
Carboxanilide (XTT) Cell Viability Assay 
THP-1 monocytes were seeded at a density of 2.5x105 cells per mL into a 96 well plate 
in RPMI Glutamax media supplemented with 20% FBS and 100 ng mL-1 PMA in order 
to differentiate the cells to adherent macrophages and incubated for 72 hours at 37°C. 
Alternatively; A549 cells were seeded at a density of 5x105 cells per mL of DMEM 
(supplemented with 10% FBS, 1% glutamine and 1% pen/strep) into a 96 well plate 
and incubated for 24 hours at 37°C. In both cases after incubation, fresh media was 
replaced in all of the wells. The cells were then incubated with serial dilutions of the 
particles at 0.1 μg mL-1, 1 μg mL-1, 10 μg mL-1, 0.1 mg mL-1, 0.5 mg mL-1 and 2 mg 
mL-1 for 72 hours. To determine the cell viability a standard XTT assay was used.44 
The cell media was replaced with 100 μL fresh media and 100 μL of a 0.0083 mM 
phenazine methosulfate (PMS)/ 0.33 mg mL-1 XTT solution in media and left to 
incubate at 37°C for 24 hours. Each well then had its absorbance recorded using a 
BioTek Cytation3 plate reader at 450 nm and 650 nm (background). The relative 
absorbance compared to a control of healthy cells as 100% cell viability was recorded 
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and used to show the percentage cell viability in each case. The experiments were 
carried out with three technical replicates in triplicate.  
4.5.2.9 Macrophage Particle Uptake Assay 
THP-1 cells were seeded at a density of 2.5x105 cells per mL into a 96 well plate in 
RPMI Glutamax media supplemented with 20% FBS, and 100 ng mL-1 PMA in order 
to differentiate the cells to adherent THP macrophages and incubated for 72 hours at 
37°C to form adherent monolayers. The media was then replaced and cells were 
inoculated for either 24, six or two hours with either PEG or mannose coated 
fluorescent particles at a concentration of 0.1 mg mL-1. At 23 hours and 30 minutes 
incubation time, 10 μL of a 50 μg mL-1 Hoescht 33342 in PBS stock solution was 
added to the wells and incubated at 37°C for a further 30 minutes to stain the nucleus 
of the cells. The media was then removed and any extra cellular particles removed by 
with PBS three times. The cells were incubated in phenol red free media and placed 
into a BioTek Citation3 plate reader, to determine the level of fluorescence in each 
cell. The nucleus of each cell was imaged as a reference, set at absorption/emission 
detection of 377/477 nm for Hoechst 33342, and the fluorescence of cyanine 3 labelled 
particles at an absoption/emission of 531/593 nm. From the nucleus a representative 
cell size cut off of 13 μm was applied and using a rolling ball algorithm for background 
calculation, particle fluorescence per cell over hundreds of cells was determined and 
an average taken. This was repeated with three technical replicates in duplicate. To 
ensure any difference in fluorescence was due to changes in uptake, and not differing 
fluorescence intensity, a fluorescence calibration for both PEG and mannose particles 
was then produced. This was determined by serially diluting a 1 mg mL-1 stock of each 
particle by half repeatedly 15 times and taking a fluorescence reading of each, this was 
repeated in triplicate. The difference in relative fluorescence intensities was then 
determined by comparing the extinction co-efficient for each calibration. The relative 
fluorescence for both particles was found to be at a ratio of 1:0.97, and as such, within 
error of each other. However to ensure that differing fluorescence did not contribute 
to any observed differences in uptake, the readings for PEG particles were multiplied 
by 0.97 (Figure 4.6). 
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4.5.2.10 Confocal Microscopy Cell Uptake 
THP-1 derived macrophage cells were cultured on LabTek II 4-well microscopy 
culture slides as described for a 96 well plate in section “Macrophage Particle Uptake 
Assay”. After incubating with fluorescent mannose particles for two, six and 24 hours 
at 0.1 mg mL-1 the cells were washed three times with PBS and fixed by incubation 
with 1 mL of a cooled 4% PFA solution at room temperature for ten minutes. This was 
then washed three times with PBS. Cells were permeabilized in 1 mL of a 1% saponin, 
0.5% Triton X-100 solution in PBS for 20 minutes at room temperature, then blocked 
with 0.5 mL of a 3% bovine serum albumin (BSA) solution in PBS for 30 minutes at 
room temperature. Culture slides were then washed with 0.5 mL of 1% BSA in PBS. 
F-actin was then stained by adding 0.2 mL of a 2.5 μg mL-1 solution of phalloidin 650 
in 1% BSA for 40 minutes in the dark at room temperature. Chamber slides were then 
washed with 1 mL of PBS three times and chambers removed from the culture slides. 
A cover slip was then secured using 10 μL of DAPI mounting medium per well, also 
staining the nuclei of the cells. Slides were then kept in the dark between 2-8 °C until 
imaging. Confocal images were taken on a Zeiss 880 at 37 °C using a 40x objective 
lens and sequential scanning for each channel. Excitation/emission used for imaging 
was as follows: nucleus DAPI 405/410-480 nm, Cy3 particles 561/567-620 nm, 
DyLight 650 phalloidin 633/639-759 nm. Images were overlaid and processed using 
Image-J software.  
4.5.2.11 BCG Invasion and Intracellular Killing Assays 
Intracellular infection was performed on THP-1 derived macrophages. Cells were 
seeded at a density of 2.5x105 cells per mL into a 24 well plate in RPMI Glutamax 
media supplemented with 20% FBS, and 100 ng mL-1 PMA in order to differentiate 
the cells to adherent macrophages and incubated for 72 hours at 37°C. A single colony 
of BCG bacteria was inoculated in Middlebrook 7H10 broth supplemented with 10% 
(v/v) OADC enrichment. The inoculum was grown to an OD600=0.8, so to be in the 
log phase, and diluted ten-fold into cell culture medium (RPMI GlutMAX + 20% 
FBS). Media was then removed from each well of macrophages and replaced with the 
inoculated media. This was incubated for three hours at 37 °C giving an MOI of 1:1. 
Extracellular bacteria were then removed with PBS three times and the macrophages 
incubated with 1 mL solution of 200 ng mL-1 amikacin in media for one hour to ensure 
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no viable extracellular BCG. Cells were then further washed with 1 mL of PBS twice. 
Four hour controls incubated at room temperature with cold water for 5 minutes 
followed by vigorous pipetting to disrupt the mammalian cell membrane, and 
immediately diluted by a factor of ten into warm PBS twice. 20 μL of each dilution 
was pipetted onto Middlebrook 7H10 ADC agar petri dishes and incubated at 37 °C 
for 14-21 days to allow bacterial growth. The remaining wells were incubated for 20 
hours at 37 °C with 1 mL media containing particle or control. After 20 hours the cells 
were washed with PBS, lysed, plated and incubated as described for the four hour 
control wells. After two weeks CFU counts for all dilutions were performed and the 
total number of CFU’s per well determined using Equation 4.2.  
𝐶𝐹𝑈𝑇𝑜𝑡𝑎𝑙 =  𝐶𝐹𝑈𝐶𝑜𝑢𝑛𝑡𝑒𝑑 × (50 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟) 
Equation 4.2. Calculation performed to determine viable number of colony forming units (CFU) using dilute 20 
μL sample from a 1 mL well 
4.5.2.12 Confocal Microscopy of Particle/Bacteria Co-Localisation 
THP-1 derived M0 macrophage cells were cultures on LabTek II 4-well microscopy 
culture slides as described for 24 well plates in the section “Intracellular BCG Killing 
Assays”, and fixed as described in “Confocal Microscopy, Cell Uptake”, with the 
addition of the excitation/emission of eGFP BCG at 490/500-540 nm. Images were 
overlaid and processed using Image-J software.  
4.5.2.13 Statistical Analysis  
All analyses were performed using IBM SPSS Statistics 24. The test used for 
comparison of the means of particle uptake at 2, 6 and 24 hours for PEG versus 
mannose coated particles was a Student’s T-test. The test performed to compare all 
CFU count data after intracellular BCG killing was a one-way ANOVA test with a 
Tukey post-hoc analysis. The assumptions for the tests were: normality of distribution 
(verified with a Kolmogorov-Smirnov non-parametrical test), homogeneity of 
variances (evaluated using a Levene test). Analysis was performed on two or three 
biological repeats performed with three technical repeats in all cases. 
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4.5.3 Synthetic Procedures  
4.5.3.1 Isoniazid-Diacetone Acrylamide Hydrazone, pH Responsive 
Monomer ((E)-N-(4-(2-isonicotinoylhydrazineylidene)-2-
methylpentan-2-yl) acrylamide) Synthesis 
5  
 
6 Figure 4.1: A) Reaction scheme for diacetone acrylamide-hydrazone-isoniazid monomer B) 1H NMR 
spectrum confirming the structure of the monomer C) Mass spectrum showing the expected single peak at 
m/z= 310.7 [Mwt + Na]+ and D) Elemental analysis of the monomer, showing percentages within the 
expected range of the proposed monomer structure 
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Isoniazid (5 g, 0.0365 mol, 1 eq.) and diacetone acrylamide (6.16 g, 0.0365 mol, 1 eq.) 
were dissolved in anhydrous methanol to a volume of 250 mL in a 500 mL round 
bottomed flask charged with a magnetic follower. Anhydrous magnesium sulphate 
(5g, 0.02 mol) was suspended in the reaction mixture to absorb water released by the 
condensation reaction, pushing the reaction equilibrium to the product. The flask was 
sealed with a rubber septum and left to stir at room temperature for 16 hours. The 
magnesium sulphate was then removed via Buchner filtration and methanol removed 
under vacuum using a rotary evaporator leaving behind a clear gel like solid, confirmed 
as the pure product by 1H NMR spectroscopy, mass spectrometry and elemental 
analysis. (Figure 4.10)   
MS m/z = 310.7 [M+Na]+ (MSth: 311.06)  
1H NMR (300 MHz, D2O) δ 8.63 (t, J = 7.1 Hz, 2H), 7.69 (dd, J = 18.0, 5.9 Hz, 2H), 
6.31 – 5.96 (m, 2H), 5.67 (dd, J = 28.4, 13.5 Hz, 1H), 2.92 (d, J = 67.0 Hz, 2H), 2.02 
(d, J = 45.2 Hz, 3H), 1.43 – 1.27 (m, 6H) 
Melting point = 82°C 
4.5.3.2 Isoniazid-Diacetone Acrylamide Urea linked Non-Responsive 
Monomer (2-(2-isonicotinoylhydrazine-1-carboxamido)ethyl 
methacrylate) Synthesis  
Isoniazid (804 mg, 5.86x10-3 mol, 1 eq.) and 2-icocyanatoethyl methacrylate (1g, 
6.45x10-3 mol, 1.1 eq.) were dissolved in 50 mL of anhydrous methanol in a 100 mL 
round bottomed flask, charged with a magnetic follower. The flask was sealed with a 
rubber septum and left to stir. After four hours the product precipitated out of solution 
as a white powder. After cooling the reaction mixture to 8°C, full precipitation 
occurred and the precipitate was recovered by Buchner filtration using filter paper with 
pore size 11 μm. The powder was recrystallised using methanol as a solvent and 
confirmed as the product using 1H NMR spectroscopy, mass spectrometry and 
elemental analysis. (Figure 4.11)   
MS: m/z = 315.2 [M+Na]+ (MSth: 315.11). 
1H NMR (300 MHz, DMSO) δ 10.44 (s, 1H), 8.75 (d, J = 5.7 Hz, 2H), 8.11 (s, 1H), 
7.79 (d, J = 5.7 Hz, 2H), 6.74 (t, J = 4.9 Hz, 1H), 6.06 (s, 1H), 5.67 (s, 1H), 4.08 (t, J 
= 5.7 Hz, 2H), 2.50 (s, 4H), 1.88 (s, 3H). 
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Melting point =168°C 
 
Figure 4.2: A) reaction scheme for non-hydrolysable isoniazid monomer (Diacetone acrylamide-urea-isoniazid), 
B) 1H NMR spectrum, C) mass spectrum showing major expected peak at m/z = 315.2 [Mwt + Na] and D) 
Elemental analysis of the monomer, showing percentages within the expected range of the proposed monomer 
structure 
4.5.3.3 Cyanine 3 Acrylamide Synthesis 
Cyanine 3 amine (5 mg, 7.965 mmol, 1 eq.), acryloyl chloride (0.793 mg, 8.76 mmol, 
1.1 eq.) and N-methylmorpholine (NMM, 2.42 mg, 23.9 mmol, 3 eq.) were dissolved 
in 10 mL of chloroform in a 20 mL glass vial charged with a magnetic follower. The 
vial was sealed with a rubber septum and moved into a cold room to react at 8°C for 
six hours. The chloroform solvent and NMM was then removed under vacuum using 
a rotary evaporator, leaving a red crystalline powder. Due to the low mass of reactants, 
no purification or 1H NMR spectroscopy was performed, the product was confirmed 
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using high resolution mass spectrometry and HPLC, showing only the shifted 
monomer peak in HPLC and m/z in mass spectrometry. (Figure 4.12)  
MS: m/z = 609.4 [Mw]+ (MSth: 609.42). 
 
Figure 4.3: A) Synthetic scheme of Cy3Am B) Mass spectrum showing expected m/z = 609.6 [Mwt], C) HPLC 
fluorescence traces of cyanine 3 amine (black) and conjugate product (red) showing clear shift with no trace left of 
cyanine 3 amine  
4.5.3.4 General Particle Synthesis Method 
Nanoparticles of varying composition were synthesised by varying the monomers in 
the reaction mixture. The general method by which nanoparticles were prepared is 
represented by the following, using P(ManAm)-co-P(DAAm-hydrazone-INH)-co-
P(DPAEMA) as an example. 50 mg VA-044 (1.6 x 10-4 mol) was added to 10 mL of 
deionised water to produce a 5 mg mL-1 initiator stock solution. 13 mg of mannose 
acrylamide (4.67 x10-5 M) and 13.5 mg (4.69 x10-5 M) DAAm-hydrazone-INH was 
weighed into a tared 7.5 mL glass vial, 1.68 mL of deionised water was then added 
into the glass vial using an auto-pipette, to which 0.3 mL of the previously described 
stock solution of VA-044 was added. The glass vial was then charged with a 1 cm 
magnetic stirrer bar, sealed with a size 21 septum and purged of oxygen by bubbling 
nitrogen through the solution for 10 minutes. In a separate 20 mL glass vial, sealed 
Chapter 4 
Andrew Lunn                                                                                                                   147 
 
 
with a size 33 septum, DPAEMA was purged of oxygen by bubbling nitrogen through 
the liquid monomer for 10 minutes. After both solutions had been purged, 18 mg of 
DPAEMA (8.4x10-5 moles, 0.02 mL)) was transferred into the 7.5 mL glass vial using 
a gas tight Hamilton syringe that had been purged of oxygen. The 7.5 mL vial was 
placed into an oil bath set to 50°C and stirred at a rate of 800 rpm for three hours. After 
approximately 5-10 minutes the reaction mixture turned a uniform white milky colour 
as the particles nucleated and the polymerisation proceeded.  At the end of three hours 
the reaction was quenched by removing the vial from the oil bath and exposing it to 
oxygen by removing the septum. The resulting latex was analysed by DLS to 
determine particle size and dispersity (diameter = 212 nm, Pdi = 0.1) (Figure 4.13)  
 
Figure 4.4 Normalised size distribution by DLS for mannose-(DAAm-hydrazone-INH)-DPAEMA particle, 
diameter = 212 nm, Pdi = 0.01 
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4.7 Appendices  
 
A4.1: Normalised size distribution by DLS for mannose-DPAEMA particle, diameter = 210 nm, Pdi = 0.08 
 
A4.2: Normalised size distribution by DLS for mannose-(urea-INH)-DPAEMA particle, diameter = 280 nm Pdi 
= 0.04 
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A4.3: Normalised size distribution by DLS for PEGA-DPAEMA particle, diameter = 212 nm, Pdi = 0.14 
  
 
A4.4: Normalised size distribution by DLS for PEGA-(DAAm-Hydrazone-INH)-DPAEMA particle, diameter 225 
nm, Pdi = 0.07  
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A4.5: Representative SEM Image of mannose-(DAAm-hydrazone-INH)-DPAEMA-Cy3Am particle, diameter = 
175 nm Pdi = 0.1 
 
A4.6: Representative SEM Image of PEGA-(DAAm-hydrazone-INH)-DPAEMA-Cy3Am particle, diameter= 205 
nm Pdi = 0.04 
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A4.7: Representative SEM Image of mannose-DPAEMA-Cy3Am particle, diameter = 231 nm Pdi = 0.03 
 
A4.8: DLS count rate of mannose-(DAAm-hydrazone-INH)-DPAEMA at different pHs, showing reduction at pH 
6, indicative of particle break up due to protonation of tertiary amine on DPAEMA 
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A4.9: Overlaid HPLC traces for mannose-(DAAm-hydrazone-INH)-DPAEMA, particle incubated at pH: 7 (A), 
5(B) and 3(C) for 30 minutes, 60 minutes, 6 hours and 24 hours, showing increased isoniazid release at lower pH 
due to hydrolysis of hydrazone linker 
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A4.10: Representative mass spectrum of non-responsive urea-isoniazid monomer at pH 3 for 24 hours, showing 
no peak from free isoniazid at an m/z of 160 [isoniazid+Na] indicating no hydrolysis of the urea linker. 
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A4.11: Example images of particle uptake taken using a Cytation3 plate reader, and analysed to determine the level 
of endocytosis. In all images: green indicates Cy3Am labelled particles, blue indicates Hoechst 33342 stained nuclei 
and images are overlaid with greyscale light microscopy. A) mannose particles 2 hrs, B) mannose particles 6 hrs, 
C) mannose particles 24 hrs, D) PEGA particles 2 hrs, E) PEGA particles 6 hrs, F) PEGA particles 24 hrs.   
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A4.12: Full ANOVA-Tukey table of results for intracellular bacterial killing comparing ManAm-(DAAm-
hydrazone-Isoniazid)-DPAEMA particles with controls 
 
A4.13: Full ANOVA-Tukey table of results for intracellular bacterial killing comparing ManAm-DPAEMA to 
PEGA-DPAEMA particles with an isoniazid control 
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5 Chapter 5 
Conclusions and Outlook 
The overall aim of this thesis has been to explore the simplest methods to synthesise 
glyconanoparticles suitable for use both in fundamental studies, and as clinically 
scalable targeted drug delivery agents. The initial use of a RAFT emulsion 
polymerisation technique performed well in producing highly controlled particles, to 
develop a DLS based technique to track particle aggregation. The subsequent 
synthesis, using a free radical and surfactant free emulsion polymerisation, was shown 
to be suitable for use in aggregation studies and also applied to drug delivery with 
successful intracellular antibiotic delivery.  
Chapter Two focussed on the synthesis of mannosylated nanoparticles via RAFT 
emulsion polymerisation. This was achieved with the initial synthesis of a 
poly(mannose acrylamide)10-b-poly(butyl acrylate)15 di-block used as a polymeric 
surfactant in an emulsion polymerisation with butyl acrylate producing a library of 
nanoparticles of varying diameter. The control of particle size was confirmed with a 
calibration of targeted molecular weight against the resulting particle volume. Using 
the characterised mannose-butyl acrylate particles an online DLS based system for 
tracking particle-lectin binding was developed. The system exploited a cannula 
injection system to introduce the lectin Con A causing aggregation, whilst the 
instrument was recording particle size. The technique was shown comparable to the 
standard UV-Vis turbidimetric experiments used for aggregation studies. Furthermore 
aggregate size data was applied to give an estimation of the number of particles present 
per aggregate (up to a sedimentation size limit). This allowed quantitative comparison 
of aggregation between particles, revealing that larger particles displayed increased 
aggregation. This finding was only possible using the developed DLS technique, as 
the increased scattering response from larger particles and aggregates could be 
separated from each other. RAFT emulsion polymerisation as a technique however has 
potential scale up and biocompatibility issues.  
In efforts to address these issues, Chapter Three focussed on developing the simplest 
technique possible for synthesising glycoparticles with comparable properties to those 
produced by RAFT emulsion polymerisation. To do this a free radical and surfactant 
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free emulsion polymerisation was investigated. Previous studies had shown that stable 
particles could be produced using this technique using a highly charged initiator. It 
was shown that the initiator, 4,4’-azobis(4-cyanovaleric acid), could also be used and 
gave adequate particle stability. The potential for this technique to produce surface 
functionalised particles was also shown. Co-polymerisation of a hydrophilic monomer 
was shown to successfully incorporate c.50% of monomer onto the resulting 
nanoparticles. This allowed for the synthesis of glycosylated nanoparticles in a three 
hour synthesis from monomer to final latex. Furthermore the incorporation of 
monomer into the particle surface facilitated particle size control. By using a sterically 
large and highly water soluble monomer, particle diameters under 100 nm were 
reliably accessed without the need for time consuming controlled polymer synthesis 
or the addition of any potentially toxic surfactant. This technique does however leave 
a large amount of linear homopolymer in solution that is able to compete for lectin 
binding sites and is limited to a total solids content of around 15-20%. Particles 
synthesised using this technique were then used to investigate the effect of particle 
core glass transition temperature (Tg) on lectin induced aggregation. Using the 
previously developed DLS aggregation method and cryo-TEM, “soft” particles above 
their Tg were shown to be able to deform and form larger aggregates, owing to the 
stronger multivalent interactions possible from the increased surface area between the 
particles.  
Finally Chapter Four took the previously explored free radical, surfactant free 
emulsion polymerisation technique for producing glyconanoparticles and applied it to 
the delivery of an antibiotic. A system was designed and synthesised to target 
intracellular mycobacteria in macrophage cells, for the eventual treatment of 
tuberculosis. The particle system had a mannose surface, to target macrophages via 
sugar lectin interactions. A relevant antibiotic was covalently loaded into the particles, 
by co-polymerising a synthesised pH responsive monomer with a hydrazone linker 
between isoniazid and diacetone acrylamide. Finally the core of the particle was made 
with poly(2-(diisopropylamino)ethyl methacrylate) (P(DPAEMA)), to impart a second 
pH response, breaking up the particles in acidic pH. The synthesised particles were 
shown to be able to target the cell surface lectins on macrophages, and using in vitro 
techniques to release the bound isoniazid and break up into linear polymer at the 
reduced phagolysosomal pH. These particles were then shown superior in killing 
intracellular bacillus calmette guerin (BCG) in THP-1 derived macrophages, showing 
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significantly superior activity against controls. They were also shown to be statistically 
equivalent to free isoniazid at the same concentration as in the particles. Furthermore 
the mannose-isoniazid particle system was the only treatment that showed complete 
bacterial eradiation (within the resolution of the technique used).  
In summary this thesis has presented two techniques for the synthesis of glycosylated 
nanoparticles. The first, RAFT emulsion polymerisation has been shown a reliable 
technique able to access a range of particle size. These particles are of particular use 
for fundamental studies as they have a known surface functionalisation and more 
controlled molecular weights, removing these as sources of error. The second, a 
simpler free radical and surfactant free technique, has been shown to be suited to the 
synthesis of glyconanoparticles for biological applications as it is cheaper, faster and 
uses fewer potentially toxic chemicals. A DLS based system for tracking and 
quantifying particle aggregation has been developed and used to show that larger 
glycoparticles undergo greater lectin induced aggregation, and that particles above 
their Tg can deform under lectin induced aggregation to show closer packing than hard 
spheres and form larger aggregates. Finally a dual pH responsive glyconanoparticulate 
drug delivery system was developed, successfully delivering isoniazid intracellularly 
in macrophages to effectively eradicate intracellular BCG.  
Going forward, the same tests bacterial killing test performed in Chapter Four would 
need to be repeated on Mycobacterium tuberculosis to show efficacy against the most 
prevalent TB causing pathogen. This would then lead to in vivo biological tests to 
determine the full benefit of delivering isoniazid with such a system, compared to a 
PEGylated equivalent and free isoniazid. The hypothesis being that intracellular 
concentrations of isoniazid would be increased compared to free isoniazid due to 
increased uptake owing to the particle size, and compared to the PEGylated system 
due to targeting of the macrophage through sugar-lectin interactions.  
It would also be of interest to produce similar drug delivery systems with varying 
particle core Tg’s and explore the influence this has on cellular uptake and ultimately 
biological activity of a delivered drug. 
 
